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Spinal cord injury (SCI) affects approximately 40,000 people in the UK; the most 
common type of SCI is a contusion injury and the majority of these cases are 
male and aged between 16 and 30 years old. The initial physical trauma to the 
spinal cord during injury leads to substantial damage and loss of neurones. After 
the primary traumatic insult has occurred a sequence of events is initiated that 
sets off a cascade of biochemical, cellular and inflammatory events that are 
massively destructive and continue for weeks to months after the initial SCI. This 
phenomenon is known as “secondary death” and leads to an increase in the size 
of the damaged area. Infiltrating monocytes and monocyte-derived macrophage 
have been implicated as a crucial component in the perpetration of secondary 
death. 
It was demonstrated in this thesis that staphylococcus protein A (SpA), when in 
complex with IgG forms homogeneous small immune complexes (SIC) that can 
polarize macrophages in vitro to an anti-inflammatory phenotype, resulting in 
increased production of the immune-suppressive cytokine IL-10 and reduced 
ability to produce the pro-inflammatory cytokine IL-12. SIC treatment of IFNγ-
primed macrophages in conjunction with LPS also induces a down-regulation of 
MHC II surface expression; however, the macrophages still exhibit normal levels 
of co-stimulatory molecule CD86 compared to a classically-activated 
macrophage.  
In an in vivo setting it was demonstrated that SpA binds to monocytes and 
preferentially to the “inflammatory” Ly6Chi monocyte sub-set. The binding of 
SpA to this monocyte population induced the maturation of the Ly6Chi 
“inflammatory” monocyte into Ly6Clow “anti-inflammatory” monocytes within 
the steady state and in the sterile inflammatory setting of SCI. In the 
inflammatory environment of the damaged spinal cord, SpA treatment induced a 
higher percentage of Ly6Clow monocytes to produce the immune-modulatory 
cytokine IL-10 compared to the control treated group. These observations 
indicate when SpA and IgG form SIC they interact with macrophages and 
monocytes in vitro or in vivo polarizing them to an anti-inflammatory 
phenotype.  
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In conclusion, it has been shown in this thesis that SIC has the potential to be 
used as a method of polarizing monocytes and macrophages to an anti-
inflammatory phenotype, which in turn has the potential to modify the overt 
inflammatory response that is responsible for the death of neurons days to 
weeks after the initial injury and is responsible for reduced functional recovery 
in SCI patients. 
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1 Introduction  
1.1 An overview  
Spinal Cord Injury (SCI) is a condition that affects thousands of people annually, 
and can lead to mild or severe paralysis depending on where and how severely 
the spinal cord is damaged.  
It has been recently theorised that the initial injury is not the only contributing 
factor to the overall damage. In fact, it is the inflammatory immune response 
that magnifies the initial trauma and perpetuates damage to neurons weeks 
after the initial trauma. 
One of the main components of the inflammatory immune response after SCI is 
the massive infiltration of monocytes from the peripheral circulation, which 
differentiate into macrophages; these can be detected 12h post injury. 
Macrophages are a component of the innate immune system that are bimodal in 
their activation phenotypes and can either be anti-inflammatory or pro-
inflammatory in nature depending on their mode of activation.  
This thesis tries to address the hypothesis: that it is possible to skew the 
infiltrating monocyte/macrophage population to anti-inflammatory phenotype 
after contusive SCI with the use of Staphylococcus aureus protein A (SpA). 
This introduction will explore monocyte and macrophages development, 
phenotypes and functions. It will then focus on SCI and what is known of the 
ensuing inflammatory immune response and the phenomenon of secondary 
death. It will finish with a review of some strategies that have been used in 
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1.2 Immune system in brief  
The immune system is entrusted with protecting the body from harmful 
pathogens and regulating tolerance to harmless antigens such as food and “self 
antigens”. However, when a breakdown in tolerance to self-antigens occurs 
auto-immunity ensues, leading to conditions such as Systemic Lupus 
Erythematosis - a condition where the immune system produces auto-antibodies 
to DNA resulting in inflammation and tissue damage. Rheumatoid Arthritis is 
another common auto-immune disease where the immune system produces an 
aberrant antibody response to immunoglobulin (i.e. rheumatoid factor), and the 
immune complexes that are formed as a consequence contribute to massive 
inflammation and joint destruction. Auto-immunity is a poignant example of the 
destruction the immune system can cause if it is not properly regulated 1. 
The immune system can be divided into two distinct branches: the innate and 
the adaptive responses. Innate immunity is highly conserved across time and 
species; it is involved in the immediate response to pathogens, and consists of 
monocytes, neutrophils, macrophages, dendritic cells and complement to 
mention only a few. The innate immune system must activate the adaptive 
immune system and is often entrusted with regulating its activation. The 
adaptive immune system is only found in more highly evolved species and its 
onset comes later than that of the innate immune system. It is more precise in 
its killing and, in addition, the adaptive immune system possesses the ability to 
generate “memory” to pathogens. The adaptive immune system consists of T 
cells and B cells, which both have many subsets and a diverse array of functions 
2.  
1.3 Innate immune system 
The innate immune system can be further sub-divided into granulocytes (also 
referred to as polymorphonuclear leukocytes) and the mononuclear phagocyte 
system (MPS) 3 4. Granulocytes are made up predominantly of neutrophils (as 
well as basophils and eosinophils). These cells can be recognised by their unique 
multi-lobed nucleus and their granular cytoplasm. Granulocytes are early 
responders to pathogen and do not possess the ability to activate the adaptive 
immune system. The other major cellular component of the innate immune is 
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the MPS. The MPS is composed of monocytes, macrophages (as well as specialist 
tissue macrophages such as Kupffer cells of the liver, microglia of the 
brain/spinal cord and osteoclasts of bone) and dendritic cells. The scope of this 
review will only focus on macrophages and their precursor monocytes of the MPS 
and not dendritic cells or granulocytes.  
1.3.1.1 Monocyte derived macrophage Ontogeny  
Monocytes in an adult originate from self-renewing hematopoietic stem cells 
(HSC), which are located in specialized niches of the bone marrow 5. HSC are 
thought to go through successive and irreversible developmental checkpoints, 
which lead to the generation of intermediate precursor populations that 
increasingly lose self-renewal capacity and become restricted to one lineage 6. 
HSC, which are defined as Lin-, c-Kit+, Sca1+, can differentiate into either the 
common lymphoid progenitor (CLP) 7 or the common myeloid progenitor (CMP) 8. 
IL-7Rα is used to define these two populations: CLP are IL-7Rα+, as IL-7 is an 
essential developmental cytokine in both B and T cell ontogeny, acting as a 
survival factor for thymocytes (T cell precursors) through the maintenance of 
Bcl-2 9. In B cells, it leads to the rearrangement of the heavy chain V segment in 
BCR development through the activation of the Pax5 gene 10. 
CMP are IL-7Rα- and can be identified as FcγRII/IIIlow, CD34+, c-Kit+, Sca1-. The 
CMP fraction of the bone marrow can then give rise to two subsequent 
populations; these populations can be sub-divided on the expression of FcγRII/III 
and CD34. FcγRII/IIIlowCD34- are megakaryocyte-erythrocyte progenitors (MEPs), 
and FcγRII/IIIhiCD34+ are granulocyte-macrophage progenitors (GMPs) 11. By this 
stage of the developmental pathway these previously pluripotent HSC have now 
lost their ability to self-renew. MEPs will go through further subsequent 
precursor steps to eventually give rise to either megakaryocytes or erythrocytes. 
GMPs have the potential to differentiate into either monocytes or the common 
dendritic cell progenitor (CDP), which will give rise to pre-DCs or plasmacytoid 
DCs. 12 (figure 1.1).  
Unsurprisingly, there is a complex interplay of transcription factors that are vital 
in controlling the process of mylopoesis. GATA-1, GATA-2 and PLZF are 
expressed at high levels in HSC. However, PLZF decreases as HSC commit to any 
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hematopoietic linage. GATA1/2 is elevated in the further differentiated CMP 
fraction of the bone marrow but is then selectively repressed when the CMP 
enters the monocyte linage - but stays at an elevated level if the CMP commits 
to other myeloid linages such as erythrocytes, mast cells and megakaryocytes 13.  
PU.1 is the transcription factor that controls the commitment of HCS to CMPs 
and is therefore indispensable in the formation of monocytes/macrophages. 
PU.1 is the product of the Spi-1/Sfp-1 gene, a member of the ets proto-
oncogene family 14 15. PU.1 is not only expressed by mature 
monocyte/macrophages but is also expressed by other cell types such as B cells 
and neutrophils 16 17. When PU.1 is knocked out in mice the embryo dies at a late 
stage of gestation and has serve defects in its hematopoietic cell compartments, 
which include defects in T cells and B cells as well as monocytes and 
granulocytes 18. When PU.1 is knocked out in embryonic stem cells (embryonic 
stem cells have the ability to be induced to differentiate, in vitro, into 
monocyte/macrophages under the appropriate culture conditions) they then lack 
the ability to differentiate into mature monocyte/macrophages in vitro that 
express Csf-1R, CD11b and FcγRI. However, the embryonic stem cells can 
differentiate into monocyte precursors, which express GM-CSFR, which is 
another early myeloid marker and is usually expressed in conjunction with CSF-
1R. This discovery led to the revelation that PU.1 is dispensable for the 
commitment to the myeloid linage but is essential for the maturation of 
precursors into mature monocytes 19 20. The ability of stem cells to complete 
myelopoiesis is due to PU.1’s vital role in cleaving the Csf-1R gene, which allows 
its expression on the surface of monocytic precursors. 
The expression of Csf-1R (also known as c-fms, M-CSFR or CD115) is an essential 
developmental check point in monocyte maturation and cannot be dispensed 
with. The Csf-1R was thought to have only one cognate ligand Csf-1/M-CSF 21. 
However, when Csf-1R-/- mice were generated and phenotyped, they possessed 
virtually all of the reported defects of Csf1op/op or Csf-1-/- mice, hence all of the 
effects of Csf-1 appear to be mediated by the Csf-1R. However, it was noticed 
that Csf-1R-/- mice display a more exaggerated phenotype than the Csf1op/op or 
Csf-1-/- mice with more severe osteopetrosis, fewer tissue macrophages and 
shortened life-spans 22. For this reason it was theorized that there may have 
been another ligand for Csf-1R which can also play a part in the orchestration of 
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monocyte development; IL-34, was recently discovered as an alternative ligand 
for the Csf-1R 23. 
C/EBP is another transcription factor that is limited to the myeloid lineage and 
is essential for its maturation. C/EBPα is expressed in immature myeloid 
precursors but decreases steadily as monocytes mature as it is essential for 
granulocytic development. However, C/EBPβ and C/EBPδ increase as 
macrophages mature into terminally differentiated cells 24. C/EBPα is 
antagonized by PU.1 at the GMP stage to drive the cells to the monocytic 
pathway at the expense of the granulocytic pathway 25. This leads to the up-
regulation of the GM-CSFR and Csf-1R 26. C/EBPα activates Gfi-1 to stably 
confirm the myeloid precursor to the granulocyte lineage, whereas PU.1 must 
activate Egr-1 and its cofactor Nab to commit the cells to a 
monocyte/macrophage fate. Egr-1 is solely expressed in 
monocyte/macrophages, although Egr-1-/- mice have macrophage populations 
and therefore it is not essential for macrophage maturation. When bone marrow 
was taken from Egr-1-/- and WT and then treated with M-CSF or GM-CSF, these 
cells were also able to be differentiate into normal macrophages and produce 
the same level of nitric oxide as the WT bone marrow derived macrophages 27. 
However, Egr-1-/-Egr-2-/- mice show a defect in Csf-1 dependent macrophage 
differentiation leading to speculation that Egr-1 and Egr-2 have the ability to 
compensate for the loss of each other and still allow the monocyte/macrophage 
to terminally differentiate when one of these molecules is lost - but not when 
both are knocked out 28. 
c-Myc is highly expressed in proliferating myeloblastic cells and is repressed 
once the cells are terminally differentiated into monocytes; it is also present in 
a large number of other undifferentiated proliferating cells, acting to down-
regulate the C/EBPα during monocyte maturation 24. c-Myc suppression is then 
necessary for the induction of C/EBPβ and C/EBPδ, which occurs later in the 
monocyte maturation process 29. IL-6 induction through stat 3 signalling is 
responsible for the repression of c-Myc and therefore can suppress monocyte 
differentiation in favour of granulocyte development 30.  
It is only very recently that the two transcription factors controlling the 
differentiation of the two-monocyte subsets have been discovered. Nurr77-/- 
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mice show a deficiency in the patrolling / anti-inflammatory Ly6Clow monocyte 
subset. However, these mice exhibit normal levels of the inflammatory Ly6Chi 
monocyte subset 31. The converse was noted in KLF4-/- mice, where they 
exhibited reduced levels of Ly6Clow monocyte but were completely deficient in 
the Ly6Chi population 32.  
There is still much controversy and mystery over the relationship that the MDP 
have with the two-monocyte subsets and the developmental relationship they 
share with each other, however, this will be explored in more detail in section 
1.3.3 
1.3.2 Microglial ontogeny and function 
Microglia are a separate arm of the macrophage family found solely in the CNS. 
They patrol the central nervous system hunting for damaged neurons and 
infectious agents, and are also associated with the pathogenesis of severe 
neurodegenerative diseases 33. In contrast to many other macrophage 
populations, it has been discovered recently that microglia do not in fact derive 
from monocyte precursors (figure 1.1) but are thought to renew independently 
from the HSC in the bone marrow under steady-state conditions 34. However, 
under inflammatory insult, Ly6Chi monocytes have been shown to infiltrate into 
the CNS and differentiate into activated microglia 35  36. 
Fate mapping studies indicate that microglia in the adult brain derive essentially 
from primitive macrophage progenitors that arise before embryonic day 8 
independent of the fetal liver and HSC 37. Recently, it was discovered that these 
primitive progenitor cells originate in the embryonic yolk sack. The yolk sack 
produces progenitor cells, which likely migrate to the brain via newly formed 
blood vessels from embryonic day 8. Myb is an essential transcription factor in 
the development of HSC while PU.1 is an essential transcription factor for 
generation of macrophages. Studies in Myb-/- knockout mice embryos have 
demonstrated that CD11bhigh CD45+ F4/80- monocytes are absent from the blood 
while the number of CD11blow CD45+ F4/80bright macrophage (microglia) in the 
embryonic brain are normal. In comparison, the CD11blow CD45+ F4/80bright 
microglial population along with the CD11bhigh CD45+ F4/80- blood monocytes are 
missing from PU.1 knockout embryos, demonstrating that CD11blow CD45+ 
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F4/80bright microglial population are of the macrophage linage. Thus, the data 
suggests that microglia do not develop from HSC and originate from the yolk sac 
during foetal development. The authors also suggest that microglia are replaced 
in adult life via a combination of proliferation and local self-renewal. How this 
local self-renewal occurs has not been explained as yet and requires further 
investigation 38 39.  
1.3.3 Murine monocyte heterogeneity 
Monocytes make up roughly 2-5% of the total white blood cells in the murine 
system. Morphologically, monocytes are irregular shaped cells that possess 
kidney shaped nucleus, cytoplasmic vesicles and have a high cytoplasm to 
nucleus ratio. Over the last 20 years, research has hinted at the possibility of 
different subsets of monocytes and it is now accepted that monocytes do in fact 
form at least two distinct subsets. Both subsets express CD115, CD11b and 
F4/80int but can be divided based on their expression of Ly6C and the fractalkine 
receptor CX3CR1 40.  
The antigens used to distinguish monocytes, Ly6C, CD11b, CD115 and CX3CR1, 
from other effector cells of the immune response are not solely expressed on the 
monocyte population, but it is the unique pattern of expression that allows their 
use in the identification of the monocytes.  Ly6C (Lymphocyte antigen 6 
complex, locus C) is a 14-17KD glycosylphosphatidylinositol-anchored cell surface 
protein that is rich in cysteine residues. It is part of the Ly6 protein 
‘superfamily’ 42. The Ly6 protein domain is 80 amino acids long and is 
characterized by a conserved pattern of 8 to 10 cysteine residues that have a 
defined disulphide-bonding pattern 43. The Ly6 protein domain is rare as it is 
thought that only 2% of all surface molecules on leukocytes contain this domain. 
The Ly6 locus is located on murine chromosome 15 44. Ly6C was first described 
as having a function in endothelial cell adhesion and homing of T cells by 
activating integrin dependent pathways 45. However, no function has been 
described for it in the context of monocytes. Ly6C is the most widely used 
marker to identify monocytes and one of two markers that are currently used to 
define the two subsets within the monocyte population. That said, it is not 
known what regulates its expression or why the two subsets differentially 
express Ly6C. 




Figure 1.1. Ontogeny of monocytes, macrophages and DCs. 
Commitment to differentiation into a monocyte or dendritic cell occurs at the MDP stage. MDP can 
give rise to CDP, which in turn can give rise to pre-DC or plasmacytoid DC. MDP also give rise to 
Ly6Chi and Ly6Clow monocytes; Ly6Chi monocyte have also been shown to have the ability to 
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Ly6Chi monocytes express CX3CR1 at a low to intermediate level and are thought 
to be the inflammatory subset of the monocytes population as they are released 
from the bone marrow in a CCR2-dependent manner 46. Ly6Clow CX3CR1hi 
monocytes are the other subset identified in mice. These monocytes are thought 
to be the patrolling/anti-inflammatory monocytes as they were found to 
circulate in the blood for 2-3 weeks seeking out damage in blood vessels and are 
said to continually migrate into tissues in the steady state to replace some 
resident macrophage and DC populations. Ly 6Chi CX3CR1low and Ly 6Clow CX3CR1hi 
monocytes are seen in the blood at a 1:1 ratio. However, in the bone marrow 
this is not the case, Ly6Chi monocytes far outnumber the Ly6Clow monocytes. 
There is some controversy over the origins and the relationship between the 
two-monocyte sub-populations. It has been frequently proposed that Ly6Clow 
cells derive from Ly6Chi monocytes. Evidence that has been put forward to 
support this theory shows that in cell depletion or cell transfer studies not only 
can MDP produce both Ly6Chi and Ly6Clow monocytes in vivo but also that Ly6Chi 
cells home back to the bone marrow where they can mature into Ly6Clow cells 47. 
However, the signals that induce Ly6Chi monocytes to mature into Ly6Clow 
monocyte are still largely unknown. In juxtaposition, it has been proposed that 
Ly6Clow monocytes can be generated independently of their Ly6Chi counterparts 
based on observations that the numbers of circulating Ly6Clow monocytes were 
not affected after prolonged antibody depletion (2 weeks) of the Ly6Chi 
monocytes 48. Nevertheless, the existence of a direct precursor relationship 
between MDP and Ly6Clow monocytes without the intermediate Ly6Chi monocyte 
has not been irrefutably demonstrated yet and is a highly debated subject in the 
field of monocyte biology (figure 1.1).  
1.3.3.1 The different role monocyte subsets play 
There are many examples of the role that monocytes or specifically the Ly6Chi 
monocyte subpopulation play in clearing infections. One of these examples is 
illustrated by work done in M. tuberculosis infection studies. CCR2-/- mice have 
significantly reduced circulating levels of Ly6Chi monocytes as they cannot egress 
from the bone marrow; however, the Ly6Clow population remains unaffected 
(this is discussed in more detail in section 1.3.5). When the CCR2-/- mice are 
challenged with M. tuberculosis, they show reduced ability to fight the 
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infection: they have higher mortality rates within the early stages of infection 
compared to WT controls. This outcome was shown to be due to reduced 
production of IFNγ, nitric oxide and effective CD4 T cell priming as the Ly6Chi 
monocyte population cannot infiltrate the lung and differentiate into 
inflammatory macrophages and DCs 49 50. T. gondii is an example of a protozoan 
infection that is reliant on the recruitment of Ly6Chi monocytes for clearance 51. 
The recruited Ly6Chi monocytes play a similar role to that described above in 
clearing the bacteria M. tuberculosis. The authors also used CCR2-/- mice to 
show that with reduced Ly6Chi monocyte recruitment there was a significantly 
decreased ability to clear the infection. The reduced ability to clear the 
pathogen was demonstrated to be due to reduced inflammatory macrophages 
and DCs at the sight of infection and therefore decreased production of IL-12, 
IFNγ and NO, which are essential for clearance 51 52.  
Transcriptional analysis studies examining monocyte presence in the early and 
late phase of L. monocytogenes infection were some of the first to define the 
separate role of Ly6Chi and Ly6Clow monocytes in inflammation; before this, little 
was known about the interplay of the two monocyte subsets with each other and 
the part Ly6Clow monocytes played in the progression of an immune response to 
an infection. All that was previously known about Ly6Clow cells, was that they 
had been shown to have “crawled” along the lumen wall of blood vessels in the 
steady state.  
These seminal studies with L. monocytogenes revealed that the early stages of 
infection (1h post infection) were associated with the presence of TNFα and IL-1 
producing Ly6Clow monocytes 53. These early-responding Ly6Clow monocytes show 
up-regulation of genes encoding lysozymes, defensins and complement, which 
are associated with pro-inflammatory macrophages. Ly6Clow monocytes are 
ideally placed to rapidly respond to infection as they patrol along the blood 
vessels and express an array of adhesion molecules, which allow them to rapidly 
extravasate into inflamed tissues. By comparison, Ly6Chi monocytes are 
recruited to the site of infection at a later phase - as they must traffic from the 
bone marrow 47 54. The transcriptional profile of Ly6Chi monocytes at the site of 
infection was consistent with that of classically-activated macrophages, which 
are typically thought of as highly inflammatory. In contrast, in the final stages of 
infection (12h post infection), the second wave of Ly6Clow monocytes that are 
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now recruited exhibit an altered differentiation pathway congruent with 
regulatory macrophages with an up-regulation of arginase 1, Fizz 1 and the 
mannose receptor; a population which are thought to be involved in the 
resolution of inflammation and tissue repair 53.  
After the L. monocytogenes seminal work was completed, other groups started 
to examine the different roles monocytes play in other diseases and conditions, 
and not just focus on what the Ly6Chi monocytes were contributing; examples of 
this is in cardiovascular disease where it was demonstrated that the splenic 
reservoir of monocytes is mobilized after myocardial infarction and this is 
thought to be important in the healing process. Ly6Chi monocytes dominate the 
first phase of inflammation at day 1 post infarct and secrete high levels of 
proteases and TNFα, which contribute to clearance of apoptotic debris. Through 
days 5-10 the second phase of infiltration occurs, which is predominated by 
Ly6Clow monocytes secreting VEGF and encouraging myofibroblast accumulation 
and angiogenesis, vital for the start of the tissue repair process 55 56. 
Atherosclerosis and hypercholesterolemia are two other conditions that have 
recently been shown to preferentially increase the production and circulation of 
Ly6Chi monocytes 57 58. The most common model for atherosclerosis research is 
the ApoE-/- knockout mouse, which when fed on a high fat and cholesterol rich 
diet develops atherosclerosis. Ly6Chi monocytes infiltrate in large numbers into 
aortic plaques via a CCR2 dependent mechanism. When in the plaques they have 
been shown to produce IL-1β, reactive oxygen species and numerous proteases 
that all contribute to lesion exacerbation 59. Ly6Clow monocytes are evident at a 
far lower level in the lesional plaque, trafficking into it in a CCR5 dependent 
manner. Unlike the Ly6Chi monocyte subset, emerging evidence suggests that 
Ly6Clow monocytes may play a role in providing added protection from 
atherosclerosis. This was demonstrated when double knock-out mice were 
produced to make the mice susceptible to atherosclerosis and deficient in 
Ly6Clow monocytes (ApoE-/- Nurr77-/-). These mice were shown to have lesions 
with significantly higher lipid burdens than the normal arthrosclerosis 
susceptible mice (ApoE-/-) - along with higher level of CD36+ macrophages that 
produce high levels of TNFα. This implies that the Ly6Clow monocyte must play a 
protective role in this model of atherosclerosis 60 61. However, more work needs 
  31 
to be done in this area to elucidate the mechanism behind this potentially 
protective role Ly6Clow monocytes play in the disease. 
Monocyte phenotypes have been a controversial issue in recent years; when the 
original discovery of the two subsets of monocytes was made, the Ly6Chi 
monocytes were described as the pro-inflammatory subset and Ly6Clow 
monocytes were the patrolling/anti-inflammatory sub-set 40. However, it has 
been demonstrated that these roles can become reversed under certain 
environmental conditions 62. It is, however, accepted that the original 
classification of “inflammatory” and “patrolling/anti-inflammatory” is the 
evolutionary conserved function of the two subsets. Moreover, there is now an 
acceptance that monocyte and macrophage activation phenotypes and functions 
are not constrained and can be affected by the environment they are activated 
within and can over-write the cells default phenotype 63. This dichotomy is 
exemplified in the gut; newly arrived Ly6Chi inflammatory monocytes 
differentiate in situ into IL-10-producing anti-inflammatory CX3CR1hi resident 
macrophages in homeostasis. However, intestinal inflammation induces the 
Ly6Chi monocytes to differentiate into pro-inflammatory macrophages, which are 
Toll-like receptor (TLR) responsive and produce vast quantities of inflammatory 
mediators. Thus, resident and inflammatory macrophages in the gut represent 
divergent differentiation outcomes of the same Ly6Chi monocyte precursor 64.  
1.3.4 Human monocyte heterogeneity  
The two distinct monocyte subsets are evolutionarily conserved across species 
and can be defined not only in mice but also in humans where the Ly6Chi 
population has been shown to correspond to the “classical” CD14++ CD16- 
population and Ly6Clow murine monocytes correspond to the “non-classical” 
CD16++ CD14+ population 65. Monocytes make up 10% of the total number of white 
blood cells present in the circulation and unlike in the murine system where 
there is a 1:1 ratio of the two subsets, there is a 9:1 ratio of CD14++CD16- to 
CD14+CD16++ in the blood 66.  
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1.3.5 Monocyte trafficking under homeostatic conditions and 
inflammation 
In steady-state, monocytes that are produced in the bone marrow are released 
into the circulation and can extravasate into distant lymphoid and non-lymphoid 
tissues. The process of extravasation typically associates with an irreversible 
program of differentiation, resulting in the generation of tissue resident 
macrophage and DC populations with specialized functions 67. Ly6Chi and Ly6Clow 
monocytes have different tropisms and fates in steady-state. Ly6Clow monocytes 
patrol non-inflamed blood vessels and have the potential to enter non-inflamed 
tissue, contributing to the replacement of resident macrophage and dendritic 
cells in conjunction with local cell renewal 38 40. Ly6Chi cells selectively migrate 
to sites of inflammation, but in the absence of this they return to the bone 
marrow and differentiate into Ly6Clow monocytes47.  
The reason monocytes have this ability to migrate into tissue or patrol blood 
vessels, is that they are equipped with multiple chemokine and integrins that 
mediate these processes. The chemokine receptor CCR2 has been shown to play 
a vital role in the recruitment of Ly6Chi monocytes. Within the bone marrow, 
inflammatory monocytes (CCR2+) are evenly distributed throughout the bone 
marrow, however, upon LPS stimulation the CCR2+ monocytes rapidly (2h) 
associate with cadherin-positive vascular endothelial cells. Ly6Chi monocytes are 
also seen in increased frequency within the lumen of blood vessels. 
Interestingly, CCR2-/- mice have significantly reduced numbers of inflammatory 
monocytes in the blood vessels when stimulated with LPS compared to WT mice 
68. Two of the ligands for CCR2, CCL2 and CCL7, have been shown to play a role 
in the migration of inflammatory monocytes out of the bone marrow. Although 
expression of CCR2 is restricted to only a few cell types, most cells, with the 
exception of red blood cells, express CCL2 in response to activation by pro-
inflammatory cytokines or stimulation of innate immune receptors by a range of 
microbial molecules 69. CCL7 is generally induced during bacterial infection. If 
CCL2 or CCL7 is deleted it reduces the recruitment of Ly6Chi monocytes from the 
bone marrow in L.Monocytogenes infection by up to 40-50% 70. The exact 
mechanism that CCL2 and CCL7 play in the recruitment of monocytes is not yet 
known. It has been suggested that by interacting with CCR2 they guide 
monocytes thorough different niches within the bone marrow and out into the 
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circulation. Interestingly, CCR2 also bind CCL8 and CCL12, though deletion of 
these two markers has no noticeable effect on monocyte recruitment 69. 
CX3CL1 (Fractalkine) is a membrane bound chemokine, which specifically binds 
to CX3CR1 and is expressed in a variety of tissues, including the marginal zone of 
the spleen, and is essential for Ly6Clow monocytes effector functions. If the 
CX3CR1 gene is deleted then there is diminished patrolling of Ly6Clow monocytes 
53. CX3CR1 and CX3CL1 not only play a pivotal role in monocyte 
patrolling/trafficking, they also provide a survival signal for Ly6Clow monocytes. 
When a Bcl-2 transgene is introduced into CX3CR1-/- or CX3CL1-/- mice, which 
show reduced numbers of Ly6Clow monocytes in the blood, it rescues the 
knockout phenotype back to the normal wild type phenotype in inflammation 
and steady-state conditions 71.  
1.4 Macrophage phenotype, heterogeneity and 
polarization 
Under homeostatic conditions macrophages provide various housekeeping 
functions that require no special activating stimuli or are activated during 
development. Macrophages are phagocytic cells that constitutively express a 
variety of scavenger receptors that facilitate the removal of aged red blood 
cells, necrotic tissues and toxic molecules from the circulation 72. However, 
many things can affect the phenotypic and functional characterization of 
macrophages 73. Macrophage activation has been described as a spectrum of 
functionally diverse phenotypes. Hence, the plasticity that is associated with 
macrophages allows them to contribute to inflammation or, conversely, 
contribute to the resolution of inflammation 74. The type of macrophage that 
matures is a direct consequence of its specific environment 75. The micro-
environmental stimuli and the resulting functional phenotypes are varied and 
there is a diverse spectrum of phenotypes; two main macrophage phenotypes 
have been suggested, mirroring the Th1/Th2 polarization concept of T cell 
activation. These two functional extremes are the “regulatory” macrophages 
and the pro-inflammatory “classically” activated macrophages 76. The functional 
diversity of macrophages can be attributed to their ability to respond to 
different microenvironments, such as the cytokine profile of the tissue it is 
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inhabiting when the macrophage is activated in and at what stage of the immune 
response the macrophage is recruited into.  
The classically-activated macrophages are known as being pro-inflammatory due 
to their production of vast quantities of pro-inflammatory cytokine such as IL-1β, 
IL-6, IL-12 and IFNy. These pro-inflammatory macrophages are sometimes 
referred to as M1 macrophages. The classically-activated macrophage was the 
first activation phenotype to be characterized in macrophages, mediating host 
defense to a variety of bacteria, protozoa and viruses. Classically-activated 
macrophages also have a role in anti-tumor properties 73. Regulatory-
macrophages, which are also known as M2 macrophages, are characterized by 
increased expression of IL-10, which is an immune-modulatory cytokine, and 
decreased expression of IL- 12 77. These macrophages participate in the 
resolution of inflammation and therefore are seen at the end of an immune 
response to a pathogen. Regulatory-macrophages can be sub-divided into two 
further broad categories depending on how they are activated: wound-healing 
and anti-inflammatory 78. A more detailed account of macrophage phenotypes, 
polarization and activation is given in section 3.1.  
1.5 Spinal Cord: A brief overview   
The spinal cord is a crucial part of the central nervous system (CNS). Its main 
function being to relay neural impulses between the brain and periphery, as it is 
the link between the CNS and the peripheral nervous system (PNS) 79. If a trans-
section of the spinal cord is taken, it can be seen that it is made up of two types 
of matter: the white matter is the outer most and inside this is the grey matter, 
which has a butterfly appearance in shape. The grey matter is made up of 
neuronal cell bodies, and the white matter is made up of axons that have been 
myelinated, hence their white appearance. Cell bodies generate electrical 
signals, which are relayed up and down the myelinated axon that carry them out 
to the PNS through the dorsal root ganglia 80. Due to the fundamental role 
played by the spinal cord in the body, it is encased in a bony process known as 
the vertebral column, which protects it from damage. It is further protected by 
the spinal meninges, which are three specialized membranes that enclose the 
spinal cord. These membranes protect it from the bony vertebrae of the 
vertebral column and help with shock absorption. The three layers are called the 
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dura, arachnoid and pia 81. The spinal cord also has an intrinsic layer of 
protection against the constantly fluctuating conditions in the blood and to 
unwanted cellular infiltration, and this is known as the blood brain barrier. 
1.5.1 Blood brain barrier (BBB) 
The BBB was first proposed by Paul Ehrlich, when he injected dyes into the 
circulation of animals, which would lead to all tissues, with the exception of the 
brain and spinal cord, becoming stained 82. When these dyes were injected 
directly into the cerebral spinal fluid, by Edwin E. Goldman, an associate of 
Ehrlich, the animal’s brain and spinal cord would become stained but no other 
tissue would. This research led to the theory that there must be a barrier of 
some sort stopping molecules passing from the blood stream to the CNS. It was 
later shown that the barrier was due to special properties of the epithelial cells 
of the capillaries in the CNS, which are joined together by tight junctions and 
have astrocytes interacting with them 83. One of the crucial roles of the BBB is to 
restrict immune cells migrating into the CNS under normal physiological 
conditions 84. When there is an infection in the CNS, which is usually very rare, 
the BBB becomes leaky for a short period of time and allows the immune cells to 
extravasate through the BBB. However, if there has been trauma to the CNS, this 
can cause damage to the BBB, allowing immune cells to migrate in an 
unregulated fashion and cause massive inflammation 85 86. 
1.6 SCI 
Even though the spinal cord is well protected, its soft tissue can still become 
damaged. This happens when there is such trauma that causes the vertebrae to 
become crushed or broken. SCI affects approximately 40,000 people in the UK 
annually. There are many types of injury that can occur to the spinal cord some 
of which are lacerations, contusions and compression injuries; the most common 
of these is a contusion injury. This form of injury occurs when a substantial force 
impacts the spinal cord causing movement of the vertebra, injuring the normally 
protected spinal cord, leading to haemorrhaging and bruising. There are in 
excess of 1200 new cases of paralysis annually attributed to SCI, costing the UK 
more than £500 million per annum. The majority of these cases are male and 
55% of those are aged between 16 and 30 years old. Almost half of all spinal cord 
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injuries occur at the cervical level in humans, the part of the spinal cord that 
controls both the upper and lower extremities. As a result, severe injuries to this 
area can leave patients as quadriplegics 87 88.  
1.6.1 What happens when the spinal cord is injured? 
Damage begins straight after the trauma, with bits of bone fragment and disc 
material damaging the fragile spinal cord and bruising the surrounding 
ligaments. This leads to shearing of axons, disruption of neuronal cell 
membranes and disruption of blood vessels, leading to heavy bleeding into the 
grey matter 89. When this happens, the site of injury will swell up, filling the 
spinal canal and thus compressing the capillaries that supply blood and oxygen 
to the spinal cord. The dramatic reduction in blood pressure can lead to a loss in 
the ability to self-regulate autonomic functions - as very low blood pressure 
interferes with neurons ability to generate electrical impulses. Evidence suggests 
that in cases of human SCI, residual neural connections normally persist after 
this stage, indicating the potential for some level of recovery 90. 
Once the initial physical trauma has occurred, a cascade of biochemical, cellular 
and inflammatory events are set in motion that are massively destructive and 
continue for weeks to months after the initial SCI 91. This cascade leads to an 
increase in the size of the damaged area 89. The phenomenon is known as 
secondary death, which will be looked at in closer detail in section 1.7.1.2. 
1.7 An overview of the “sterile” immune response to SCI 
Immune cells play a critical role in the resolution of inflammation and 
pathologies that occur in peripheral organs. However, in the CNS, which is 
considered an immune-privileged site, after SCI the contribution of these cells to 
the healing and regeneration of the damaged cord remains a subject of 
controversy. Early reports indicated that when the infiltration of 
monocytes/macrophages into the damaged spinal cord was blocked, this 
resulted in neuro-protection due to a reduction in the release of inflammatory 
mediators 92 93  94 95. An example of one macrophage-specific factor that 
promotes damage in the spinal cord is Leukemia Inhibitory Factor (LIF). LIF 
induces the proliferation of microglia and the infiltration of neutrophils and 
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macrophages owing to its own chemo-attractant properties and its ability to 
induce CCL2 expression 96. IL-6 is another cytokine that is released by infiltrating 
monocyte/macrophages and promotes astrogliosis, a stereotypical response to 
CNS injury that inhibits axon regeneration - in part through the transcriptional 
activation of genes associated with chondroitin sulphate proteoglycan (CSPG) 
formation, which is a major component of the glial scar 97 98. On the other hand, 
more recent studies have suggested that there are potentially beneficial roles 
for monocytes/macrophages in SCI regeneration and recovery: leukocytes were 
demonstrated to promote removal of tissue debris, secrete neurotrophic factors, 
and support axonal regeneration 99. However, this beneficial role may only be 
transient. 
1.7.1 Time course of the immune response to SCI 
The immune response that ensues after SCI can be broken up into phases. The 
acute phase is dominated by the infiltration of neutrophils at 4-8 hours after 
injury and these peak 3 days post-injury 100. Neutrophils are cells of the innate 
immune system that become activated when they enter tissue. They are highly 
phagocytic cells and produce chemicals such as reactive oxygen species, 
chemokines and cytokines, which are highly destructive to the fragile spinal cord 
101. However, it is hypothesised that in the early stages of injury, to decrease 
the likelihood of auto-reactive responses, their highly phagocytic activity is 
essential for the clearance of neural cellular debris. Next is the sub-acute phase, 
from 12h on, and is characterized by activated resident microglia and infiltrating 
monocyte/macrophages 91. These cells are also phagocytic and release a vast 
array of chemokines and cytokines 102 103. From day 7 post-injury, T and B cells 
start to migrate into the CNS and the glial scar forms from 7-14 days post injury. 
 
1.7.1.1 Glial scar  
The glial scar forms around the injured site after SCI when astrocytes become 
activated by inflammation caused by immune cell infiltration. This is not only a 
physical barrier to axonal regeneration but also an environment awash with 
soluble factors such as CSPG, slit proteins and ephrin-B2 that inhibit axonal 
regeneration 104. Various therapeutic approaches have attempted to eliminate 
and reorganize the chemical components of the glial scar or to regulate its 
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negative effects. These include degrading enzymes to eliminate scar components 
(especially CSPGs) 105 106, blocking the activity of the growth inhibitors using 
specific antibodies, blocking the receptors that recognize the growth-inhibitory 
factors, regulating intracellular signals induced by the growth-inhibitory 
compounds 107, inhibiting astrocyte proliferation to attenuate scar formation, 
and applying growth-inducing agents and growth factors to form bridges across 
the injury site 108. Obviously, all of these approaches have been based on the 
perception that the glial scar is an obstacle to recovery that should be modified, 
eliminated, suppressed or circumvented.  
However, accumulating evidence indicates that scar tissue and its components 
might have an important role in the immediate response to CNS injury. Reactive 
astrocytes, which are the main cellular component of the glial scar, have an 
important role in scavenging, which regulates the levels of potassium, glutamate 
and other ions. The abolition of astrocytes leads to a vast decrease in the 
presence of glutamate transporters 109. Recently, it has been implied that the 
glial scar contributes to immuno-modulation within the injury site.  
Two weeks after SCI, microglia and blood monocyte/macrophages were 
discovered to associate with each other at the margins of the glial scar, where 
vast quantities of CSPG are produced. The localization of the 
monocyte/macrophages and microglia at this location was shown to result in the 
production of high levels of neuronal survival factor, IGF-1 110. When the 
production of CSPG is inhibited via Xyloside, a knock-on effect of this is that the 
reduction in the production of IGF-1, which leads to an increased production of 
TNFα from the monocytes/macrophages and microglial that had co-localized at 
the margins of the lesion. The consequence of this is an increase in lesion size 
and decrease in functional recovery 111. It should also be appreciated that the 
infiltrating immune cells can have an impact on the size of the glial scar too. At 
7 days post-SCI, IL-10-producing monocyte/macrophages are present at the 
CSPG-rich region of the lesion. These macrophages produce increased levels of 
metalloproteinase-13 (MMP), which in turn lead to the degradation of the glial 
scar, demonstrating a unique balance between regulation of the myeloid 
response and size of the glial scar 112.  
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1.7.1.2 Monocyte/macrophages and microglia in secondary death 
after SCI 
As discussed above a robust innate immune response occurs following SCI. One-
week post injury, the lesion has been abundantly infiltrated by macrophages and 
microglia. Many groups have previously published data to suggest macrophage 
and or microglial depletion or inhibition has a neuro-protective consequence 
95,100. It has also been shown that the injection of zymosan (a potent inducer of 
inflammation that has been used to replicate the inflammation seen after SCI) 
into the CNS parenchyma activates resident microglia and leads to an influx of 
monocyte/macrophages from the periphery. This infiltration sets off a chain of 
negative events, which leads to the withdrawal of astrocytes, axonal damage, 
fluid- or matrix-filled cysts and cavities, and deposition of growth inhibitors such 
as CSPGs 113. These toxic effects appear to be mediated by soluble factors 
derived from macrophages, i.e. IL-1, TNFα and reactive oxygen species, as well 
as direct physical interactions between macrophages and dystrophic axons 114. 
Deletion of macrophages through clodronate liposomes diminishes astrocyte 
withdrawal, cavitation and axon dieback after zymosan injection or at the post 
SCI stage 94 115.  
 Macrophages and microglia express a variety of TLR such as TLR2 and 4 in the 
injured CNS. When TLRs are engaged by their ligand this sets off a signalling 
cascade that involves NFκB and leads to the production of pro-inflammatory 
cytokines 116. TLR activation has been implicated in the propagation of pathology 
in certain models of SCI and CNS auto-immune conditions such as demyelination. 
It was shown by in-situ hybridisation that TLR2 and CD14 (an accessory molecule 
for TLR2 and 4) expression is increased after SCI. There was also an increase in 
NFκB-α expression in conjunction with TLR2 and CD14 expression leading to the 
proposal that there is an increased signalling by these molecules after injury, 
and the resulting production of large amounts of pro-inflammatory products 117. 
TLRs recognise pathogen-associated molecules as well as also recognising some 
self-molecules, which are known as “danger signals”. Danger signals are released 
from cells when they become stressed; this can happen when they are being 
attacked by pathogens or are injured due to trauma 118. An example of some of 
these danger signals are heat shock proteins, extracellular matrix proteins, 
certain proteolytically-cleaved products, oxidized lipids and necrotic cells. The 
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concept of “sterile inflammation” is now widely accepted in SCI, in that TLR 
activation of macrophages and microglia after SCI is linked to the production of 
self-danger signals rather than pathogen-associated molecules 119 120.  
1.7.1.3 Apoptosis versus necrosis after SCI 
The process of apoptosis is how cells commit suicide; this process is biologically 
advantageous, as it effectively clears away old or damaged cells without 
exposing the cellular contents to the rest of the system. This programed cell 
death is characterized by cell membrane blebbing and formation of apoptotic 
bodies, which contain the toxic components of the cell and are then quickly 
cleared by phagocytosis. Necrosis occurs when cells rupture and their toxic 
components are released, potentially causing damage to the surrounding 
environment. Necrosis is the primary form of cell death immediately after SCI by 
virtue of the traumatic event suffered. However, a short time after the initial 
trauma neuronal death is no longer predominated by necrotic death, in fact 
neurons start to die by apoptosis at the lesion margins. Oligodendrocytes also 
start to die by apoptosis at the site of degenerating axons after the initiation of 
neuronal apoptotic death. Neurons and glial cells can die by apoptosis even 
weeks after the initial trauma 121. CD95, CD95L and TNFα are all seen to be up-
regulated by neurons and glial cells after SCI.  
Neutralizing antibodies was used against these molecules to assess the impact of 
apoptosis on SCI recovery. After blockade, animals showed better functional 
recovery in behavioural testing than untreated controls 122, thus showing that in 
this situation excessive apoptosis leads to the death of healthy cells that would 
otherwise participate in regeneration after SCI. Another contributing factor to 
secondary death, is the release of excess neuro-transmitters such as glutamate, 
which can also lead to the perpetuation of apoptotic-induced cell death. At the 
site of SCI, dying neurons flood the area with glutamate, which in excess kills 
healthy neurons and oligodendrocytes, and also leads to the activation of 
microglia. Interestingly, when microglia become activated they release more 
TNFα and CD95L. Infiltrating immune cells, such as macrophages, also contribute 
to this initiation as they can also release TNFα, CD95L and cause oxidation of 
proteins, lipids and nucleic acid 100. 
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1.7.2 When the immune system works towards repair and 
regeneration of the damaged spinal cord 
Contrary to the above evidence - that the immune response plays only a sinister 
role in SCI - it has been shown in numerous studies that this is not the case 123.  
Despite having the ability to damage neurons and glia, microglia and 
macrophages can be intrinsically neuro-protective; both have the ability to 
produce neuro-protective cytokines and growth factors. An example of this is 
TGFβ, which is a potent anti-inflammatory cytokine, displaying beneficial effects 
on neuronal survival, including limiting oligodendrocyte toxicity 124.  
Macrophages and microglia also possess the ability to produce neurotropic 
factors including insulin-like growth factor, platelet derived growth factor and 
brain-derived neurotropic factor 125 126, which are all beneficial to neuronal 
survival and growth. Macrophages can even play a role in modulating glutamate 
excitotoxicity and promoting the growth of injured axons via increasing their 
Na+-dependent transporters that are able to take up extracellular glutamate and 
clear it away from neurons 127. 
Within the first few hours after injury to the brain or spinal cord, concentrations 
of IL-6 increase in the CNS. Neurons, glia and infiltrating leukocytes all produce 
and respond to IL-6, signifying that it is a pivotal mediator of the acute CNS 
injury response; for example, injecting anti-IL-6 antibodies early after SCI 
confers neuro-protection. This response is mediated through the reduced 
monocyte infiltration and increased efficiency of microglia phagocytosis 128. 
However, IL-6 that is produced by macrophages and microglia can also be of 
benefit to neuronal growth. Transection of axons in a hippocampal slice culture 
increases IL-6 levels, which in turn leads to spontaneous recovery of synaptic 
activity and regenerative sprouting. If this is done in the presence of an anti-IL-6 
antibody, the expression of regeneration-associated genes (GAP43) and recovery 
of synaptic activity are abolished 129. 
During postnatal development, iron is an essential component in the normal 
process of myelination. Microglia are thought to be the source of iron for the 
oligodendrocytes during this process of myelination as their levels are high 
before myelination, and then decrease when oligodendrocytes iron levels 
increase (at the point at which myelination starts) 130. After SCI, there is a build 
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up of free iron at the sight of trauma, and this can become toxic to 
oligodendrocytes when it is at too high a concentration through a processes of 
oxidative damage. Macrophages and microglia have been shown to sequester iron 
after trauma and then shuttle it back to oligodendrocytes at lower 
concentrations, which is essential and therefore beneficial to the process of re-
myelination after injury 131.  
1.7.3 Attempts at modulating the immune response to be more 
conducive to recovery and regeneration 
Immediately after SCI, the immune system plays an essential role in clearing 
away debris and initiating the wound-healing cascade as well as being able to 
produce neurotropic and neuro-protective factors. Nevertheless, it has been 
exhibited in many studies that the potential for regeneration in the CNS after SCI 
is far increased when the overt inflammatory immune response is down-
regulated after the initial acute phase 132. Normally, inflammatory cascades are 
self-limiting and typically resolve quickly after the initial “danger” has been 
contained outside the immune privileged site of the CNS. However, within the 
injured spinal cord, neuro-inflammatory cascades persist for extended periods of 
time. Activated macrophages and microglia are found in the injured spinal cord 
of rats up to 6 months after injury due to limited mechanisms for extinguishing 
the inflammation 101. This is why there has been so much research done to 
develop therapies that can harness the initial beneficial effects of the immune 
response and then “turn it off” before it becomes destructive; some of these 
strategies are discussed below. 
1.7.3.1 Macrophage polarization as a method of reducing 
inflammation after SCI 
 Macrophage/monocyte infiltration is a major component of the inflammatory 
immune response after SCI; it is also known that macrophages and monocytes 
can exhibit not only a pro-inflammatory state of activation but also an anti-
inflammatory one. Taking into consideration the beneficial roles macrophages 
can play in neuro-protection and neuro-regeneration, studies have started to try 
and exploit the different states of activation macrophages adopt and question if 
anti-inflammatory macrophages could play a beneficial role in SCI.  
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Supernatants taken from cultures of inflammatory macrophages or anti-
inflammatory macrophages have already been shown to induce quite different 
phenotypes on the regrowth of axons in vitro. When treated with toxic pro-
inflammatory macrophage supernatants, cortico-spinal tract neuronal cultures 
experience vast amounts of apoptotic death, whereas cultures treated with anti-
inflammatory macrophage supernatants did not 133. In addition, DRG neurones 
were shown to have significantly increased growth after treatment with anti-
inflammatory macrophages supernatants compared to pro-inflammatory 
macrophage supernatants. Neurons were also shown to be far less branched and 
were longer when conditioned with the anti-inflammatory macrophage media 
133. Interestingly, IL-10, which is produced by anti-inflammatory macrophages, 
helps with the resolution of the redundant inflammatory immune response seen 
in peripheral tissue. Local infusions of IL- 10 or insertion of a viral vector that 
expresses IL-10 have been shown to be neuro-protective after SCI due to its 
ability to resolve inflammation through antagonizing pro-inflammatory signaling 
(NF-κB) at the site of injury 134. The neuro-protective effect of IL-10 after SCI is 
not only via down-regulation of the inflammatory immune response, it also has 
direct neuro-protective effects on neurons with the inhibition of apoptotic 
mediators cytochrome C and caspase 3 activation, along with inducing an 
increase in expression of pro-survival factors Bcl-2 and Bcl-xL 135. 
A major problem for SCI patients, months to decades after their initial injury, is 
the formation of fluid-filled cyst/cavities. In rats, treated with the autologous 
skin or peripheral nerve-activated macrophages, cyst/cavity formation was 
significantly decreased 136 137. Macrophages that are incubated with autologous 
skin displayed increased expression of CD86 and MHC II, which is associated with 
an anti-inflammatory macrophage phenotype 138. Examination of the macrophage 
secretory profile demonstrated that they had decreased expression of TNFα, 
increased expression of IL-1β but showed no change in IL-6 production. 
Importantly, macrophages also increased their production of brain-derived 
neurotropic factor, which stimulates axonal sprouting 139. For optimum 
beneficial results, the autologously-activated macrophages must be injected into 
the lesion margins during the sub-acute phase of injury, which is from day 3, and 
no later than two weeks after SCI. It is noteworthy to mention that injection of 
the skin-activated macrophages into the non-injured spinal cord had no adverse 
  44 
clinical or histological effects. Due to these findings, this experimental 
treatment for SCI was taken into phase I clinical trials and was named Pro-cord. 
The Pro-cord phase I clinical trial was carried out on 16 patients with complete 
SCI. This was done after the hyper-acute phase and once their American Spinal 
Injury Association score was confirmed as A (the most severe grading of injury). 
After treatment, 5 patents showed marked recovery, two patients increased 
their score to B and three patents improved their scores to level C 140. After the 
success of the phase I clinical trial, phase II clinical trials were initiated but 
were later cancelled. There were two reasons for the cancellation: 1, 
macrophages were not injected until day 14, instead of administration in the 
hyper-acute phase. 2, in the phase I clinical trials macrophages were implanted 
at the same time as the patient received their spinal fusion operation 132. This 
did not happen in the phase II study, meaning patients had to go through a 
secondary operation. Although Pro-cord was terminated in its phase II trial, it 
nevertheless demonstrated the beneficial effect macrophages can have on SCI 
when they are not activated in a pro-inflammatory setting.  
1.7.3.2 Dendritic cell-based therapy 
Dendritic cells are an alternative differentiation state of cell within the myeloid 
compartment. They can also be activated to pro-inflammatory and anti-
inflammatory phenotypes. Dendritic cells have received little attention in SCI 
research, as they are not seen in the damaged cord to any great extent. 
However, dendritic cells may be beneficial after SCI, especially if they are 
prepared ex vivo where they can be polarized to an anti-inflammatory 
phenotype before implantation into the injury site. Dendritic cell transplantation 
was shown to activate neuronal stem cells, leading to the regeneration of 
neurons and significantly increased functional recovery in a murine model of SCI 
141. Dendritic cell implantation was also shown to be beneficial in a non-human 
primate (common marmoset) model of SCI where reduced levels of axonal de-
myelination in close proximity to the injury site and increased functional 
recovery after injury was observed 142.  
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1.7.3.3 Adaptive immune system targeting 
Inflammation induced by auto-immunity has been viewed as an important 
mediator of CNS secondary damage that occurs following the initial trauma of 
SCI, including neuronal and glial cell death, axon fracture or demyelination, as 
well as the formation of cavities and glial scar 143. However, in animal models of 
SCI, active or passive immunization with CNS myelin-associated self-antigens 
reduced neuronal loss and exerted immune neuro-protection 144 145. Recently it 
was demonstrated that neonatally-thymectomized rats that were reconstituted 
with myelin basic protein-activated T cells had increased levels of neuro-
protection and a decreased level of neuronal Wellarian degeneration after SCI 
146. However, the mechanism for this neuro-protective effect has not been 
elucidated yet. 
1.7.3.4 IgG administration as a treatment of SCI 
Preparations of human immunoglobulin G (IgG), usually referred to as IVIg, are 
well known immune-modulators that suppress some of the destructive pathways 
of the inflammatory cascade and promote recovery in many auto-immune and 
inflammatory conditions such as ITP 147. Intra-peritoneal injection of a single 
dose of IgG at the time of SCI was associated with significantly increased 
neurologic function in rats 148. Interestingly, histological and biochemical 
markers of neuronal injury were significantly reduced in the treated group 
compared to controls. The IgG treatment group had relatively well-preserved 
neuronal ultrastructure and reduced cavity and cyst formation. Additionally, it 
was demonstrated that there was a decrease in neuronal infiltration in the IgG-
treated group compared to the untreated group 149. This is an interesting and 
novel treatment that can modulate the immune response after SCI. 
Nevertheless, the authors have no theory on the mode of action of this 
treatment or even what cell types it works though. This is potentially very 
dangerous, as many inflammatory and auto-immune conditions, such as 
Rheumatoid Arthritis and type III hypersensitivity, have implicated immune 
complex deposition as a cause of destructive pathology and perpetuation of the 
inflammatory immune response 150. However, immune complexes, if utilized in 
an appropriate manner, can induce anti-inflammatory immune responses in cells 
like macrophages 151.  
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1.8 Immunoglobulin G (IgG) and its interactions with Fc 
receptors  
In 1890 Von Behring and Kitasato demonstrated that serum taken from a 
previously immunized animal with diphtheria could confer protection to another 
unimmunized animal 152. Over many years, researchers investigated the active 
component(s) of serum that could neutralize toxins, precipitate toxins and cause 
agglutination of bacteria. It was initially thought that a different component of 
the immune serum caused each of these effects. However, it was not until the 
late 1930s that Elvin Kabat discovered a fraction of the immune serum that 
contained all of these functional activities. The active component of the fraction 
that he purified is known today as immunoglobulin or antibody 153.  
There are five classes of antibodies: IgG, IgA, IgM, IgD and IgE. Each of the 
subclasses is specialised for a different function and located to different 
compartments of the body. Antibodies have an approximate molecular weight of 
150KD and consist of two heavy chains of 50KD and two light chains of 25KD. The 
light chains can either be κ or λ 154. Each component chain is made up of one 
NH2-terminal variable and a COOH-terminal constant immunoglobulin 
superfamily domain (IgSF). The IgSF domains are made up of two β-pleated 
sheets pinned together by disulfide bridges between two conserved cysteine 
residues. Each of the variable and constant domains consists of 110-130 amino 
acids; the light chains only consist of one constant domain whereas the heavy 
chains can consist of three or four. The variable region is the region in which 
antigen binding is mediated. It contains three complementarity-determining 
regions, which are embedded in framework regions. When folded correctly, all 
three of the complementarity regions are brought together to form the antigen-
binding site 155. The constant regions of the antibody molecule confer the class 
of immunoglobulin and mediate other functions like binding to effector cells and 
participation in the complement cascade. 
IgG is the most common of all the immunoglobulins in the circulation; 75% of 
immunoglobulin in murine and human serum is IgG, and it is a vital component of 
the immune system. This is exemplified in the early days of a foetus, as it and 
IgA are the only isotypes that are transported by the Fc neonatal receptor across 
the placenta and so continues to protect the infant until its own immune system 
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matures. This is partly due to the long half-life in serum of IgG and the 
supplementation via breast milk 156 157. IgG is made up of a number of subclasses 
in humans: these are IgG1, IgG2, IgG3 and IgG4; mice do not have the IgG4 
subclass but instead possess IgG2a and IgG2b 154. The constant region of an 
antibody does not only confer the isotype of the antibody, it also plays an 
integral role in antibody function for binding receptors such as Fc receptors and 
complement proteins. 
1.8.1 Glycosylation of the Fc domain in Immunoglobulin 
Antibodies are glycoproteins, and the glycans that are associated with the Fc 
portion of the immunoglobulin molecule are very important for the antibodies’ 
function. The particular immunoglobulin isotype determines the amount of 
glycosylation; for IgG there is an N-linked glycosylation site on Asparagine 297 on 
each of the CH2 domains 158 159. Variation in glycosylation can be seen between 
IgG molecules - as well as within 3 sites on the same molecule because of 
differences in terminal sialic acid, galactose, N-acetylglucosamine, and 
fucosylation of the core sugars. These differences can lead to as many as 32 
possible glycosylation patterns 160 161. These glycans interact with a hydrophobic 
pocket on the Fc domain that stabilizes the immunoglobulin structure. It has 
been shown by mutagenesis studies that glycosylation is very important in 
allowing IgG to bind to FcγR as, if glycosylation does not occur due to mutations 
in the IgG amino acid sequence, this abrogates bind to FcγR. This is in contrast 
to IgA and IgE who do not lose their ability to bind to FcRs if they are not 
glycosylated 162 163.  
1.8.2 Fc Receptors and their interaction with IgG molecules 
FcγR are a well-characterized part of the Ig superfamily: Ig superfamily 
molecules are characterized by having sequences similar to the variable or 
constant domains of antibodies. FcR are highly conserved through numerous 
species including humans, mice, rats, dogs and monkeys; the genes that encode 
FcR in humans, mice and monkeys are clustered on chromosome 1; rats’ and 
dogs’ FcR genes are located on chromosome 13 and chromosome 38 respectively 
164. FcγR are widely expressed on cells of the immune system; however, the 
exception to this is in T cells, which do not express any FcγR. In humans, there 
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are three types of FcγRs (FcγRI, FcγRII and FcγRIII), however, there are various 
isoforms of each receptor. In mice there are four FcγR (FcγRI, FcγRIIb, FcγRIII 
and FcγRIV). All FcγRs are type I trans-membrane proteins comprising an 
extracellular region containing two or more IgG-like domains and either a 
polypeptide or lipid anchor in the membrane 165. Until a co-crystalline structure 
of the human FcγRIIIA and IgG1 was produced it was uncertain if one IgG 
molecule could bind to two FcγR as the IgG molecule is composed of two 
identical constant heavy chains. Theoretically, one IgG molecule could bind two 
FcγRs and therefore cross-link two receptors 166. However, this seemed unlikely, 
as the biological consequence could be the permanent triggering of unnecessary 
inflammatory cascades. When the co-crystalline structure of IgGI and FcγRIIIA 
was produced, it showed a 1:1 stoichiometry for the IgG and FcγR. It also 
demonstrated that the FcγR interacts with both of the two-polypeptide chains of 
the IgG1 molecule at their lower hinge region. It is now accepted that this is the 
relationship all IgG and FcγR molecules share with each other 167 168. 
1.8.2.1 FcγRI 
FcγRI is the high affinity IgG receptor that only binds monomeric IgG. Murine 
FcγRI has high-binding affinity for IgG2a and lower affinity for IgG2b but does 
not bind IgG1 or IgG3. IgG2a and IgG2b have been shown to be the most pro-
inflammatory IgG isotopes in the murine system. FcγRI contains three 
extracellular immunoglobulin-like domains unlike FcγRII and FcγRIII, which are 
the low affinity receptors and contain two extracellular domains 169. The first 
two extracellular domains of FcγRI have high sequence similarities to the two 
extracellular immunoglobulin-like domains of FcγRII and FcγRIII. This has led to 
the conclusion that the third domain must confer the high affinity binding 
properties. Mutagenic and chimeric studies have shown that the removal of the 
third Fc domain leads to the loss of high affinity binding of monomeric IgG, 
although the mutant FcγRI molecules can still bind IgG with low affinity 169. 
However, if FcγRI’s domain 3 is linked to FcγRII it does not confer high affinity 
binding properties to the low affinity receptor. It has also been proposed that 
the Cγ2 domain of IgG is important for the interaction of FcγRI with IgG in 
particular residues 234-237 of the lower hinge region and residue 331 in the Cγ2 
domain 170. The binding domains for the lower affinity receptors binding sites to 
IgG have been mapped to similar regions.  
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FcγRI is expressed primarily on monocyte, macrophages and dendritic cells. Due 
to its ability to bind monomeric IgG, which is constantly present in serum, the 
FcγRI receptor is always saturated; however, cells are not activated until the 
occupied receptors are cross-linked by multi-valiant antigen ensuring against 
false activation - which can lead to excess inflammation and auto-immunity 171. 
1.8.2.2 FcγRII 
FcγRIIB binds monomeric IgG with very low affinity in comparison to FcγRI. This 
ensures FcγRIIB only binds IgG that has been previously aggregated by a 
multivalent antigen. FcγRIIB only binds immune complexes that contain the IgG 
subclasses IgG1, IgG2a and IgG2b. FcγRIIB is the only negative inhibitory FcγR, 
transmitting a negative signal through an immunoreceptor tyrosine-based 
inhibitory motif (ITIM) 172. The main area of FcγRIIB binding is confined to the 
second extracellular domain of the receptor, specifically residues 154-161, 109-
116 and 130-135. FcγRIIB along with FcγRIII and FcγRIV have been recently 
shown to be the low affinity receptors for IgE, interestingly, FcγRI does not 
share this property and is strictly an IgG receptor, showing no binding potential 
for IgE 173. In the murine system this inhibitory receptor is the only Fc receptor 
found on B cells, it is also found on other cell types too such as monocytes, 
macrophages, neutrophils and mast cells. On B cells, cross-linking of the 
receptor by IgG in complex with antigen sends a negative modulation signal to 
the B cell 174. In the instance of the mouse, there are two forms of the FcγRII 
gene, giving a β1 and β2 transcript. The β1 transcript has an insertion of 46 
amino acids in its cytoplasmic tail, which renders it unable to endocytose 
immune complexes, though it can still transmit a negative activation signal. B 
cells preferentially express the β1 isoform of the receptor - unlike all other cell 
types 172. FcγRIIB has also been shown to be a negative regulator of mast cells 
that can override the activatory signal, received when their high affinity FcεRI is 
triggered by IgE 154. FcγRIIB-/- mice spontaneously develop lupus, which can be 
ameliorated when bone marrow from WT mice is engrafted, showing this 
receptor is vital in maintaining tolerance in mice 175 176. FcγRIIB has also been 
shown to help with the resolution of inflammation in the murine model for 
atherosclerosis (Apoe-/- mice develop atherosclerosis when fed on a high fat 
diet). When mice were double knock outs for FcγRIIB and Apoe they experienced 
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an increase in pro-inflammatory cytokine production, such as IL-17 and IL-23, in 
the aortas which correlated with exacerbated disease progression 177. 
1.8.2.3 FcγRIII 
FcγRIII is another low affinity FcR that only binds IgG when it is in immune 
complexes. FcγRIII binds to the same subclasses of IgG as the inhibitory receptor 
FcγRIIB, IgG1, IgG2a and IgG2b. FcγRIII is the only Fc receptor that is found on 
natural killer cells; it is also expressed on all myeloid cell population in mice 171. 
In vitro experiments have demonstrated that FcγRIII is involved in the process of 
endocytosis and phagocytosis. Murine FcγRIII mediates the fast internalization of 
antigen-antibody complexes, which leads to increased antigen presentation on 
the cell surface. FcγRIII has also been shown to be involved in antibody-
dependent cell-mediated cytotoxicity (ADCC), which is the process where 
immune cells lyses target cells that are opsonised by antibody. Mice that are 
deficient in the common γ chain are unable to mediate ADCC 178. FcγRIII on mast 
cells has been linked with the involvement of the propagation of the murine 
model of auto-antibody mediated arthritis (K/BxN serum transfer model) as 
when mice are deficient in FcγRIII they are protected from disease 179. The 
cause of this protection was later demonstrated to be through mast cells’ 
inability to become activated and produce IL-1 early in the initial phase of 
disease 180. 
1.8.2.4 FcγRIV 
FcγRIV is the newest Fc receptor to be discovered and is the only one that is 
found in mice and not in humans. It is a medium affinity receptor, that interacts 
with IgG2a and IgG2b; it is expressed on neutrophils, macrophages and the 
Ly6Clow monocyte subset 181. IgG2b has been shown to preferentially bind to 
FcγRIV in murine models of idiopathic thrombocytopenia purpura (ITP) and 
nephrotoxicity. In circumstances where FcγRIV was knocked out, mice were 
protected from ITP and nephrotoxicity. IgG2b’s ability to fix complement was 
shown to be very important in the pathogenesis of these disease models 171 182. 
FcγRIV-/- deficient mice and mice that have had cell-specific deletion of FcγRIV 
in their osteoclast population were protected from the K/BxN serum transfer 
arthritis. In the passive serum transfer model of inflammatory arthritis it was 
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shown that Ly6Chi monocytes, when stimulated with RANKL, differentiate into 
mature osteoclasts and simultaneously up-regulation FcγRIV. These cells are 
thought to represent the precursor cell population of osteoclasts in the inflamed 
tissue. Cross-linking of FcγRIV enhanced osteoclast differentiation, 
demonstrating that immune complex binding to osteoclasts via the FcγRIV is 
directly involved in the maturation process under inflammatory circumstances 
183. 
1.8.2.5 FcRn  
The neonatal FcR is the only FcR that has specificity for all IgG isotypes at a pH 
of 6.5 or below. Interestingly, unlike the other Fc receptors, FcRn does not play 
a role in the activation or inhibition of any cell type and its primary function is 
to conserve IgG and protect it from destruction within cells by recycling it back 
out into the circulation 184. This is the reason why IgG has a far longer half-life 
(roughly 28 days) than the other antibody classes. When IgG is non-specifically 
taken up by endothelial and epithelia cells, it is shuttled to acidic lysosomes; if 
IgG binds to the FcRn in the lysosome it will be returned to the surface of the 
cell and back into the circulation. However, if it does not bind, the IgG will be 
degraded. FcRn is unrelated to classical FcRs and binds to a different region in 
the antibody Fc fragment as structurally it is related to the MHC class I molecule 
185.  
1.8.3 Signalling molecules associated with the Fcγ receptors  
The three activatory FcγR in the murine system are FcγRI, FcγRIII and FcγRIV: 
these receptors are not able to signal themselves as they have very short 
cytoplasmic tails. Therefore they must associate with the common γ chain sub-
unit. The common γ chain has a long cytoplasmic tail, which contains an 
immunoreceptor tyrosine-based activation motif (ITAM). ITAMs are motifs that 
are found in the cytoplasmic tails of TCRs and BCRs as well as being associated 
with activatory FcγRs. ITAM motifs are defined by a twice-repeated YxxL 
sequence separated by 6-12 variable residues 186.  
The activation of FcγR is not just down to being bound by its ligand, it also 
requires the cross-linking of multiple Fcγ receptors by the same multi-valiant 
  52 
antigen or immune complex 187. Notably, high and low-affinity FcγR trigger cell 
responses with equal efficiency. The difference between the activation of the 
signaling cascade is based on the order in which FcγR aggregation occurs. The 
high affinity FcγRI receptor is constantly engaged by monomeric immunoglobulin 
prior to aggregation by multivalent antigens, whereas low affinity receptors only 
bind immunoglobulin that has complexed with antigen prior to binding 188. 
Whether the FcγR is high or low affinity the first intracellular event following 
aggregation of FcγR is the phosphorylation of the tyrosine residues in the ITAM 
motifs on the common γ chains. Phosphorylation of ITAMs is correlated with the 
activation of several sets of cytoplasmic protein tyrosine kinases. The first sets 
are the Src family kinases, followed by the recruitment and activation of the Syk 
family kinases. Syk then activates a signaling cascade leading to downstream 
activation of MAP kinases and the transcription factor NF-κB, which are 
important signaling effectors and inducers of gene expression that lead to the 
activation of the cell 189. 
FcγRIIB is the only inhibitory Fcγ receptor, which is present on all immune cells 
except T cells 174. FcγRIIB does not associate with an accessory molecule as it 
can signal through its cytoplasmic tail, whose intra-cytoplasmic domain 
possesses a and ITIM motif that inhibits cell activation 190. This motif contains a 
single YxxL sequence that was designated as an ITIM 191. Engagement of ITIM-
containing receptor FcγRIIB results in Src family kinase–mediated 
phosphorylation of the ITIM’s tyrosine residues and recruitment of inhibitory 
signaling molecules such as the tyrosine phosphatases SHP-1 and SHP-2 and the 
inositol phosphatase SHIP that attenuate ITAM-induced signaling by 
dephosphorylating the tyrosine residues on the ITAMs and thereby inactivating 












Figure 1.2, Fcγ receptors and their associated signalling molecules in the murine system. 
The Fcγ receptor family in mice are made up of three activatory receptors (FcγRI, FcγRIII and 
FcγRIV), which associate with the FcR common γ chain containing two ITAMS that are used by 
the receptor to send an activatory signal to the cell. FcγRIIB is the inhibitory receptor of the Fcγ 
receptor family; unlike the three activatory receptors it does not associate with two FcR common γ 
chain molecules as it contains an ITIM in its cytoplasmic tail, which delivers an inhibitory signal to 
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1.9 Therapies involving IgG as a modulator of 
inflammation 
1.9.1 IVIg’s anti-inflammatory properties and mechanisms 
Since IgG and Fc receptors have been shown to be vital to the initiation and 
resolution of autoimmune/inflammatory-mediated diseases it is not surprising 
that they play a vital role in their treatment. One such treatment that takes 
advantage of this essential regulatory role is IVIg, which is the pooled product of 
highly purified polyclonal IgG from multiple donors. In the 1950s, IVIg was 
initially administered intramuscularly to patients suffering from hypogamma-
globulinemia, particularly those with X-linked agammaglobulinemia, Bruton 
disease and common variable immunodeficiency, as an antibody replacement 
therapy 193. It was noted that the IgG preparation had many beneficial properties 
and was adapted over the next 20 years so it could be given intravenously in the 
early 1980s. A physician named Imbach was treating his patients, who had B cell 
deficiency disorders, with the new preparation of IgG and noticed that it also 
relieved and in some cases resolved the patients’ ITP. ITP is a condition in which 
the sufferer has low platelet levels usually caused by the production of auto-
antibodies, which attack the platelets. Along with this and other discoveries, 
IVIg is now primarily used to treat autoimmune and inflammatory conditions 
rather than as a replacement therapy 147. 
There has been much speculation over the mechanism by which IVIg elicits its 
immuno-modulatory effect, but no unified mechanism has been agreed on how 
to explain IVIg’s effect. Some of the mechanisms that have been proposed are 
discussed in the following paragraphs.  
1.9.1.1 Glycosylation pattern of IVIg as a mode of action 
Recent studies have proposed that the sialyation pattern of the N-linked glycan 
of IgG plays an important role in the mode of action of IVIg’s anti-inflammatory 
properties 163,194. If the terminal sialic acid is removed from IVIg this abrogates 
its anti-inflammatory effects in animal models of serum-induced arthritis, EAE 
and nephrotoxic nephritis. Consistent with this, if the sialyated fraction of IVIg is 
enriched, its anti-inflammatory activity is greatly increased 195.  When this was 
investigated further it was shown that not only is the sialic acid crucial, but a 
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specific type of sialic acid was critical. Sialic acid can be found in either a 2,3 or 
a 2,6-linkage to the final galactose on the complex glycan found at the 
Asparagine 297 position on the IgG molecule. When mass spectrometry was 
performed on IVIg preparations it was discovered there was a preferential 
sialyation pattern of the 2,6-linkage. The importance of this linkage was 
confirmed by treating IVIg with either a 2,3 or 2,6 sialidase. The 2,3 and 2,6 
purified preparations were then used to treat K/BxN, which is a serum-transfer 
arthritis model. This action revealed that when IVIG was treated with the 2,6 
sialidase, which removes all of the 2,6-linked sialic acid, the IVIg anti-
inflammatory effect was abrogated, but it was unaffected with the 2,3 sialidase 
treatment. The authors indicate that the sialiated Fc of IVIg binds to a specific 
receptor, DC-SIGN, inducing the production of IL-33, which leads to the 
expansion of an IL-4-producing basophil population. The IL-4 induces the up-
regulation of the inhibitory FcγRIIb on monocytes and macrophages, increasing 
the threshold level of activation on these pro-inflammatory effector cells 196.  
1.9.1.2 Anti-idiotypic antibodies in IVIg 
Another concept that has been proposed for the mechanism by which IVIg 
mediates its anti-inflammatory effect is the discovery of anti-idiotypes in IVIg. 
Antibodies have been purified from IVIg that had the ability to bind auto-
antibodies against DNA, Factor VIII and thyroglobulin 197. Other studies have 
shown that auto-antibodies to GM1 ganglioside in patients with Guillain-Barre 
can be neutralized by antibodies present in IVIg 198. It has been suggested that 
this may be the mechanism by which IVIg works. Essentially the anti-idiotypes 
bind to auto-antibodies and inhibit their destructive effect on the body. Critics 
of this proposed mechanism say that idiotypic antibodies make up too small a 
proportion of the IVIg for this to be the sole mechanism it mediates its effect 
though 199. This has turned the focus of research from the Fab portion of the IgG 
to the Fc portion and its interaction with Fc receptors on many different cell 
types. 
1.9.1.3 Neonatal Fc receptor saturation by IgG 
Saturation of the neonatal Fc receptors has also been proposed as a potential 
mechanism for IVIg. Neonatal Fc receptors bind serum IgG in the lysosome and 
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protect them from degradation by recycling them back to the plasma 
circulation. This is the reason why IgG has such a long half-life (FcRn is also 
discussed in section 1.8.2.5). It was theorised that IVIg saturates the neonatal Fc 
receptor leading to an increase in the degradation of pathogenic autoantibodies. 
This has been shown in mouse models of arthritis where IVIg has reduced 
pathogenic antibody levels (below disease-causing levels) and this effect is 
ablated in neonatal Fc receptor knock-out mice 200. However, recently it has 
been shown in a murine model of ITP that the neonatal Fc receptor was not 
required or necessary for IVIg to be protective in this setting 201. This result has 
left confusion over the part the neonatal Fc receptor plays in the anti-
inflammatory role exerted by IVIg. 
1.9.1.4 ITAMi induction by IVIg 
ITAMi signalling through FcγRIII might be another mechanism by which IVIg 
works. The classical concept of ITIM and ITAM, where ITIM is the inhibitory 
signalling motif and ITAM is the activatory signalling motif, which has been 
explained in greater detail in section 1.8.3 and figure 1.2, has been challenged 
recently with the concept of ITAMi. In this concept, FcγRIII associates with two 
Fc common γ chains, which contain ITAMs in their cytoplasmic tail. Each 
common γ chain contains two ITAMs each. In general, when the receptor is 
activated, via crosslinking induced by a multivalent antigen in complex with IgG 
molecules, all four of the tyrosines are phosphorylated by Syk (kinase of the Src 
family), which subsequently initiates an activatory signalling cascade. However, 
when the receptor is bound in a low affinity manner with a monovalent ligand 
that does not aggregate the receptor, this leads to hypo-phosphorylation of the 
tyrosine molecules (only 2 phosphorylated) in the Fc common γ chains. This 
results in the transient recruitment of Syk kinase (but the stable recruitment of 
SHP-1), which induces an inhibitory signalling cascade 202.  
An example of this type of signalling has been demonstrated using various FcγR 
knock-out mice in studies of antibody-independent obstructive nephropathy. It 
was shown that IgG1 or IVIg could reduce MARCO-dependent endocytosis, reduce 
production of ROS in macrophages and reduce transcript levels of TNFα and MCP-
1 through an FcγRIII ITAMi-dependent mechanism. Furthermore, when mice 
deficient in SHP-1 were used, the inhibitory effect of IVIg was ablated. This 
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mechanism proposes a very interesting novel pathway, outlining the pleiotropic 
properties of FcγR and IgG as mediators of inflammation and also the crucial 
role they also play in the resolution of inflammation 203. 
1.9.1.5 Modulation of cytokine production by IVIg 
IVIg has been seen to have an effect on adhesion molecules. For example, it 
causes the down regulation of ICAM-1 and VCAM-1 mRNA transcripts in 
endothelial cells in vitro. Endothelial cells were also shown to down-regulate 
their production of a number of pro-inflammatory mediators such as GM-CSF and 
TNFα, IL-1β and IL-6 in response to IVIg; it is of note that the authors do not 
speculate on the mechanism by which this effect is mediated 204. However, if 
this phenotype could be demonstrated in an inflammatory in vivo setting the 
down-regulation of adhesion molecules on endothelial cells would have a 
massive effect on cell infiltration into inflamed tissue. 
IVIg has been shown to induce immature dendritic cells (DC) refractory to LPS 
stimulation, with a significant decrease in the levels of co-stimulatory CD40, 
CD80 and CD86; however there was no effect on MHC II expression. The DCs 
were induced to produce IL-10 but did not produce IL-12 in comparison to LPS 
only-treated counterparts. IVIg did not only change the cytokine and co-
stimulatory profile of these DC, it also rendered autologous cells inactive and 
non-proliferative. The author demonstrated that in this setting both the Fc and 
Fab regions of the IVIg were important for the modulation of DC phenotype 205. 
IVIg has also been shown to drive monocytes and macrophages to an anti-
inflammatory phenotype. When monocytes from human blood were treated in 
the presence of LPS and IVIg, it induced inhibition of IL-1, TNF-α and IFNγ 
release; furthermore, an up-regulation of IL-1 receptor antagonist was also seen. 
Additionally, it has been shown that IVIg makes murine and human macrophages 
refractory to phagocytosis by IFNγ, by down-regulation of the IFNγ receptor 2 
sub-unit 206. 
1.9.1.6 Fcγ blockade or FcγR binding on phagocytes  
Finally, studies have suggested that IVIg exerts its effect via a simple blockade 
of the FcγRs on phagocytes, therefore slowing down their ability to phagocytose 
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opsonized antigen such as platelets in the case of ITP. However, it has been 
demonstrated that in some cases the effects of IVIg are long-lasting after the 
initial treatment, implying that a simple block of receptors is not the mode of 
action. It was demonstrated in a mouse model of ITP, where platelets are coated 
with an anti-platelet antibody, that platelet numbers could only be rescued 
when IVIg was given that had dimers of IgG - and non-dimeric IgG containing IVIg 
showed little effect. It was also demonstrated that FcγRIII played a role in the 
mechanism as no ITP was exhibited when FcγRIII-/- mice were used in the model 
207. There seem to be many modes of action that IVIg can work by, but the 
recurring theme is that Fc receptors play a major role in the mediation. 
1.9.2 The downside of un-optimized IVIg treatment 
As demonstrated by the vast array of potential modes of action of IVIg, it has 
been revealed to be a very non-specific treatment option for the modulation of 
an overt inflammatory immune response. IVIg has also been shown to have side 
effects, which are not only due to the impurities of the perpetration method. 
The most common side effects of IVIg specifically associated with the IgG 
component are headaches, fever, nausea, back pain, cardiovascular 
malfunctions (such as tachycardia) and changes in blood pressure. These mostly 
start within 30-60 minutes of infusion and are generally associated with the 
formation of large aggregates of IgG, which leads to the activation of the 
complement system 208. Another issue with IVIg as a therapeutic, is the use of 
human IgG in rodent models of disease to define its therapeutic abilities. An 
example of this was the use of IVIg treatment in adjuvant arthritis in a rat model 
(an animal model of Rheumatoid Arthritis), which showed amelioration of 
disease but which had little clinical benefit 209,210. This dichotomy could be 
attributed to the non-optimized nature of IVIg treatment. Another potential 
issue with the use of IVIg as a general therapeutic is that the immune complex 
component of the preparation is not of a defined conformation in every 
preparation and though immune complexes have been shown to modulate 
macrophages to an anti-inflammatory phenotype (section 3.1.2.2 and figure 
3.1), immune complexes also have reported roles in the destructive pathogenesis 
of Rheumatoid Arthritis and type II hypersensitivity. 
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1.9.3 Staphylococcal protein A and its immune-modulatory 
effects 
A well-known protein that can harness IgG is SpA (Staphylococcus protein A). It is 
a 42KD bacterial protein, which is a key virulence factor of Staphylococcus 
aureus, a gram-positive bacterium 211. SpA has the ability to bind IgG on B cells 
through the Fab region, but unlike conventional antigens it does not bind using 
the complementarity determining region of the IgG molecule’s Fab portion but 
binds through interactions with the framework region of the variable domain 212. 
This interaction is restricted to VH3-encoded BCR, a subset of B cells that 
accounts for 30-50% of the B cell repertoire of humans 213. However, this is not 
the only mechanism by which SpA can interact with immunoglobulin. The 
“classical” binding interaction is via the Fc portion of the IgG molecule. SpA 
binds a wide variety of IgG subclasses from different species; in the murine 
system it binds IgG2a, IgG2b and IgG1, whereas in the human system SpA binds 
IgG1, IgG2 and IgG4 214. Due to SpA’s IgG binding ability it has been used as a 
tool for the detection and purification of IgG in the past 215. The ability of SpA to 
bind IgG was further exploited when it was used as the active component of a 
discontinued US Food and Drug Administration (FDA)-approved apheresis therapy 
(Prosorba column) for inflammatory and autoimmune diseases, which included 
Rheumatoid Arthritis. It was noted that the prosorba column has the ability to 
remove IgG from 60 litres of plasma which, compared to traditional 
plasmapheresis techniques, was a very small amount. However, the prosorba 
column was used when the traditional apheresis techniques did not work and the 
prosorba column showed long lasting effects after treatments. Interestingly, it 
was discovered that during each treatment, SpA could be proteolytically cleaved 
and enter the patient’s circulation 216. The quantity of SpA entering was 
significantly less than the amount of circulating immunoglobulin, and it had been 
demonstrated that, when immunoglobulin is present in excess, SpA will form 
only one type of immunoglobulin complex with 2 molecules of SpA binding 4 
molecules of IgG (figure 1.3) 217.  
Interestingly, immune complexes have been used for sometime now to induce 
macrophages to an anti-inflammatory phenotype (see section 3.1.2.2 and figure 
3.1); however, the majority of previous studies have depended on the use of rat 
or rabbit IgG to generate immune complexes 218 219. The interaction of rabbit IgG 
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with murine Fc receptors has never been specifically examined, though results 
suggest that rabbit IgG has an order-of-magnitude lower affinity for mouse Fc 
receptors compared to mouse IgG 220 221. As SpA can co-opt endogenous IgG, it 
would therefore be of interest to investigate the effect SpA-IgG complexes have 
on macrophages in an inflammatory setting and to determine how macrophages 
are induced to exhibit anti-inflammatory properties. SpA has another major 
advantage to its use as a potential therapeutic: as well as being able to co-opt 
with endogenous IgG, it also forms specific homogeneous immune complexes, 
unlike IVIg and many other antibodies/protein complexes 222. It is also proposed 
that the small size of the SpA:IgG complex will have other potential benefits 
over complexes which are formed in non-specific ways. Their small size would 
decrease the risk of immune complex mediated pathology (section 1.9.2) and 
may have less likelihood of activating complement, which is an issue with 
standard IVIg treatment. 
SpA is also known for its immune-modulating properties as a B cell super-antigen 
as it induces massive clonal expansion 223  224, which subsequently leads to 
apoptosis of the B cell via an IgG-dependent but complement-independent 
mechanism (unpublished data, Goodyear). SpA treatment was used in a murine 
model of Rheumatoid Arthritis, Collagen-Induced Arthritis (CIA), which showed 
protection from the disease 225(Appendix 2).  This phenotype could not be 
attributed totally to B cell depletion, as murine B cells only have 5-10% of B cells 
with the specific VH3 portion, and may indicate that SpA treatment could have 
an anti-inflammatory effect which is mediated by the formation of immune 












Figure 1.3, SpA bound to IgG through interaction in the constant region. 
When SpA is in the presence of excess IgG, it will form homogeneous complexes. These 
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1.10 Research Aims 
Immune complexes have been used previously to induce macrophages to an anti-
inflammatory phenotype; however, the immune complexes used in previous 
studies were not homogenous in conformation and were not species-specific to 
the model of disease used to show their anti-inflammatory effects. Given that 
SpA can form small immune complexes with IgG of relevant and assay 
complementary species, it is plausible that it can be used to evaluate species-
specific homogenous complexes on macrophage phenotype. 
• Can SpA generated immune complexes polarize macrophages and 
monocytes to an anti-inflammatory phenotype?  
A large volume of research has already been published demonstrating that 
classically activated (pro-inflammatory) macrophage and their precursors, 
monocytes, are detrimental to recovery in SCI. Conversely, it has also been 
noted that macrophages can produce neurotropic and neuro-protective factors 
that contribute to regeneration if they are polarized to an anti-inflammatory 
phenotype. Therefore, it was hypothesized that if macrophages could be 
successfully polarized to an anti-inflammatory phenotype, via immune 
complexes formed with endogenous IgG and SpA, they would contribute to the 
recovery of SCI in a more protective and productive role. 
• Is SpA a potential therapeutic for SCI through its potential ability to 
polarize macrophages and monocytes to an anti-inflammatory phenotype? 
Evaluation of SCI is generally through behavioural testing, however, to date the 
vast majority of research has been on rats. The final aim of this thesis was to 
determine whether in a mouse model of SIC there was an appropriate 
behavioural test that was both sensitive enough to detect subtle changes and 
reliable enough that it could be repeated without large variations within the 
data collected  
• Can a mouse model of SCI and suitable behavioural tests be used to 
demonstrate SpAs potential as a therapeutic for SCI?
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2 Material and Methods 
2.1 Mice 
C57BL/6 mice (7-10 weeks) were purchased from Charles River (Massachusetts, 
USA). µMT, CX3CR1-GFP and OTII mice were bred and maintained at the 
University of Glasgow. FcRγ-/-, FcγRI-/- and FcγRII-/- (C57BL/6 background) 
mice were bred and maintained at the University of Southampton. The Ethical 
Review Process Committee and the UK Home Office approved all experimental 
procedures.  
2.2 Generation of bone marrow-derived macrophages 
(BMDM) 
2.2.1 Isolation of bone marrow cells 
Skin and muscle were cleared from the hind legs of schedule 1, CO2-asphyxiated 
mice. Bone marrow was flushed out by inserting the tip of a 21g needle into the 
marrow space and flushing with 3ml of RPMI 1640 (Gibco, Invitrogen, Paisley, 
UK) from a 5ml syringe (Becton-Dickinson, New Jersey USA). The marrow was 
flushed into a 90mm petri dish (Sterilin, UK) and dissociated by passing up and 
down the syringe multiple times. Cells were subsequently filtered through sterile 
Nitex mesh (Cadisch and Sons, London UK) into a 50ml conical falcon (Corning, 
Massachusetts, USA). The single cell suspension was centrifuged at 450g for 5 
minutes, counted and resuspened at 5x106 cells/ml. 1ml of the single cell 
suspension was seeded into a non-tissue culture-treated 90mm petri dish 
containing 9ml of complete medium (see appendix 1) containing 20% (v/v) 
supernatant from the L929 cell line (refer to 2.2.2 for further information). The 
petri dishes were cultured at 370C in 5% CO2. On day 3 or 4 of culture, 5ml of 
fresh complete media containing 20% (v/v) L929 supernatant was added to the 
petri dishes.  
2.2.2 Generation of L929 supernatant  
L929 cell line is a murine fibrosarcoma cell line that secretes M-CSF (macrophage 
colony stimulating factor) into its supernatant. When the supernatant is used as 
a 20% (v/v) supplemented in bone marrow cell cultures it induces macrophage 
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differentiation after 6- 7 days 226. To generate the supernatant, L929 cells were 
grown to 70% confluence in 10ml of complete media in a T75 flask (Corning, 
Massachusetts, USA). They were then split equally into 5 T150 flasks and 98ml of 
complete media was added to each. The cells were grown to confluence and 
then left a further 3-4 days before the supernatant was removed and centrifuged 
at 450g for 5 minutes. Aliquots were made and frozen at -200C. Upon use, 
aliquots were doubly sterile filtered with 0.2µm minisart filters (Sartorius, 
Epsom Surry, UK). 
2.2.3 Harvesting macrophages  
Differentiated macrophages were harvested on day 6 or 7 of culturing. Culture 
media was removed and 9ml of ice-cold phosphate saline buffer (PBS) (refer to 
appendix 1) was added. Adherent cells were gently disassociated with cell 
scrapers (Corning, Massachusetts, USA) and transferred into 50ml conical tubes. 
Cells were centrifuged at 450g for 5 minutes, counted, and resuspended at the 
desired concentration for flow cytometery or cytokine assays (see sections 2.3) 
in complete medium. Routine purity checks were carried out by staining cells 
with antibodies to CD11b and F4/80 and determining their cellular expression via 
flow cytometery (see section 2.5). 
2.3  Conditioning and activation of BMDM 
Harvested BMDM were resuspended at a final concentration of 5x105/ml in 
complete medium. For flow cytometric analysis, 1x106 cells per well were 
cultured in 6 well tissue culture plates (Costar Corning, Massachusetts, USA) 
along with 100U/ml of IFNγ (Sigma-Aldrich, Missouri, USA) overnight. For 
determination of cytokine secretion via ELISA, 1x105 cells per well were cultured 
in 96 well tissue culture plates (Costar Corning, Massachusetts, USA) overnight at 
370C in 5% CO2.  
The next day, cells were stimulated with 10µl of either media, SpA (Repligen, 
Massachusetts, USA)  (1.56µg/ml), IgG (chrome pure, Jackson ImmunoResearch, 
Philidelphia, USA) (25µg/ml), SpA:IgG complexes (see section 2.3.1) (IgG at 
25µg/ml and SpA at 1.56µg/ml), OVA (Sigma-Aldrich, Missouri, USA), anti-OVA 
antibody (2B scientific, Oxfordshire, UK), or OVA:anti-OVA antibody complex 
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(see section 2.3.1) that had been left to form for an hour at 370C. In addition, 
the wells received either media or LPS (100ng/ml E.coli 0127:B8, Sigma-Aldrich, 
Missouri, USA) and were cultured for 6h at 370C in 5% CO2. After stimulation, 
media was removed and BMDM were dissociated for flow cytometric analysis or 
180µl of supernatants were harvested from the 96 well plates and stored at -
200C until required. 
2.3.1 Complex formation 
SpA immunoglobulin complexes (SIC) were generated by incubating 25µg/ml of 
IgG and 1.56µg/ml of SpA (1:4 molecular weight ratio) for 1h at 37°C, allowing 
them to form a complex containing 2 SpA molecules for every 4 IgG molecules. 
OVA immune complexes (OIC) were formed by the generation of a 10-fold excess 
of anti-OVA antibody to OVA protein. This was left for 30min at room 
temperature and used at 150µg/ml. 
2.4 ELISA 
To determine the levels of IL-10 (BD pharmingen, New Jersey USA) and IL-12p40 
(ebioscience, California, USA), ELISAs were performed as per the manufacturers 
instructions. In brief, 96 well half-area plates (Costar Corning, Massachusetts, 
USA) were coated overnight at 40C with anti-IL-10 or anti-IL-12 capture antibody. 
The plate was washed 3 times with PBS/0.05% Tween (v/v) (Sigma-Aldrich, 
Missouri, USA), blocked with 150µl of PBS/10% FCS (v/v) for 1h at room 
temperature and then washed a further 3 times. 50µl of supernatant was added 
per well, either neat or diluted as required. The standards were serially diluted 
1:2 and applied at 50µl per well. The top standard for IL-10 was used at 2µg/ml 
and IL-12p40 at 300pg/ml. After 2h incubation at room temperature, the plates 
were washed 5 times before 50µl of biotinylated detection antibody and 
streptavidin-HRP were added for 1h at room temperature. After a final 7 
washes, 50µl of tetramethylbenzidine (TMB) substrate was added per well and 
left to develop. Stop solution (3M sulphuric acid) was added to the plate, which 
was then read using a MRX II micro plate reader (Dynex, Virginia, USA) at 450nm 
wavelength. 
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2.5 Flow cytometry 
Cells were pre-incubated with or without Fc Block (BD pharmingen, New Jersey, 
USA) or rat serum for 20 minutes in the dark at 40C to block any non-specific 
antibody binding. Cells were stained with specific antibodies or isotype controls 
for 20 minutes in the dark at 40C (see appendix 1 for a list of antibodies and 
isotypes used). Cells were washed with 400µl of FACS buffer (please refer to 
appendix 1) and resuspended in 300µl of FACS buffer. Cells were filtered through 
nitex mesh to remove cellular aggregates. DAPI (Sigma-Aldrich, Missouri, USA) 
was added at a 1:10000 dilution to cells immediately prior to acquisition to allow 
for dead cell exclusion. Data were acquired on a FACSCalibur, LSRII, FACSAia cell 
sorter (Becton-Dickinson, New Jersey, USA) or MACSQuant (Miltenyi, Bergisch 
Gladback, Germany) and analysed using FlowJo software (Treestar Inc, Oregon, 
USA). 
2.6 T cell activation assay 
2.6.1 Pulsing of BMDM 
BMDM were harvested from petri dishes on day 6, resuspended at 1x106 cells in 
2ml of complete media and aliquoted into wells of a 6 well tissue culture plate. 
Cells were treated with various conditions (as described in section 2.3) for 6h. 
Three hours into the incubation, BMDM were pulsed with 10µg/ml OVA 323-339 
peptide (Sigma-Aldrich, Missouri, USA). After the total 6h incubation, BMDM 
were dissociated and transferred to 15ml conical tubes (Corning, Massachusetts, 
USA) before being centrifuged at 450g for 5 minutes. To remove any residual 
peptide, pelleted cells were resuspended in fresh complete media and 
centrifuged as described. This washing step was repeated once. Cells were 
finally resuspended in complete media and transferred back to fresh 6 well 
plates. 
2.6.2 Isolation of CD4+ T cells 
OTII mice, which have a transgenic TcR for the OVA 323-339 peptide, were killed 
by schedule 1 CO2 asphyxiation and spleen and lymph nodes were removed. The 
tissues were dissociated and pooled to make a single cell suspension. In brief, 
tissue was passed through a 70µm nitex cell strainer (BD falcon, New Jersey, 
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USA) into 2ml of media. The single cell suspension was transferred to a 15ml 
conical tube and centrifuged at 450g for 5 minutes. Cell pellets were 
resuspended in 1ml of Ammonium-Chloride-Potassium (Ack) lysis buffer (Gibco, 
Invitrogen, Paisley, UK) for 1 minute to lyse red blood cells. Cells were then 
washed with 10ml of complete media to remove residual lysis buffer, counted 
and resuspended at a final concentration of 1x107/ml in complete media. 
An Easy-Sep (Stemcell technologies, Grenoble, France) mouse CD4+ T cell 
enrichment kit was used to isolate CD4+ T cells from the single cell suspension 
according to the manufacturer instructions. In brief, cells were resuspended as 
stated above at 1x107/ml in separation media (refer to appendix 1) and 
transferred into a 5ml polystyrene (BD Falcon, New Jersey, USA) tube. 50µl/ml 
of CD4+ T cell enrichment cocktail was added to the cell suspension and 
incubated at 40C for 15 minutes. Biotin selection (100µl/ml) was subsequently 
added and incubated at 40C for a further 15 minutes. After this incubation the 
magnetic nanoparticles were added (50µl/ml) and incubated for a further 15 
minutes at 40C. The cell suspension was increased to a final volume of 2.5ml 
with separation media without rat serum. The 5ml tube containing the cells was 
placed into a kit-specific magnet (Stemcell technologies, Grenoble, France) 
minus the cap for 5 minutes. To obtain the enriched T cells the magnet and tube 
were inverted in one swift motion so that the enriched T cells were poured into 
a fresh 5ml polystyrene tube. The magnetically labelled, unwanted cells 
remained in the tube contained within the magnet. Unlabelled T cells were then 
counted and resuspended at 1x106/ml in complete media. 
2.6.3 Culturing BMDM and T cells 
T cells were added at a 1:1 ratio with macrophages for 18h. After incubation, 
macrophages and T cells were removed from the 6 well tissue culture plates and 
transferred to 5ml polypropylene FACS tubes where they were stained as 
previously described in section 2.5. Macrophages were distinguished with the use 
of CD11b and F4/80 antibodies and T cells with an anti-CD4 antibody. Activation 
of T cells was assessed with CD25 and CD69 surface expression, whereas surface 
expression of MHC II was indicative of macrophage activation.   
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2.7 SpA labelling and binding assays 
2.7.1 Labelling SpA and OVA with Alexa-488  
To visualise the binding of SpA to cells both in vitro and in vivo, SpA was 
labelled using an Alexa-488 kit (Invitrogen, Paisley, UK) and OVA was used as a 
control protein. Labelling was carried out in accordance with manufacturer’s 
instructions. In brief, this involved taking 2mg of recombinant SpA or OVA and 
adding 50µl of sodium bicarbonate (1M, pH 9) to the provided Alexa-488 vial, 
which was left to stir for 1h to allow chemical conjugation to Alexa488-N-
hydroxyl succimide. A column was used to exclude non-conjugated dye and non-
labelled protein from labelled protein using Bio-Rad BioGel P-30 fine exclusion 
purification resin. The resin is contained in PBS with 2mM sodium azide. Labelled 
protein runs quicker through the resin and is collected at the bottom of the 
column in a vial leaving the unlabelled protein and excess dye in the column 
matrix. The labelled protein was analysed on a nano drop (Thermo scientific, 
Massachusetts, USA) to examine protein concentration at wavelength of 280nm 
and the fluoresce intensity of the conjugation at 494nm. The labelling efficiency 
was determined using the following calculation-  
Moles dye per mole protein = A494 / 71,00 x protein concentration (M) 
(Where 71,000cm-1M-1 is the molar extinction coefficient of the Alexa-488 dye at 
494nm)                        
2.7.2 In vitro binding of SpA-488 
BMDM were dissociated from petri dishes as described in section 2.2.3 on day 7 
and 1X106 cells were transferred to 5ml polypropylene FACS tube. Complexes 
were formed as stated previously in section 2.3.1 with the substitution of non-
labelled SpA or OVA for Alexa-488 labelled protein. BMDM were incubated with 
complexes for 30mins at 40C. Cells were washed in 400µl of FACS buffer before 
5% (v/v) of rat serum was added to block non-specific binding. Cells were 
stained with anti-CD11b and anti-F4/80 fluorochrome-labelled antibodies for 
30mins at 40C. Further to this cells were washed for the penultimate time in 
400µl of FACS buffer and resuspended in 300µl of FACS buffer after the wash 
step. Tubes were analysed by flow cytometery.  
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2.7.3 In vivo binding of SpA-488 in C57BL/6 
C57BL/6 mice that had or had not received SCI (described in section 2.10) were 
injected intraperitoneally with labelled protein (500µg) and 2h later blood, bone 
marrow (BM), spinal cord and spleen were harvested.  
2.7.3.1 Isolation of blood, spleen, BM and spinal cord.  
Mice that had or had not received SCI were euthanised using asphyxiation with 
CO2. Cardiac puncture was then immediately performed with a 1ml syringe and 
21g needle that had been flushed with 5mM EDTA, to prevent the blood clotting.  
Spleens were removed and transferred to a 35mm petri dish containing 1ml of 
complete medium. Cells were dissociated from the tissue by disrupting the 
spleen with the blunt end of a 5ml syringe plunger through nitex.  
Bone marrow was extracted as previously described in section 2.2.1. In brief, fur 
was cleared from hind legs and bones were cut off at the hip joint before being 
placed in 1ml of complete media in a 35mm petri dish. Cells were dissociated 
from the bones using hydrostatic pressure.  
For the spinal cord, a scalpel was used to make an incision between the ears of 
the mouse to half way down the back. The muscle layer was bluntly dissected so 
the vertebral column was visible. The spinal column between segments cervical 
4 (C4) and thoracic 2 (T2), which contained the damaged portion of the spinal 
cord, between C5-C6 and a corresponding undamaged portion of spinal cord from 
uninjured mice, were cut free and hydrostatic pressure was applied to release 
the spinal cord from the column.  
2.7.3.2 Preparing freshly isolated cells for FACS analysis  
As described previously (Section 2.7.3.1), cells were isolated from spleen and 
bone marrow and red blood cell lysis were performed (1ml of ACK lysis buffer 
per sample for 1 minute at room temperature). Red cell lysis was also carried 
out on blood samples using a 1:10 dilution of blood to ammonium chloride 
solution (Stemcell technologies, Grenoble, France). Blood samples were left on 
ice for 20 minutes and vortexed every few minutes throughout the incubation.  
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Freshly lysed cells were subsequently washed twice with 10ml of complete 
media before being resuspended in FACS buffer at 20x106/ml. 50µl of cells were 
transferred to each 5ml polypropylene FACS tube.  
The spinal cord was passed though a 25g needle and then a 21g needle to 
macerate the tissue into smaller sections. The solution was then centrifuged at 
450g for 5 minutes and excess liquid was removed carefully. The tissue was 
resuspended in a 1ml solution of DNase (1mg/ml) and Collagenase D (1mg/ml) 
(Roche, Bavaria, Germany). Tissue was left to digest for 30mins at 370C. After 
the incubation, cells were washed twice in complete media and all cells were 
transferred into 5ml polypropylene FACS tubes.  
All cells were then FACS stained as described in section 2.5. 
2.7.4 In vivo binding of SpA in µMT mice 
As	  μMT mice lack functional B cells and have no endogenous IgG, mice were 
preconditioned with intravenous injections of either PBS or 6mg of mouse IgG 
(Europa, Cambridge, UK) in PBS. This was followed by an intraperitoneal 
injection of 300-500μg of labelled protein (Section 2.7.1). 2h later, the blood 
and spleens were harvested after the mice had been asphyxiated with CO2 and 
cells were prepared as stated in the above sections.  
2.8 SpA treatment in vivo 
600µg of SpA or OVA was administered intraperitoneally to mice 24h after they 
received SCI. SpA or OVA was also administered to uninjured mice in the same 
manner. 24h later, mice were asphyxiated with CO2 and blood, bone marrow and 
spinal cord was harvested as detailed in section 2.8.3.1/2. Cells were stained 
and flow cytometric analysis was performed as described in section 2.5. 
2.9 Adoptive transfer of Ly6Chi monocytes 
2.9.1 Isolation of GFP+ Ly6Chi monocytes from BM 
Twenty CX3CR1-GFP+ mice were euthanised by CO2 asphyxiation. Bone marrow 
was recovered from the hind legs of the mice as described in section 2.8.3.1 and 
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2.8.3.2. In brief, the fur and muscle was cleared from the hind legs, which were 
then removed from the torso by cutting the femur at the hip joint. Paws were 
also removed by cutting the tibia at the ankle joint. Bone marrow was flushed 
out by hydrostatic pressure. Cells isolated from the bone marrow were then 
subjected to passage through 70µm cell strainers into 50ml conical tubes and red 
cells were lysed with ACK buffer. Cells were then washed and resuspended at 
10x106/50µl for FACS staining, whereby the cells were incubated for 20min at 
40C with Fc block, CD11b, CD117, Ly6C and Ly6G. Cells were washed in 25ml of 
FACS buffer and centrifuged at 400g for 5 minutes before being resuspended at a 
concentration of 10x106/ml and transferred to 5ml polypropylene tubes. Cells 
were passed through 70µm nitex cell strainers immediately before being loaded 
onto a Flow cytometric cell sorter (FACSAria). CD11b+, CD117-, Ly6G-, Ly6Chi 
cells were sorted into 15ml conical tubes, which had previously been filled a 
third full with complete medium. Once cell sorting was finished, the proportion 
of dead cells in the sorted population was tested using DAPI.  
2.9.2 Adoptive transfer of Ly6Chi cells in C57BL/6 mice 
Cells were washed with PBS at 400g for 5 minutes and resuspended at a 
concentration of 1.5X106/200µl. Ly6Chi cells were then injected intravenously 
into the tail vein of male C57BL/6 mice. Along with the cells, mice were given 
intraperitoneal injections of 600µg SpA or OVA. After 22h, mice were schedule 1 
killed by asphyxiation and blood, spleen and bone marrow were removed, as 
described in section 2.8.3.1. Cells were prepared for FACS as described in 
section 2.8.3.2 with one modification; instead of 2x106 cells per FACS tube for 
spleen and bone marrow, 10x106 cells were used per tube. Total cell counts of 
live leukocytes were acquired using the MACSQuant as a cell counter and cells 
were analysed on the LSR II.   
2.10 SCI model 
 Mice were treated with Buprenorphine (Baxter Healthcare, Berkshire, UK) 
(vetergesic 0.05mg/kg) for pain relief via subcutaneous injection. Mice were 
anesthetised with Isoflurane (Baxter Healthcare, Berkshire, UK) before hair was 
removed, via shaving, from the area above the C2 to T2 vertebrae. The animals 
were placed in a restraining device and anaesthesia was supplied through a mask 
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that was secured over the animals’ mouth and nose throughout the surgery. The 
skin was disinfected with ethanol and an incision was made at the shaved area. 
The layers of muscle overlying the vertebral column were bluntly dissected. A 
dorsal laminectomy was performed above the C5 and C6 vertebrae. Contusion 
injuries were induced using the Infinite Horizons (IH) Impactor (Precision 
Systems & Instrumentation, Ohio, USA). The impactor tip, the diameter of which 
was 1.25mm, was centered over the exposed C5 C6 border of the spinal cord and 
a measured force (50, 80, 100 or 120 Kilodynes (Kdyn)) was delivered. The 
wound was closed in layers, muscle was sutured together with 3-0 vicryl 
(Ethicon, New Jersey, USA) and skin was closed using skin clips. Mice were 
moved to heated recovery boxes and their bladders were palpated 3 times a day 
for the first 24h or 48h depending on the survival term.  
2.11 Basso Mouse Scale (BMS).  
BMS is an adaptation of the Basso, Beattie, Bresnahan locomotor rating scale 
(BBB), which quantifies recovery of hind limb function after SCI in rats. One 
week prior to surgery, mice were acclimatised to the equipment used for the 
BMS, which is a large circular pen 1m in diameter. Baseline data were recorded 
at the end of this week. Mice were individually placed into the pen for 4 minutes 
and the mouse’s hind limbs were observed by two people and scored according 
to categories outlined in table 5.1. Mice were in recovery for one week post-
surgery prior to being retested. Testing continued for a total of 6 weeks post-
injury. 
2.12 DigiGait – measurement of gait change after SCI  
In order to quantify changes in the mouse gait after SCI, commercial equipment 
(DigiGait) was used. DigiGait (Mouse Specifics Inc, Massachusetts, USA) apparatus 
consists of a digital camera placed under a clear plastic belted treadmill. Mice 
were acclimatised for 1 week prior to acquiring baseline data. Baseline data, 
prior to SCI surgery, were acquired for three 4 second runs at two speeds; 15 and 
20 meters/second. Mice received injuries of 50Kdyn, 80Kdyn, 100Kdyn and 
120Kdyn severity. Data for week 1 post injury were gathered in the same way as 
baseline data and collection continued for a further 6 weeks post operation. 
Data were analyzed using the Digigait system software, which plots the 
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footprints of the mice and gives a readout of over 20 different parameters of the 
mouse’s gait (refer to table 5.2). 
2.13 Grip strength 
In order to assess the changes in forelimb function in mice after SCI, the grip 
strength test was employed. This consists of a force meter (Andilog, Vitrolles, 
France) with a protruding bar for the mice to grasp onto while they are being 
pulled back. Mice were allowed to adjust to the force meter for a week prior to 
surgery. At the end of this week baseline data were taken, which consists of 
allowing the mouse to grab the bar and then pulling the mouse back by its tail 
until it releases the bar and a value will be registered on the force meter. This 
was done three times per session with each mouse. Mice received either 80Kdyn, 
100Kdyn or no injury. One week post-surgery data were collected as described 
for the acquisition of baseline data. Data were collected once per week from the 
animals for 6 weeks post-surgery.  
2.14 Tract tracing of the cortico spinal tract 
The scalp was incised and a small window drilled into the skull over the left 
sensorimotor cortex. Using the bregma as an anatomical reference point, 
injections of Biotinylated Dextran Amine (BDA) (Invitrogen, 20% solution in 0.3% 
(w/v) triton-x-100 in 0.1M Phosphate Buffer, pH 7.4) were made at four sites. 
Approximately 300 - 400 µl of BDA was delivered at each location using pressure 
injection through a fine glass pipette (tip diameter 30 - 40 µm). Injections were 
made at depths of between 0.5 mm and 1 mm from the surface along each 
injection track. The pipettes were left at the top of each injection track for 1 - 
2 minutes before removal from the cortex. The scalp incision was sutured closed 
with 3-0 vicryl and the mice were allowed to recover for 14 days. 
2.14.1 Perfusion of mice 
Mice were transcardially perfused with freshly depolymerised 4% (w/v) 
paraformaldehyde solution in 0.1M phosphate buffer, pH 7.4, using the following 
method. Each animal was first deeply anaesthetised with intraperitoneal sodium 
pentobarbital solution (0.15ml of 200mg/ml Euthatal, Vericore Ltd, New York, 
USA). Animals were then fixed onto a corkboard with pins through each paw 
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while in a supine position. The thoracic cavity was opened with scissors, a 25G 
needle inserted into the left ventricle and the right atrium opened. 
Approximately 10ml of mammalian Ringer's solution was gravity-fed through the 
25G needle followed by 25ml of 4% (w/v) paraformaldehyde fixative solution. 
2.14.2 Tissue processing  
Immediately after perfusion, a block of cervical spinal cord containing the injury 
site was removed and post-fixed overnight in sucrose-fix (see appendix 1 buffers 
and solutions) before being stored at 40C in sucrose-buffer (see appendix 1 
buffers and solutions). The blocks were subsequently cut into 70µm sagittal 
sections on a freezing microtome, incubated for 30min in 50% ethanol and 
washed for 10min in 0.3 M PBS. Sections were then incubated for 72h in 
Streptavidin-488 and primary antibodies to NF200 and GFAP (see appendix 1). 
Sections were subsequently incubated for 3-4h in fluorophore-conjugated 
species-specific donkey IgG secondary antibodies (see appendix 1), then washed 
for 10 min in 0.3ml PBS. All antibodies were diluted in PBS with 0.3 % (w/v) 
triton X-100. Sections were mounted in Vectashield (Vector Labs, California, 
USA) and stored at -20oC. Slides were then imaged at a later date. 
2.14.3 Microscopy  
Sections were initially examined at low power under the epi-fluorescence 
microscope (Nikon Eclipse E600). Selected sections were further looked at by 
serially scanning the tissue at 2 µm intervals using a Bio-Rad Radiance 2100 
confocal system (Spectra-Physics, California, USA). Z-series’ of these confocal 
image stacks were put together using ImageJ software (Rasband) and projections 
of multiple fields of view were pulled together into single images using Adobe 
Photoshop CS3 (Adobe Systems, California, USA). Images selected for use were 
processed with minor changes in brightness and contrast for presentation. 
2.15 Statistical analysis 
Prism (GraphPad software, California, USA) was used for all statistical analyses. 
T-test was performed when comparing two sets of normally distributed data. 
One-way ANOVA was employed when comparisons of more than two groups of 
data were required. Two-way ANOVA with repeated measure was performed 
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when tracking multiple groups of animals though various time points. Post hoc 
Bonferroni test was used to test for significance in with groups after the use of 
one or two-way ANOVA’s. The specific statistical test for each experiment will 
be identified in the figure legend. 
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3 The ability of SIC to polarize macrophages to an 
anti-inflammatory phenotype via CD64  
3.1 Introduction 
It was Ilya Ilyich Metchnikov who first defined macrophages over a century ago, 
pioneering work which was to win him a Noble prize in ‘Physiology and 
Medicine’ in 1908 227.  
Macrophages, in the murine system, can be detected at embryonic day 9. These 
cells have their origins within the foetal yolk sac and are precursors for the long-
lived tissue-resident macrophages of the skin, brain and kidneys. Interestingly, it 
is not until embryonic day 16 that macrophages originating from haematopoietic 
stem cells (HSC) of the foetal liver can be detected. These macrophages are 
constantly replaced throughout life by blood monocytes that have previously 
differentiated from the HSC in the bone marrow 38.  
3.1.1 Classical macrophage activation 
Macrophages are an integral cog in the finely tuned machine that is the immune 
system. They are at the forefront of innate immune defence and are 
gatekeepers to the adaptive immune system. Deficiencies in human macrophage 
functioning lead to conditions such as chronic granulomatous disease (CGD) and 
leukocyte adhesion deficiency (LAD), which are caused by a deficiency in mac-1 
228,229. Macrophage deficiencies can also lead to high susceptibility to Neisseria 
meningitides and Salmonella infections. This gives us a small insight into the 
essential role macrophages play in host defence. Macrophages are equipped with 
a variety of receptors to sense invaders; these include Toll-like receptors (TLR), 
Nod-like receptors (NLR), many scavenger receptors such as CD206 (mannose 
receptor), MARCO and Dectin-1 230.  
Classically activated macrophages (also referred to as M1 macrophages) are 
some of the first cell types, after neutrophils, to become activated at the site of 
pathogen invasion. Classical macrophages adapt well to this role as they are 
highly phagocytic and produce large volumes of pro-inflammatory cytokines. 
Thus these cells are highly specialised at containing and fighting the pathogen at 
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the primary site of infection. Other immune cells are also attracted into the 
battle site by the inflammatory milieu macrophages create. An example of how 
macrophages become activated in a classical inflammatory manner, via one of 
their most highly studied and utilised receptors in both in vivo and in vitro 
laboratory settings, is the interaction of TLR4 with lipopolysaccharide (LPS) 231, a 
gram-negative bacterial product. This interaction activates macrophages to a 
pro-inflammatory “classical” activation state via a MyD88-dependent signalling 
pathway in conjunction with IFNγ 232. The induction of the MyD88 signalling 
pathway induces a cascade of pro-inflammatory transcripts such as IL-1β, IL-6, 
IL-12 and TNFα 233. When macrophages become activated in this setting they not 
only produce pro-inflammatory cytokines but they also become highly phagocytic 
to eliminate the invading pathogen and produce reactive oxygen species and 
nitric oxide 234.  
Both innate and adaptive immune cells can produce the essential IFNγ signal 
that is required for macrophage polarization to a classical phenotype. Natural 
killer cells are an important, innate, early source of this cytokine, as natural 
killer cells respond to stress and infections by producing IFNγ 235. However, the 
IFNγ produced initially by the natural killer cells is usually only transient. 
Consequently, an adaptive immune response is usually necessary to maintain 
classically-activated macrophages and confer stable host defense. Th1 cells can 
produce IFNγ, which has been demonstrated to require IL-12 production from 
classically-activated macrophages leading to a positive feedback loop as IFNγ 
then stimulates additional macrophage activation 236. 
3.1.1.1 Macrophages as antigen presenting cells (APCs) 
An essential function of the classically activated macrophages, shared only with 
DC and B cells, is their ability to present antigen to CD4+ T cells. When 
macrophages become activated in a classical manner in the presence of IFNγ, 
they increase their phagocytic activity and up-regulate their MHC II expression. 
This is done in conjunction with an increased expression of co-stimulatory 
molecules; CD40, CD80 and CD86 237. The MHC II complex presents antigen from 
the extracellular microenvironment to the antigen’s cognate T cell. The upsurge 
in phagocytic activity by classically activated macrophages allows an 
intensification of the take up of an invading pathogen into its endosomes. Once 
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the pathogen has been secured in an endosome, the endosome moves further 
into the cell, becoming increasingly acidic as it approaches the cell’s interior. 
The endosomes then fuse with lysosomes, which contain proteinases that 
become activated at low pH and in turn degrade the antigen in the lysosome. 
Pre-formed MHC II molecules are exported from the endoplasmic reticulum in a 
vesicle where an invariant chain occupies their binding sites. The vesicles bind 
and fuse with the low pH lysosome containing the degraded pathogen. The 
invariant chain is degraded by proteases in the lysosome and peptide can then 
bind to the MHC II molecule. The complex is then trafficked to the cell surface 
238 239. 
The up-regulation of MHC II loaded with pathogen-derived peptides on 
macrophages can lead to the initiation of the adaptive immune response in 
secondary lymphoid tissue, though this is very rare and usually the job of a DC. 
Therefore, it is more likely that macrophages contribute to the continual 
priming of an already initiated humoral immune response in the tissue by re-
stimulating T cells with their cognate antigen. This induces the clonal expansion 
of Ag-specific T cells that recognise the invading pathogen - which leads to 
stimulation of B cells (by these T cells) inducing antibody production and class-
switching.  
3.1.2 The broad category of regulatory macrophage 
In steady-state, tissue macrophages have intrinsic anti-inflammatory functions; 
for example, colonic macrophages spend their life languishing in IL-10 and 
extinguish any inflammatory response to the gut flora and their products. 
Therefore, disruption to the normal sources or quantities of IL-10 or IL-10 
signaling in immune cells leads to massive inflammation in the gut 240. Another 
example of how macrophages in homeostasis exhibit anti-inflammatory functions 
is in the marginal sinus of the spleen, where macrophages interact with 
apoptotic cells and consequently contribute to decreased self-reactivity within 
the T and B cell repertoire. In support of this, depletion of marginal zone 
macrophages leads to the formation of DNA-specific antibodies and a systemic 
lupus erythematous-like auto-immune syndrome in mice 241. 
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It should also be appreciated that, even in an activated state, macrophages can 
have anti-inflammatory functions. Macrophage activation has been described as 
a spectrum of functionally diverse phenotypes. The functional extremes of the 
spectrum are the “regulatory” anti-inflammatory macrophages (also referred to 
as M2 macrophages in some literature) and the “classical” pro-inflammatory 
activated macrophages 76, described in section 3.1.1. The regulatory 
macrophage phenotype is characterized by increased production of the immune-
suppressive cytokine IL-10 and decreased production of the pro-inflammatory 
cytokine IL-12. The regulatory macrophage category can be sub-divided into two 
further broad categories, wound-healing/alternative (also referred to as M2a) or 
anti-inflammatory (also referred to as M2b) macrophages 78. The pliability of 
macrophage activation allows them to contribute to both inflammation and the 
resolution of inflammation over the course of the same immune response (figure 
3.1) 74, and the phenotype that the macrophage adopts is dependent in the 
manner of its activation 75.   
3.1.2.1 Wound-healing/alternative macrophages 
In contrast to pro-inflammatory macrophage responses, macrophages, as 
mentioned above, can also exhibit potent anti-inflammatory activity and hold 
important roles in wound-healing and fibrosis. Macrophages that exhibit this 
wound-healing phenotype antagonize the established pro-inflammatory 
macrophage responses, and this is crucial for the activation of the wound-
healing cascade (and also for tissue homeostasis to be restored). Recent studies 
have shown that pro-inflammatory macrophages can ‘transform’ into regulatory 
macrophages that have wound-healing phenotype 62. 
Macrophages are polarized to the wound-healing phenotype after IL-4 and IL-13 
stimulation. When tissue damage is incurred, one of the most significant soluble 
mediators produced is IL-4, which can be secreted by mast cells, neutrophils and 
basophils after injury 242. When macrophages are exposed to IL-4 after tissue 
injury they are induced to produce extracellular matrix proteins such as 
fibronectin 243. Wound-healing macrophages also up-regulate the production of 
arginase, which allows the conversion of arginine to ornithine, a precursor of 
polyamines and collagen. The production of these extracellular matrix proteins 
allows the macrophage to play a major role in the repair of damaged tissue 244.  
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Wound-healing macrophages also produce growth factors that stimulate 
epithelial cells and fibroblasts, including TGFβ and platelet-derived growth 
factor. TGFβ produced by the wound-healing macrophages contributes to tissue 
regeneration and wound repair by promoting fibroblast differentiation into 
myofibroblasts. This is done by enhancing expression of tissue inhibitors of 
metalloproteinase that block the degradation of extracellular matrix, and by 
directly stimulating the synthesis of interstitial fibrillar collagens in 
myofibroblasts 245 246.  Wound-healing macrophages can also be induced as a 
consequence of helminths and parasite infections, as Th2 cells produce copious 
amounts of IL-4 and IL-13 75. IL-33 is another cytokine that is produced in a Th2-
driven immune response and leads to an expansion of IL-13 induced wound-
healing alveolar macrophages. The expansion of these alveolar macrophages is 
not always beneficial to the host as they can contribute to airway inflammation 
and have detrimental effects if expansion is not tightly regulated 247. IL-33 is not 
the only other Th2 cytokine linked with the alternative-activated macrophage; 
IL-21 can also play a role in polarizing and expanding Kupper cells, which are 
macrophages of the liver, to the alternatively activated/wound-healing 
phenotype and has also been linked to the cause of liver fibrosis after clearance 
of pathogens in this organ 248. Markers that are specifically used to identify the 
wound-healing macrophages subset are CD206 (mannose receptor), transcription 
factor FIZZ1 and the chitinase family protein Ym1 249 250.  
3.1.2.2 Anti-inflammatory macrophage  
As mentioned earlier, the other category of regulatory macrophage that is often 
referred to in literature is the anti-inflammatory macrophage. Anti-inflammatory 
macrophages can arise during the later stages of adaptive immune responses and 
the primary role of these cells seems to be to dampen the immune response and 
limit additional cellular and tissue damage due to aberrant inflammation. There 
are many different ways in which regulatory macrophages are generated, but a 
single molecular mechanism that mediates this phenotypic switch has yet to be 
identified.  
Phagocytosis of apoptotic bodies in the presence of pro-inflammatory stimuli can 
induce macrophages to an anti-inflammatory phenotype by the induction of 
TGFβ and prostaglandin E2. These can both function in an autocrine and a 
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paracrine mechanism to inhibit the production of pro-inflammatory cytokines 
such as IL-1β 251. Macrophages can be polarized to an anti-inflammatory 
phenotype, high IL-10 and low IL-12 production, via an immune complex-
mediated FcγR-dependent mechanism when given in conjunction with 
inflammatory stimuli such as LPS 252 222. Anti-inflammatory macrophages that 
have been induced via immune complexes have been shown to reduce 
inflammation and disease progression in an in vivo murine model of multiple 
sclerosis and in experimental autoimmune encephalomyelitis (EAE). In this 
setting, the administration of macrophages that have been stimulated with 
immune complexes in the presence of IFNγ and LPS can protect mice from 
disease 253. Another physiological mechanism for generating anti-inflammatory 
macrophages is with the treatment of glucocorticoids. These are produced by 
the hypothalamic-pituitary-adrenal (HPA) axis, as a response to stress-induced 
inflammation and can inhibit the transcription of pro-inflammatory cytokine 
genes such as IL-12, IFNγ and TNFα in macrophages after exposure 254. A few 
other stimuli that have been noted to induce anti-inflammatory macrophages are 
adenosine, dopamine, histamine and vasoactive intestinal peptide 255 256 257. 
Each mechanism for generating an anti-inflammatory macrophage has a slightly 
different phenotype, but all possess a common mechanism of polarization, such 
that they must be activated in a two-signal process with one signal being non-
inflammatory and the other being an inflammatory signal. When these signals 
are combined they induce the macrophage to produce high levels of IL-10 and/or 
TGFβ. This can set up a positive feedback loop as anti-inflammatory 
macrophages can be induced by exposure to IL-10 when in the presence of an 
inflammatory stimuli. And in so doing, IL-10 exposure has the ability to stop the 
induction of pro-inflammatory cytokines such as IL-1α, IL-6, IL-8 and TNFα, as 
well as down-regulating MHC II expression on the macrophages’ surface -  
compared to macrophages that received LPS and IFNγ without IL-10 258.  IL-10 
and TGFβ have also been shown to be an essential mechanism for the generation 
of inducible Tregs that are generated in the tissue (and not the thymus) 259, 
which help to resolve inflammation.  
In conjunction with the up-regulation of anti-inflammatory cytokines, anti-
inflammatory macrophages have been recognised to reduce production of IL-12. 
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This phenotype is the most reliable way of characterising a macrophage as an 
anti-inflammatory phenotype 234. Some anti-inflammatory macrophages still 
possess the ability to produce some other pro-inflammatory cytokines such as IL-
6. Interestingly, IL-6 has a dual role in the CNS where it can also play a 
protective role in neuronal survival during injury and inflammation 260. Anti-
inflammatory macrophages may also express co-stimulatory molecules including 
CD80 and CD86 on their surface and can present antigen/interact with T cells 
219.  
3.1.3 SpA and its potential to interact with macrophages 
SpA is a key virulence factor of Staphylococcus aureus (discussed further in 
section 1.9.3) that has the ability to bind to the Fc portion of immunoglobulin. 
Using a separate non-overlapping area of the SpA, it can also bind to VH3-
encoded BCR. When SpA binds to B cells via their BCR it induce massive clonal 
expansion 223 224, which consequently leads to apoptosis of the B cell via an IgG 
dependent mechanism (unpublished data, Goodyear). In collagen-induced 
arthritis (CIA), a murine model of rheumatoid arthritis, SpA treatment inhibits 
disease 225. The protective effect of SpA could not be attributed to B cell 
depletion as the murine B cell repertoire is only composed of 2-5% VH3-encoded 
B cells. It has been shown previously that SpA can complex with IgG to form 
immune complexes and that they can interact with macrophages via an Fc 
dependent binding 261. Macrophages can be polarized to an anti-inflammatory 
phenotype (high IL-10, low IL-12) via an immune complexes and FcγR dependent 
mechanism when given in conjunction with inflammatory stimuli such as LPS in 
vitro 252 222. These macrophages are particularly important in controlling 
inflammatory-mediated disease as demonstrated in an in vivo model of EAE 253. 
It has therefore been hypothesised that SpA generated immune complexes may 
be interacting with macrophages through their various Fc receptors, polarizing 
the macrophages to a regulatory phenotype that leads to the amelioration of 
inflammation in the CIA model - and not the previous assumption that this was 
dependent on deletion of auto-reactive B cell clones. 
 
 




Figure 3.1. Different fates of macrophage activation 
Macrophages are heterogeneous in their phenotype. This is dependent on how they have become 
activated. If monocytes are recruited to a site of inflammation where they encounter IFNγ and TNF 
or IFNγ and LPS, the monocyte will differentiate and become activated to a classically activated 
pro-inflammatory macrophage. Whereas, regulatory macrophages, which can be broadly sub-
divided into tissue repair and anti-inflammatory macrophages, are generated when macrophages 
are activated in the presence of IL-4 + IL-13 and immune complex (IC) + LPS respectively. 
However, it must be noted that these are not the only ways to generate macrophages of the 
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3.1.4 Aims of this experiment  
The aim of the research undertaken in this chapter was to examine the ability of 
SIC to modulate macrophage phenotype to an immune-regulatory state. This was 
achieved by: 
• Assessing the ability of SpA to bind to bone marrow-derived macrophages 
in the presence and absence of IgG and examining what receptor this is 
mediated through.  
• Examining the potential of SpA in-conjunction with IgG to polarize BMDM 
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3.2 Results  
3.2.1 SpA can bind to BMDM but only when in complex with IgG  
To examine the binding potential of SpA to macrophages when in complex with 
IgG (SIC), BMDM were generated as stated in the ‘materials and methods’ section 
2.2. On day 7, BMDM were harvested and stained for purity using two phenotypic 
antigens, F4/80 and CD11b (figure 3.2A). The macrophages generated via this 
method of culture were a highly pure homogeneous population. The complexes 
of interest were formed with Alexa-488-labelled SpA and polyclonal IgG (in 
excess), (known as SIC from here on in). Alexa-488-labelled OVA was incubated 
with excess polyclonal IgG to demonstrate that SpA exhibited a specialised 
ability to form complexes with IgG and that it was not a non-specific protein 
interaction. OVA was specifically chosen as the control protein as it has the 
same molecular weight as SpA. Alexa-488-labelled OVA was also incubated with 
excess anti-OVA IgG to form immune complexes (known as OIC from here in) that 
had been previously used in the literature to polarize macrophages to a 
regulatory phenotype. 
Macrophages were incubated with SIC-488, SpA-488, OVA-488, OVA-488+IgG or 
OIC-488 for 40min at 4° before being assessed by flow cytometry. SpA, OVA and 
OVA+IgG were unable to bind to BMDM; however, SIC and OIC showed substantial 
binding (figure 3.2B). Furthermore, it is interesting to note that SIC has a higher 
affinity for binding to BMDM than the OIC, which are used in established 
protocols to generate regulatory macrophages. Since it has now been shown that 
SIC can bind to macrophages, the next logical step was to examine if there was 
any functional/phenotypic changes to the macrophages after SIC binding.  
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Figure 3.2. SpA has the ability to bind to BMDM only when it is in complex with IgG.  
(A) Cells were stained with macrophage phenotypic markers F4/80 and CD11b to check purity. (B) 
Representative FACS plots of different binding profiles of SpA and OVA when alone or in the 
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3.2.2 BMDM polarization by SIC 
It was established in section 3.2.1 that SpA can form complexes with IgG and can 
only bind to macrophages when in complex. Studies have already demonstrated 
that when macrophages interact with immune complexes in the presence of 
inflammatory stimuli they are polarized to a regulatory phenotype, which is 
characterised by high IL-10 production and reduced IL-12 production 252.  
To assess the potential of SIC to induce the polarization of macrophages to a 
regulatory phenotype, BMDM were generated as described in section 2.2. On day 
6 macrophages were seeded into 96 well tissue culture plates at a concentration 
of 1X105/200µl per well. Cells were left overnight to equilibrate. On day 7, pre-
formed complexes were added to the macrophages in the presence or absence of 
LPS (100ng/ml) and incubated for 6h before removal of supernatants. The 
supernatants were screened via IL-10 and IL-12p40 ELISAs. In the absence of LPS, 
SIC had the ability to induce IL-10 production in macrophages (Figure 3.3A) but 
did not alter the production of IL-12 (Figure 3.3B). The addition of LPS 
substantially increased the production of IL-10 in all culture conditions but was 
highest in the SIC-treated cultures (figure 3.3A). In parallel, there was a 
significant reduction in IL-12 production in cultures treat with SIC and LPS 
compared to control cultures (figure 3.3B). Thus, when SIC is given in 
conjunction with an inflammatory stimulus such as LPS, macrophages are 
induced to produce high levels of IL-10 and reduced production of IL-12p40, 
which is the classical cytokine signature of a regulatory macrophage.  
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Figure 3.3. SIC has the ability to polarize macrophages to an anti-inflammatory cytokine 
profile.   
BMDM were seeded on day 6 at 1x105/200μl per well. On day 7, macrophages were stimulated 
with or without LPS in the presence or absence of SIC or SpA for 6h before supernatants were 
removed. This experiment was carried out in quadruplicate and graphs are representative of two 
separate experiments that showed the same pattern of results. Statistical analysis was conducted 
using one-way ANOVA for either with or without LPS stimulation. Significant differences between 
groups were identified using a post-hoc Bonferroni test, which compared all controls to SIC, ** = 
P<0.01; *** = P<0.001 (A) The mean ± SD ng/ml for IL-10 production after macrophages have 
been stimulated for 6h (IL-10 LPS group, F 2, 11 = 189.2, P<0.0001. IL-10 non-stimulated group, F 2, 
11 = 70.96, P<0.0001). (B) The mean ± SD pg/ml for IL-12p40 production after macrophage 
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3.2.3 SIC does not alter the ability of macrophages to secrete IL-6 
and Nitric oxide (NO) 
To assess further the phenotype of macrophages that SIC treatment induces, 
supernatants from the previously described experiment (section 3.2.2) were 
probed for IL-6 and NO as they are both known to be produced by macrophages 
when they become classically activated. NO is a free radical that is produced by 
inducible nitric oxide synthase (iNOS) when macrophages are activated. It is 
toxic to bacteria and one mode of action for the killing of pathogens is the 
induction of DNA damage. To evaluate NO production in BMDM cultures 
stimulated with LPS and/or SIC, a Griess assay was performed. The data showed 
that LPS induced the production of NO in macrophages and SIC did not reduce 
this (figure 3.4A). The same result was seen with an IL-6 ELISA (figure 3.4B). LPS 
conditioning induced macrophages to produce IL-6, and addition of SIC does not 
have the ability to inhibit the production of IL-6 when given in the presence of 
LPS. Although IL-6 is thought of as a pro-inflammatory mediator, regulatory 
macrophages that have been generated with immune complexes and an 
inflammatory stimulus still retain their ability to produce IL-6 when they lose 
their ability to produce IL-12 and acquire the ability to produce IL-10 78,138. 
3.2.4 SIC induced MHC II down-regulation  
The phenotype of the macrophages that have been polarized by SIC have so far 
fallen neatly into the stereotypical definition of a regulatory macrophage that 
has the ability to produce high levels of IL-10 and IL-6, but low levels of IL-12. 
However, SIC-treated macrophages also have the ability to produce NO, which is 
not normally seen in regulatory macrophages; this indicates that SIC may not be 
inducing the stereotypical regulatory macrophage and further phenotypic 
classification is therefore still needed. Another classical marker of a regulatory 
macrophage is that they express MHC II and CD86 on their surface and retain the 
ability to interact with T cells.  
BMDM were harvested on day 6 and seeded at a concentration of 5x105/ml in 24 
well plates before being stimulated with 100U/ml of IFNγ overnight. The next 
day, SIC was added with or without LPS for 6h before media was discarded and 
macrophages were dissociated from the plates and flow cytometric analysis 
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performed to examine MHC II and CD86 expression (figure 3.5). To compare SIC 
to previously validated immune complexes that generate a regulatory phenotype 
253, macrophages were also treated with OIC (immune complexes generated with 
OVA and anti-OVA antibodies). As previously stated, OIC immune complexes and 
LPS have been used in the past to generate regulatory macrophages, which 
produce high IL-10 and reduced IL-12 production 219. 
Under non-inflammatory conditions BMDM express minimal levels of MHC II, but 
when they are treated with LPS and IFNγ they increase their expression of MHC II 
significantly. When the macrophages were treated with SIC in conjunction with 
LPS and IFNγ they show a significant reduction in the level of MHC II expressed 
compared to the classically-activated macrophages (figure 3.5A). Macrophages 
activated with OIC do not show reduced MHC II expression compared to the 
classically activated counterparts, which is similar to previous observations 253. 
Unlike MHC II levels, CD86 was unchanged by the treatment of SIC compared to 
the classically-activated and OIC activated-macrophages (figure 3.5B). The 
observation that SIC macrophage polarization, in terms of MHC II expression, 
differs from OIC, highlights the heterogeneity of macrophage activation and 
confirms the concept of macrophage activation being a spectrum, and not simply 
three steadfast phenotypes.  
 
  91 
 
Figure 3.4. SIC does not have the ability to change BMDM production of Nitric oxide or IL-6 
when stimulated with LPS.  
BMDM were seeded on day 6 at 1x105/200μl per well. On day 7, macrophages were stimulated 
with or without LPS in the presence or absence of SIC or IgG for 6h before supernatants were 
removed. (A) The mean ± SD for Nitric oxide (µM) production after macrophages have been 
stimulated for 6h. (B) The mean ± SD for IL-6 (ng/ml) production after macrophage stimulation for 
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Figure 3.5. SIC treatment leads to the down-regulation of MHC II levels but has no effect on 
CD86 up-regulation. 
BMDM were seeded on day 6 at 5X105/ml per well and treated with 100U/ml of IFNγ overnight. On 
day 7, macrophages were stimulated with or without LPS in the presence or absence of SIC, SpA, 
OVA or OIC for 6h before supernatants were removed and cells stained for flow cytometric 
analysis. This experiment was carried out on three separate occasions and results have been 
pooled together for statistical analysis purposes. Statistical analysis was conducted using one-way 
ANOVA for LPS + IFNγ stimulation. Significant differences between groups were identified using a 
post-hoc Bonferroni test, which compared all controls to SIC, *** = P<0.001. (A) The mean ± SD 
MFI values for MHC II (F 4, 14 = 29.29, P<0.0001), along with a histogram of MHC II levels to the 
right (media alone grey, SIC+LPS+IFNγ - red, LPS+IFNγ – blue, OIC+LPS+IFNγ – green). (B) The 
mean ± SD MFI values for CD86, histogram of CD86 to the right (media alone grey, 
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3.2.5 T cell activation is not affected by SIC-conditioned 
macrophages  
MHC II expression is a vital part of T cell activation, and therefore it was 
hypothesised that the ability of SIC to reduce the level of MHC II may be linked 
to their ability to activate T cells. To examine this, a co-culture system was set 
up with T cells from OTII mice that have T cell receptors (TCRs) transgenically 
engineered to be specific for an OVA peptide sequence 323-339. Macrophages 
were incubated for 16h with or without IFNγ and then for a further 6h with or 
without LPS, plus SIC or appropriate controls and TCR-specific OVA peptide. 
Macrophages were washed and were incubated with the CD4 OTII T cells for a 
further 20h. Cells were harvested, stained and analysed by flow cytometry to 
examine T cell activation state via CD69 expression (figure 3.6).  
Macrophages that were treated with SIC, IFNγ, LPS and co-cultured with T cells 
had far lower levels of MHC II on their surface compared to macrophages treated 
exactly the same way but with the omission of SIC (figure 3.6A). T cells that 
were cultured with the stimulated SIC-treated macrophages that had low MHC II 
on their surface showed the same level of CD69 expression as T cells cultured 
with the classically-activated macrophages, which had high MHC II levels on their 
surface (figure 3.6B). Thus the regulatory phenotype induced by SIC does not 
have an effect on subsequent T cell activation. However, under normal 
physiological conditions, macrophages do not migrate to draining lymph nodes 
with antigen and no evidence exists for macrophage participation in the 
activation of naïve CD4 T cells 262. In that respect, macrophages are thought to 
be involved in the expansion of primary or secondary responses already initiated 
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Figure 3.6. SIC did not affect the ability of macrophages to activate T cells.  
BMDM were stimulated overnight with or without IFNy. 16h later, BMDC were pulsed with OVA in 
the presence or absence of SIC, SpA and or LPS for 6h. BMDM were then cultured with OTII CD4+ 
T cells at 1:1 ratio for 20h. (A) The mean ± SD MFI values for MHC II expression on CD11b+ 
macrophages. (B) The mean ± SD MFI values for CD69 on T cells co-cultured with macrophages. 
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3.2.6 SIC binding in WT, CD64-/-, CD32-/- and common γ chain-/- 
Having established that SIC can polarise macrophages to a regulatory phenotype, 
it was important to investigate the mechanism by which SIC could induce this 
regulatory phenotype. Thus we sought to identify the specific receptor(s) that 
enable SIC to interact with macrophages. In previous work with SpA, which 
looked into its ability to induce proliferation and then apoptosis in B cells with 
VH3 specific BCR, studies demonstrated that this process was dependent on the 
presence of FcγRIII in conjunction with IgG (unpublished data). Taking these 
studies into account and those which have previously shown that immune-
complexes work via FcγR 252, the logical next step was to examine the role of 
FcγR receptors in the SIC-mediated production of regulatory macrophages. To 
investigate whether Fcγ receptors are required for SIC binding and function, 
bone marrow was acquired from FcyRI-/- (CD64), FcγRIIb-/- (CD32) and the 
common γ chain-/- mice and BMDM were generated.  
As in previous experiments, Alexa-488 labelled SpA was incubated with IgG to 
form SIC, then incubated with the macrophages for 40min at 4°C. Macrophages 
were stained with F4/80 and analysed by flow cytometry (Figure 3.7). The 
common γ chain deficient macrophages were unable to interact with SIC. The 
analysis of BMDM from CD64-/- mice demonstrated that they were also unable to 
interact with SIC (figure 7B); proving that the presence of FcγRI, which is 
knocked out on both the common γ chain-/- BMDM and the CD64-/-, is essential 
for SIC binding. In juxtaposition, CD32-/- (FcγRIIb) macrophages did show 
significant increased binding to SIC compared to CD64-/- and common γ chain-/- 
BMDM; nevertheless, this was at a decreased level compared to the WT control 
BMDM (figure 3.7B).  
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Figure 3.7. SIC has the ability to bind to BMDM only when CD64 and the common γ chain is 
present.  
BMDM were generated with the use of M-CSF from the cell line L929. Cells were harvested on day 
7 and incubated with preformed SIC, SpA, OVA+IgG or OVA. SpA and OVA were fluorescently 
labelled with alexa-488. This experiment was carried out on three separate occasions and data 
pooled together for statistical analysis purposes. Statistical analysis was conducted using a one-
way ANOVA to compare the differences in SIC-488 binding. Significant differences between groups 
were identified using a post-hoc Bonferroni test, which compared all groups to each other, *** = 
P<0.001 (A) Representative image of the binding potential of SIC-488 to WT, CD64-/-, CD32-/- and 
common γ chain-/- BMDM. (B) The mean ± SD MFI values for SIC-488 (F 2, 8 = 1564, P<0.0001) 
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3.2.7 SIC has the ability to polarize macrophages to a regulatory 
phenotype in WT and CD32-/- BMDM but not CD64-/- or 
common γ chain-/- BMDM  
To validate that CD64 was not only essential for binding of SIC, but was also 
essential for the polarization of macrophages to a high IL-10 and low IL-12 
producing regulatory state (figure 3.3), macrophages were generated from WT, 
CD64-/-, CD32-/- and the common γ chain-/- bone marrow and seeded at 
1x105/200 per well and cultured overnight. The following day, the macrophages 
were treated with SIC, SpA or media in the presence or absence of LPS. 
Supernatants were removed from the culture 6h later and ELISAs for IL-10 and 
IL-12p40 were performed (figure 3.8).  
WT macrophages behaved as characterised before (figure 3.3) with significantly 
higher IL-10 production and significantly reduced production of IL-12p40 in SIC 
and LPS-treated macrophages compared to LPS alone or LPS in the presence of 
SpA (figure 3.8A). Interestingly, CD64-/- and common γ chain-/- macrophages 
when treated with SIC and LPS showed no change in their production of IL-10 
and IL-12p40 when compared to the LPS alone control, demonstrating that SIC 
cannot induce the polarization of macrophages to a regulatory phenotype in the 
absence of CD64 (figure 3.8B&C). Examination of the cytokine profile of CD32-/- 
macrophages showed that when SIC is given in conjunction with LPS it induces 
the same regulatory phenotype seen in the WT cells, i.e. a significant increase in 
IL-10 and a significant decrease in IL-12p40 (figure 3.8D). It should be 
appreciated, however, that CD32-/- macrophages produce reduced levels of 
cytokine compared to the WT macrophages (figure 3.8A). Furthermore, SIC 
binding to the CD32-/- macrophages was slightly reduced, leading to the 
assumption that this receptor may still play a small role in how SIC manipulates 
macrophage activation states. 
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Figure 3.8. SIC has the ability to polarize macrophages to an anti-inflammatory cytokine 
profile in WT and CD32-/- macrophages but not CD64-/- and common γ chain-/- macrophages.  
BMDM were seeded on day 6 at 1x105/200μl per well. On day 7, macrophages were stimulated 
with or without LPS in the presence or absence of SIC or SpA for 6h before supernatants were 
removed. This experiment was carried out in quadruplicate and graphs are representative of two 
separate experiments that showed the same pattern of results. Statistical analysis was conducted 
using one-way ANOVA for LPS stimulation. Significant differences between groups were identified 
using a post-hoc Bonferroni test, which compared all controls to SIC, *** = P<0.001. The mean ± 
SD for IL-10 (pg/ml) and lL-12p40 (pg/ml) production after macrophages have been stimulated for 
6h. (A) Wild type macrophages (IL-12p40 LPS group, F 2, 11 = 16.92, P<0.0009) (IL-10 LPS group, 
F 2, 11 = 28.28, P<0.0009). (B) CD64-/- macrophages. (C) Common γ chain-/- macrophages. (D) 
CD32-/- macrophages (IL-12p40 LPS group, F 2, 11 = 58.18, P<0.0001) (IL-10 LPS group, F 2, 11 = 
16.54, P<0.001). 
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3.2.8 The ability of SIC to induce the down-regulation of MHC II is 
not affected when IL-10R is blocked in WT and CD32-/- 
macrophages 
It was shown that CD64-/- macrophages cannot bind SIC or become polarized to a 
regulatory phenotype in the presence of SIC and LPS (Figures 3.7 & 3.8). To 
prove further that SIC imparts this regulatory phenotype through CD64, the 
ability of SIC to down-regulate MHC II expression was examined in CD64-/- and 
CD32-/- cells. The experiment was carried out as described previously (section 
3.2.5). In brief, on day 6 BMDMs were harvested and stimulated with IFNγ 
(100U/ml) overnight. SIC, SpA and media were added in the presence and 
absence of LPS for 6h before cells were examined by flow cytometry. A slight 
modification to this experiment involved the addition of an IL-10R blocking 
antibody in conjunction with SIC to examine if the autocrine production of IL-10 
was the mechanism that led to the down-regulation of MHC II (figure 3.9). It was 
important to examine this as it had previously been demonstrated that if 
macrophages are polarized to a regulatory phenotype via IL-10 they have 
reduced MHC II on their surface 258. 
In WT BMDM, SIC induces the down-regulation of MHC II in the presence or 
absence of the IL-10R blocking antibody (figure 3.9A). This finding demonstrates 
that IL-10 is not the factor that elicits the down-regulation of MHC II expressed 
on macrophages that have been polarized with SIC and LPS. Moreover, the 
absence of CD32 on macrophages did not affect the ability of SIC to induce the 
suppression of MHC II after IFNγ and LPS stimulation, and this was also IL-10 
independent (figure 3.9B). Macrophages deficient in CD64 did not show any 
increase in their surface expression of MHC II when stimulated with IFNγ and 
LPS. Therefore, we were unable to investigate the effect of loss of this receptor 
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Figure 3.9. SIC has the ability to down-regulate MHC II expression in WT and CD32-/- 
macrophages.  
BMDM were seeded on day 6 at 5x105/ml per well and treated with 100U/ml IFNγ overnight. On 
day 7, macrophages were stimulated with or without LPS in the presence or absence of SIC, SpA 
or IL-10R blocker (annotated as IL-10B on graphs) for 6h before supernatants were removed and 
cells stained for flow cytometric analysis. The WT experiment was carried out on three separate 
occasions and data pooled together for statistical analysis purposes. CD64-/- and CD32-/- 
experiments were carried out only once and therefore no statistical analysis was performed. 
Statistical analysis was conducted using one-way ANOVA for LPS + IFNγ stimulation. Significant 
differences between groups were identified using a post-hoc Bonferroni test, which compared all 
groups to media, *** = P<0.001. The mean ± SD MFI values for MHC II. (A) Wild type 
macrophages (F 5, 22 = 92.55, P<0.0001). (B) CD32-/- macrophages. (C) CD64-/- macrophages. 
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3.2.9 SpA can engage cell-bound IgG to interact with cells 
In an in vivo setting, the high affinity FcγRI (CD64) receptor is always occupied 
with IgG. To examine whether or not SIC and/or SpA can interact with cells 
when CD64 is occupied with IgG macrophages from WT, FcyRI-/- (CD64), FcγRIIb-/- 
(CD32) and the common γ chain-/- were coated with or without IgG for 20mins 
before incubation with fluorochrome-labelled SIC or SpA and assessed via flow 
cytometry (figure 3.10).  
Initially, cells were probed with an anti-IgG antibody to show that the cells were 
coated with IgG (Figure 3.10A). The level of IgG on WT and CD32-/- cells was 
comparable. Conversely, CD64-/- macrophages show a reduced ability to bind to 
IgG compared to WT and CD32-/-, most likely because CD64 is the high affinity 
receptor for monomeric IgG. IgG binding to the CD64-/- macrophages might be 
explained by the IgG having formed aggregates and then binding via one of the 
low affinity FcγRs the macrophages still express. However, this is not likely as 
the IgG was centrifuged prior to their use to exclude aggregates that might have 
formed. The other possibility is that FcγRIV, which has intermediate binding 
affinity for IgG 263 is compensating for CD64-/-. The common γ chain-/- cells 
showed no binding of IgG, and FcγRIV does associate with the common γ chain-/- 
and would be knocked out in these cells too, explaining why no binding of IgG 
was observed (figure 3.10A). 
As expected when SpA-488 is administered to cells that have not been pre-
incubated with IgG or do not bind IgG, SpA-488 was unable to bind to these 
macrophages (figure 3.10B). However, when macrophages are pre-incubated 
with IgG, WT and CD32-/- cells still show binding of SpA-488 as they can interact 
with the IgG on the macrophage surface. This binding is at a slightly reduced 
level compared to binding levels of preformed SIC in both WT and CD32-/-. Even 
though CD64-/- macrophages could bind IgG, it may be at too low a level for 
them to interact with the SpA and therefore no binding of SpA-488 or SIC-488 
was exhibited in these cells. These results demonstrate the role that CD64 plays 
in SIC’s ability to bind to macrophages. Furthermore, complexes do not have to 
be preformed as SpA can interact with IgG already present on the macrophage’s 
surface-bound receptor.  
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3.2.10 Complex formation with SpA and IgG2a induces IL-10 
production in macrophages in the presence of LPS 
So far, it has been proven that SpA must be in complex with IgG for it to bind to 
macrophages and to impart a regulatory phenotype on them. However, it is not 
known what sub-classes of IgG are required in the complex to induce 
polarization to a regulatory phenotype.  
To address this issue, purified IgG1 and IgG2a were used to form complexes with 
SpA in the same manner as previously stated (section 2.3.1). Macrophages were 
stimulated for 6h with or without LPS in the presence of SIC made from 
polyclonal IgG, IgG1 or IgG2a. Supernatants were removed and assessed via IL-10 
ELISA to characterize the macrophage phenotype (figure 3.11). 
Macrophages that were treated with SIC formed with polyclonal IgG in the 
presence of LPS, as before, exhibited the same significant up-regulation of IL-10 
production (figure 3.11A). Complexes formed with purified IgG2a showed the 
same up-regulation of IL-10 as the complexes formed with polyclonal IgG, though 
IL-10 production was at a slightly reduced level (figure 3.11B). However, 
complexes formed with IgG1 alone did not induce the regulatory phenotype 
(figure 3.11C). This data indicates that IgG2a must be a component of the SIC 
complex. This is consistent with the idea that IgG2a binds preferentially to 
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Figure 3.10. SpA has the ability to bind to WT and CD32-/- BMDM when the cells have been 
pre-coated with IgG.  
BMDM were generated with the use of M-CSF from the cell line L929. Cells were harvested on day 
7 and incubated with or without IgG for 20mins, cells were then washed to remove unbound IgG. 
Macrophages were then incubated with preformed SIC-488 or SpA-488. SpA was fluorescently 
labelled with alexa-488. (A) Cells were stained with anti-IgG to show IgG binding. (B) 
Representative histograms of different binding affinities of SpA when alone or in complex with IgG 
coated cells. This experiment was conducted on two separate occasions; the data shown is a 
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Figure 3.11. SIC that has been preformed with purified IgG2a but not IgG1 can induce 
macrophages to a regulatory phenotype.  
BMDM were seeded on day 6 at 105/200μl per well. On day 7, macrophages were stimulated with 
or without LPS in the presence or absence of SIC that had been pre-formed with polyclonal IgG, 
purified IgG2a or IgG1 for 6h before supernatants were removed and assessed for IL-10 (ng/ml) 
production via ELISA. This experiment was carried out in quadruplicate and graphs are 
representative of two separate experiments that showed the same pattern of results. Statistical 
analysis was conducted using one-way ANOVA for LPS stimulation subset only. Significant 
differences between groups were identified using a post-hoc Bonferroni test, which compared all 
controls to SIC, *** = P<0.001. (A) SIC that had been preformed with polyclonal IgG (F 2, 11 = 18, 
P<0.0007). (B) SIC that had been preformed with purified IgG2a (F 2, 11 = 35.31, P<0.0001). (C) SIC 
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3.2.11 SIC generated with IgG2a induces down-regulation of 
MHC II but not to the same extent as SIC made with 
polyclonal IgG  
When SIC were generated with IgG2a, they could induce macrophages to 
significantly up-regulate their IL-10 production and become polarized to a 
regulatory phenotype; however this was not seen with complexes formed with 
IgG1. To investigate further if IgG2a is a required component of SIC to induce 
macrophages to a regulatory phenotype, IgG2a complexes were examined to 
determine their ability to down-regulate MHCII expression. Complexes were 
formed with alexa-488-labelled SpA and either polyclonal IgG, purified IgG1, 
IgG2a or IgG2b. The ability of these complexes to interact with cells and inhibit 
the surface expression of MHC II was studied via flow cytometric analysis. 
Flow cytometric binding studies demonstrated that polyclonal IgG has the 
highest level of macrophage binding (figure 3.12A). This correlated with the 
ability of these polyclonal SIC complexes to substantially down-regulate MHC II 
expression (figure 3.12B). In comparison, complexes formed with IgG1 or IgG2b 
were unable to interact with macrophages and hence could not down-regulate 
MHC II expression. Interestingly, SIC formed with IgG2a was able to interact with 
macrophages and to some degree down-regulate MHC II expression. However, in 
both instances this was not as substantial as the polyclonal SIC complexes, 
confirming what was demonstrated via IL-10 ELISA (figure 3.11), that IgG2a 
formed SIC is the only purified sub-set that has the ability to bind to 
macrophages and cause functional and phenotypic alteration. However, it has 
also been shown that the effect exerted by SIC formed with IgG2a, in 
comparison to SIC formed with polyclonal complexes, was not as pronounced. 
3.2.12 Mixed IgG sub-classes down-regulate MHC II to the 
same extent as polyclonal IgG 
SIC made with purified IgG2a can induce significant reduction of MHC II 
expression and can significantly increase the production of IL-10 by macrophages 
when treated with LPS. However, the effect that was wielded by SIC formed 
with IgG2a was not observed to the same degree as SIC formed with polyclonal 
IgG. This led to the speculation that the complexes formed with polyclonal IgG 
contain multiple subclasses of IgG and that they must therefore be more potent. 
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To address this, SIC were generated using two subclasses of IgG and 
macrophages were treated with the complexes in the presence and absence of 
LPS and IFNγ as previously described (section 3.2.4). Macrophages were 
examined for their potential to bind the complexes and for altered surface MHC 
II levels (figure 3.13). 
When complexes containing IgG2a with either IgG1 or IgG2b are formed with 
alexa-488-labelled SpA they show increased binding compared to complexes 
formed without IgG2a which showed only background levels of binding (figure 
3.13A). It is important to note that none of the combinations of IgG subclass SIC 
induced the same level of binding as the polyclonal SIC. Upon examination of the 
ability of these combinatorial SIC complexes to down-regulate MHC II, it was 
found that IgG1/2a SIC had the same capacity to down-regulate MHC II 
expression as polyclonal IgG derived SIC (figure 3.13B). The complexes formed 
with IgG1/2b showed no ability to down-regulate the expression of MHC II and 
complexes formed with IgG2a/2b showed the same reduction in the level of MHC 
II expression as IgG2a alone, leading to the assumption that the down-regulated 
expression is an effect of IgG2a and not an effect of the mixed complex of 
IgG2a/2b. 
SIC that were generated with the subclasses IgG1/2a show the same ability as 
SIC formed with polyclonal IgG to induce macrophages to a regulatory 
phenotype; however, they do not show the same intensity of binding as 
polyclonal SIC. This may be due to the ability of SpA to bind to IgG3, though 
these complexes have no functional effects in the polarization of macrophages 
to a regulatory phenotype (data not shown). When IgG3 was combined with any 
other sub-class, complexes interacting with macrophages was exhibited, but 
there was no functional effect of macrophage polarization (data not shown). 
Elucidating the subclasses of IgG that bind to SpA to form SIC - that have the 
ability to polarize macrophages to a regulatory phenotype - is vitally important if 
a therapeutic is ever to be designed.    
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Figure 3.12. SIC that has been preformed with purified IgG2a but not IgG1 or IgG2b can 
induce the down-regulation of MHC II levels on BMDM.  
BMDM were seeded on day 6 at 5X105/ml per well and treated with 100U/ml IFNγ overnight. On 
day 7, macrophages were stimulated with or without LPS in the presence or absence of SIC that 
has been pre-formed with polyclonal IgG, purified IgG1, IgG2a or IgG2b for 6h before supernatants 
were removed and cells stained for flow cytometric analysis. This experiment was carried out on 
three separate occasions in single or duplicate and data for MHC II MFI pooled together for 
statistical analysis purposes. This was not however possible for Alexa-488 MFI and the graph is a 
representative of the three experiments. Statistical analysis was conducted using one-way ANOVA 
to compare the differences in MHC II expression when stimulated with LPS+IFNγ. Significant 
differences between groups were identified using a post-hoc Bonferroni test, which compared all 
groups to each other, *** = P<0.001 (A) The mean ± SD MFI values for Alexa-488. (B) The mean ± 
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Figure 3.13. SIC that has been preformed with a mixture of purified IgG2a and IgG1 can 
induce macrophages to a regulatory phenotype.  
BMDM were seeded on day 6 at 5X105/ml per well and treated with 100U/ml IFNγ overnight. On 
day 7, macrophages were stimulated with or without LPS in the presence or absence of SIC that 
has been pre-formed with polyclonal IgG or a 1:1 mixture of purified IgG1, IgG2a or IgG2b for 6h 
before supernatants were removed and cells stained for flow cytometric analysis. (A) The mean ± 
SD MFI values for Alexa-488. (B) The mean ± SD MFI values for MHC II. This experiment was 
carried out on two separate occasions and data has been combined, however, due to too small an 
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3.3 Discussion 
SpA has been previously demonstrated to have immune-modulating activities as 
it was already classified as a B cell superantigen. It has the ability to interact 
with VH3-encoded BCR and induce Bim-mediated apoptosis 264 via a FcγRIII 
mechanism, which is dependent on the presence of IgG (unpublished data). SpA 
has also been shown to bind to macrophages when it is in complex with IgG via 
FcγR 261. Furthermore, it is known that when SpA is in the presence of excess IgG 
it will always form a specific immune complex made up of four IgG molecules 
and two SpA molecules 217. Macrophages have been shown to become polarized 
to an anti-inflammatory phenotype by the binding of many different types of 
immune complexes when in the presence of an inflammatory stimuli 253 219 252. 
Therefore, the ability of SpA, when in the presence of IgG (SIC), to polarize 
macrophages to an anti-inflammatory phenotype was investigated. The results 
demonstrate that when SpA is in complex with IgG it can induce macrophages 
stimulated with LPS to significantly up-regulate their production of IL-10 and 
inhibit their production of IL-12, which are key phenotypic features of anti-
inflammatory macrophages. It was also discovered that SIC can down-regulate 
MHC II expression when macrophages were stimulated with SIC in conjunction 
with LPS after IFNγ priming, which did not have an effect on the ability of T 
cells to become activated. The anti-inflammatory phenotype that was induced 
when macrophages were treated with SIC was regulated through the binding of 
SIC to FcγRI. Interestingly, complexes composed of a mix of IgG1/2a induced the 
same anti-inflammatory phenotype as those made up with polyclonal IgG.  
The ability of SIC to induce macrophages to an anti-inflammatory phenotype is 
intriguing as SpA is the active component of an (FDA) approved apheresis 
therapy (Prosorba column) for inflammatory and autoimmune diseases 265. 
However, there has been longstanding controversy over the mechanism of action 
and the unpredicted beneficial effects of this therapy, especially where 
conventional plasmapheresis has failed (the Prosorba column could only remove 
IgG from roughly 60ml of plasma where traditional methods can remove IgG from 
500-600ml of plasma).  
It was discovered that a small quantity of SpA was released from the column via 
proteolytic cleavage and would enter the patient’s circulation. Several 
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hypotheses have been proposed for the mode of action of the therapy, including 
removal of immunoglobulin and/or immune complex and depletion of B cells 216. 
However, the SpA that leaches from the column into the patient’s circulation 
could lead to the generation of anti-inflammatory macrophages that produce 
high levels of IL-10, leading to the resolution of inflammation. 
SpA can form homogeneous immune complexes with IgG when it is in excess and 
it has also been well documented that macrophages can be induced to a 
regulatory phenotype when they interact with immune complexes in an 
inflammatory setting 77 151. Interestingly, the majority of previous studies have 
utilized xenogeneic immunoglobulin, primarily rabbit or rat IgG, for the 
generation of immune complexes to examine their potential to polarize 
macrophages to an anti-inflammatory phenotype. The interaction of rabbit IgG 
with murine Fc receptors has never been specifically examined; though, results 
suggest that rabbit IgG has an order-of-magnitude lower affinity for mouse Fc 
receptors compared to mouse IgG 220 221. In this study, immune complexes were 
formed with the use of SpA and mouse IgG - as rabbit IgG-formed immune 
complexes could have altered binding activity to mouse Fc receptors, and could 
have produced dramatically different outcomes when compared to mouse IgG 
immune complexes. This was found to be true when the binding affinity of SIC 
and OIC, which were formed using rabbit anti-OVA IgG, to macrophages were 
tested and OIC were shown to have lower affinity to murine BMDM than SIC, 
which was formed with autologous murine IgG. 
 SIC’s ability to polarize macrophages to an anti-inflammatory phenotype was 
examined. When macrophages were treated with SIC in the absence of any 
inflammatory stimuli, SIC induced a significant increase in IL-10 production. 
Importantly, this attribute has never previously been seen with immune-
complexes 252. In the presence of LPS, SIC induced macrophages to produce 
significantly lower levels of IL-12 and significantly higher levels of IL-10 in 
comparison to LPS-treated macrophages. This cytokine profile is one of the key 
features of anti-inflammatory macrophages. In accordance with work previously 
published 261, it was demonstrated that SpA - when in complex with IgG - can 
bind to macrophages via an FcγR-dependent mechanism. However, the authors 
of the previous work did not define which FcγR was specifically involved in the 
binding of the complexed SpA to macrophages. Interestingly, it was discovered 
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that the high affinity IgG receptor, FcγRI, was essential for SIC to bind to 
macrophages. This was a slightly unexpected result as FcγRIIb is the inhibitory 
FcγR (as it has an ITIM) and has been shown to be involved in the resolution of 
inflammation 176,266; whereas FcγRI is normally an activatory receptor 165. CD64 
was not only shown to be essential for SIC to bind to macrophages but, in its 
absence, the ability of SIC to impart an anti-inflammatory phenotype was also 
abrogated. Furthermore, and in support of the former finding, it had been 
previously demonstrated that anti-inflammatory macrophages production of IL-
10 - which have been polarized by immune complexes (opsonized sheep 
erythrocytes) plus LPS - are dependent on CD64 expression 252. Notably, ERK 
activation, following FcγRI ligation, leads to a remodeling of the chromatin at 
the il-10 locus, making it more accessible to transcription factors 267. The exact 
signaling mechanism of SIC-induced polarization of macrophages to an anti-
inflammatory phenotype via CD64 signaling has not been fully elucidated, but 
ERK may be a molecule of interest for future investigation.    
To try to categorise further the phenotype of the macrophage SIC was inducing, 
supernatants from SIC-treated macrophages were screened for other cytokines 
such as NO and IL-6, which were still secreted at high levels in the SIC-treated 
macrophages. This secretion at high levels was not expected as NO is a 
component produced normally by inflammatory macrophages. However, IL-6 can 
be produced by both pro-inflammatory classical macrophages and anti-
inflammatory macrophages that are induced by immune complexes - and can 
play a beneficial role in CNS injury by protecting neurons from death due to 
excitotoxicity 260.    
Another interesting feature of anti-inflammatory macrophages is that in the 
majority of cases they show up-regulated MHC II on their surface 253; however, 
macrophages that have been treated with LPS or IFNγ in the presence of SIC 
show significantly lower expression of MHC II in comparison to LPS and IFNγ-only 
treated macrophages. It is known that if macrophages are polarized to an anti-
inflammatory phenotype via exposure to IL-10, they show reduced levels of MHC 
II 258. An example of this in vivo, is the ability of the cytomegalovirus to induce 
infected cells to produce IL-10, which leads to the down-regulation of MHC II on 
macrophages 268. As it has been shown that SIC-stimulated macrophages produce 
large amounts of IL-10, an IL-10-dependent autocrine mechanism of reduced 
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MHC II expression was investigated. This was carried out with the blockade of IL-
10R on macrophages using a blocking antibody. When the IL-10R was blocked on 
macrophages it did not alter the MHC II down-regulation induced by SIC, showing 
that this is not an IL-10-dependent mechanism and is most likely to be post-
translational modification of MHC II as IFNγ alone increases the expression of 
MHC II before the addition of SIC and LPS - demonstrating that MHC II is down-
regulated rather than inhibited by SIC.  
Some very early work on immune complexes, and their ability to alter 
macrophage function, showed that immune complexes had the ability to down-
regulate macrophage MHC II expression after IFNγ stimulation. However, this 
work showed that this was only possible when the complexes were plate-bound 
and had been cultured for up to a week to see immune complex-mediated down-
regulation of MHC II, which was not reproducible with soluble immune complexes 
or over short culture periods. The conclusion to be drawn suggests that SIC does 
not exert its effects in the same manner. Interestingly, the authors showed that 
immune complexes, made with either IgG1, 2a, 2b or IgE, could induce this 
down-regulation of MHC II. However, no other immune-regulatory features of 
these macrophages were characterized 269. SIC-induced MHC II down-regulation 
was only discovered to be dependent on complexes being generated with 
polyclonal IgG and/or a mix of IgG1/2a - and to a lesser extent IgG2a by itself. 
The only other work on immune complex-mediated down-regulation of MHC II 
involved the use of heat-aggregated human IgG. In these studies, incubation of 
PBMC with heat-aggregated IgG, before or after IFNγ stimulation, resulted in a 
reduction in MHC II compared to IFNγ-only treated PBMCs. This down-regulation 
of MHC II was reversible when immune complexes were removed. The data also 
implied that complexes induced metalloproteases and aspartic proteases, which 
subsequently down-regulated MHC II via cell-surface cleavage. It is therefore 
possible that SIC is down-regulating MHC II expression via this mechanism, but 
future experiments will need to address this. It should be appreciated, however, 
that in the heat-aggregated IgG study the authors looked at total MHC II 
expression in PBMCs and did not pre-gate on monocytes. They incorrectly 
attributed this phenomenon totally to monocytes and did not take into 
consideration B cells that are a component of PBMCs (and also express MHC II 
and FcγR). Therefore, this phenomenon cannot be attributed to a unique 
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monocyte-immune complex association - as they have not specifically isolated 
monocytes from the PBMCs, or looked at MHC II on these cells in isolation with 
immune complexes 270.  
As SIC leads to the down-regulation of MHC II on macrophages treated with LPS 
and IFNγ, it was therefore considered whether this abrogation of MHC II would 
have an effect on the ability of macrophages to activate CD4+ T cells after SIC 
treatment. This was performed by examining the expression of the activation 
marker CD69 on T cells after co-culture with macrophages which had been 
previously incubated with OVA and activated with LPS and IFNγ in the presence 
or absence of SIC. It was found that SIC had no effect on CD69 expression (and 
therefore early T cell activation after co-culture with macrophages). 
Nevertheless, under normal physiological conditions in vivo, macrophages do not 
activate naïve T cells as they do not traffic to draining lymph nodes and 
therefore cannot take part in the initiation of the primary adaptive immune 
response. This task is performed by dendritic cells; no investigation into the 
effects SIC would have on dendritic cells have been carried out. However, we 
speculate that SIC would not have an effect on the activation phenotype of 
dendritic cells as they do not express CD64, which is the receptor shown to be 
essential for SIC’s ability to bind to and polarize macrophages to an anti-
inflammatory phenotype 271.  
Although macrophage are not pivotal in the initiation of an immune response, 
they are essential for the perpetuation of the primary and secondary phases of 
the adaptive immune response via T cell clonal expansion at the site of 
infection. SIC-induced down-regulation of MHC II may help with the resolution of 
an immune response as the reduced levels of MHC II available to re-stimulate T 
cells could inhibit subsequent activation and expansion.  
An alternative avenue of investigation in the future could be to examine the 
ability of SIC-treated macrophages to induce Treg cells. Inducible Tregs have 
also been shown to express CD69 and can be generated in the tissues if they are 
surrounded by cells that produce high levels of IL-10 272 273. Further work is 
needed to answer these questions.  
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In conclusion, it has been demonstrated in this chapter that SIC in conjunction 
with LPS can polarize macrophages to an anti-inflammatory phenotype with 
significantly increased IL-10 production, significantly reduced IL-12 production, 
and unaltered NO and IL-6 production when compared to LPS-only treated 
macrophages. SIC and LPS also exhibited the ability to down-regulate MHC II 
expression after macrophages had been treated with IFNγ. The fact that SIC can 
induce anti-inflammatory macrophages in the presence of inflammatory stimuli 
shows potential for this as a therapeutic agent in overt inflammatory conditions 
and merits further investigation into its exact mode of action through FcγRI. 
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4 SPA has the ability to induce maturation of 
Ly6Chi monocytes into Ly6Clow monocytes under 
steady-state or inflammatory conditions 
4.1 Introduction 
The MPS is composed of monocytes, Langerhans cells, Kupffer cells, microgila, 
alveolar macrophages, dendritic cells and neutrophils, amongst others 3 4. It is 
known that the MPS is in a constant state of flux with a high turnover of cells 
under both steady-state and inflammation. Much debate surrounded the exact 
process by which cells of the MPS are replaced. In an inflammatory setting there 
is both renewal of differentiated cells resident in tissues and infiltration of bone 
marrow precursors such as monocytes 40; and these two processes most likely 
work synergistically. Interestingly, it has recently been demonstrated that 
microglia along with some other tissue-resident macrophages (Langerhans cells 
of the skin and pulmonary macrophages of the lung) do not derive from HSC as 
previously thought. They are actually derived from an early embryonic 
progenitor, which originates in the yolk sac at embryonic day 8, whereas 
monocyte/macrophages derived from HSC are not seen until embryonic day 12 in 
the foetal liver 38 39. Microglia have been shown to be self-renewing under 
steady-state conditions but when inflammation is present in the CNS, monocytes 
from the bone marrow can extravasate through the BBB and differentiate into 
microglia under these specialised circumstances 35,36.  
Monocytes can remain in the circulation from 2 days up to 2 weeks before 
migrating into tissue and differentiating into macrophages/DCs or homing back 
to the bone marrow. When monocytes are in the circulation they exhibit no 
ability to proliferate. However, it is unknown what proliferative potential they 
possess when in the bone marrow or newly arrived in tissue before they 
differentiate into macrophages 274. Studies by Geissmann et al have 
demonstrated that there are two monocyte subsets in mice (this concept has 
been covered in great detail in section 1.3.3; however, it will also be reviewed 
briefly here too). These subsets have been distinguished on the basis of their 
expression of Ly6C and CX3CR1 40. The monocyte subset that expresses high 
levels of Ly6C and low-intermediate levels of CX3CR1, also expresses the 
chemokine receptor CCR2 and the adhesion molecule L- selectin. These Ly6Chi 
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monocytes are classified as the 'inflammatory' subset due to their tendency to 
migrate to sites of inflammation where they produce pro-inflammatory 
cytokines. This has been shown in numerous models of infection, inflammation 
and tissue-damage models, such as L. major, T. gondii, atherosclerosis, acute 
peritoneal inflammation and post ischemic brain injury 51 275 58 276 46. The second 
monocyte subset in mice is defined by low expression of Ly6C, high levels of 
CX3CR1, but no expression of CCR2 or L- selectin. Ly6Clow monocytes have been 
deemed 'patrolling' or 'anti-inflammatory' monocytes as they are found to crawl 
along blood vessels and have the potential to migrate into tissue in the steady-
state to replace tissue-resident macrophages/DC populations. Furthermore, they 
have the ability to participate in the resolution/tissue repair phase of an 
immune response in inflamed tissues 53 277 278. Monocytes are conserved across 
many species and it has more recently been demonstrated that the sub-
populations of monocytes that were first demonstrated in humans (see section 
1.3.4) and more recently in mice, have also been discovered in rats, pigs and 
cows, further demonstrating the importance and differing roles these two 
subsets of monocytes must play in maintaining a competent immune system in 
both health and disease 279 280 281. 
The previous chapter of this thesis has demonstrated that SIC has the ability to 
skew macrophages to a regulatory phenotype in vitro. Hence, it was 
hypothesized that SIC would also have an effect on their myeloid precursors in 
tipping the balance from Ly6Chi inflammatory monocytes to Ly6Clow anti-
inflammatory monocytes, which could differentiate into regulatory macrophages 
under inflammatory conditions, leading to the resolution of inflammation and 
the initiation of the tissue repair process. 
Inflammation is associated with a number of auto-immune diseases or traumatic 
conditions. To evaluate the ability of SIC to interact with the innate immune 
system in the absence of an overt auto-reactive adaptive immune response a 
contusion model of spinal cord injury was used, which is driven by a traumatic 
event resulting in significant inflammation at the site of injury.  
The vast majority of SCI results in paralysis of the victim; the extent of paralysis 
depends on the level that the injury to the spinal cord occurs at. The reason 
paralysis is such a common outcome rate for SCI victims is due to two distinct 
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events: the primary event is the initial trauma from the injury itself; the 
secondary event is the so-called “secondary death” that occurs days to weeks 
after the initial trauma. The pathogenesis of secondary death was a major 
contributing factor in the choice of which murine model of inflammation to use 
to evaluate SIC’s ability to skew members of the myeloid lineage to a 
regulatory/anti-inflammatory phenotype. As described in section 1.7.1.2, the 
phenomenon of secondary death describes the aberrant inflammatory immune 
response that occurs after SCI with the infiltration and activation of microglia 
and leukocytes at the site of injury - where they release pro-inflammatory 
mediators such as cytokines, reactive oxygen species and matrix 
metalloproteinases, which lead to additional neuronal death after the initial 
injury 94 282. 
Monocytes play a major role in the perpetuation of the inflammatory immune 
response after SCI (diagram 4.1) as they have been shown to differentiate into 
activated inflammatory macrophages once they have trafficked to the site of 
injury. These cells are one of the main culprits in the production of the vast 
amount of inflammatory mediators responsible for death of healthy neurones not 
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This chapter aims to: 
• Characterize the binding profile of SpA within the myeloid compartment 
in steady-state and after SCI  
• Assess any phenotypic changes that SpA induces in this compartment 
• Determine whether or not SpA can modulate the vast amount of 
inflammation that is perpetuated by monocytes and macrophages in the 
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Figure 4.1: Time course of innate immune cell infiltration into the damaged spinal cord after 
injury.  
Neutrophils arrive in the damaged spinal cord 4h after injury and can be seen at the site of injury 
until post injury day 2. Monocytes infiltrate into the damaged cord 12h after injury where they 
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4.2 Results 
4.2.1 SpA binding to Monocytes and Neutrophils 
To examine the ability of SpA to bind to cells of the myeloid lineage in an in vivo 
setting, 500µg of fluorochrome-labelled SpA or OVA was injected i.p. into 
C57BL/6 mice. Two hours later mice were culled and blood (figure 4.2), spleen 
(data not shown) and bone marrow (figure 4.3) were harvested for flow 
cytometric analysis. In the blood, the negative control (OVA-488) did not 
interact with CD11b+ GR1low Ly6C+ monocytes; however, SpA-488 showed 
significant binding to CD11b+ GR1low Ly6C+ monocytes with a mean ± SD MFI of 
2759 ± 450 (Figure 4.2A). Examination of the circulating neutrophil 
compartment, CD11b+ Gr1hi Ly6C-, demonstrated that SpA-488, when compared 
to control (OVA-488), was able to bind to circulating neutrophils with a mean ± 
SD MFI of 193 ± 18. Nevertheless, it is important to note that the binding of SpA-
488 to neutrophils was 10-fold lower than to monocytes. The difference in 
binding between the two cell populations can most likely be attributed to the 
differential expression of Fcγ receptors on the cell surface. 
The substantial binding of SpA to the monocyte compartment led to a further 
interrogation of this population. As discussed in the introduction to this chapter, 
the circulating monocyte population can be divided into Ly6Chi and Ly6Clow 
monocyte subsets that can define their functional outcomes in both steady-state 
and inflammation. Analysis of SpA-488 binding illustrates that both populations 
of monocytes significantly interact with SpA-488 when compared to control 
protein (OVA-488) (Figure 4.2B). Although not a significant difference, it should 
still be noted that Ly 6Chi monocytes have increased binding (mean ± SD MFI, 
2907 ± 490) compared to Ly6Clow monocytes (mean ± SD MFI, 2086 ± 335).  
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Figure 4.2 SpA-488 binding in monocytes and neutrophils in blood.  
C57BL/6 mice received either 500μg of SpA-488 or OVA-488 i.p. After 2h mice were culled and 
blood was harvested and prepared for flow cytometric analysis on the MACS Quant. Data were 
analysed by a two-tailed, unpaired t-test, ** = P<0.01; *** = P<0.001. (A) The mean ± SD MFI 
values for SpA-488 and OVA-488 binding for blood monocytes T15= 6.07, P<0.0001 (left panels) 
and neutrophils T15= 2.98, P<0.01 (right panels) with representative histogram plots below; SpA – 
blue line, OVA – red line. (B) The mean ± SD MFI values for Ly6Chi T15= 5.93, P<0.0001 (right 
panels) and Ly6Clow T15= 5.71, P<0.0001 (left panels) monocyte populations, binding with 
representative histogram plots below; SpA – blue line, OVA – red line. This experiment was carried 
out on three separate occasions; the data were then pooled together for purposes of statistical 
analysis. The three experiments had a total N of; SpA N=8 and OVA N=9.  
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The binding of SpA-488 to myeloid cells within the bone marrow was also 
examined 2h after injection. The control protein (OVA-488) did not interact with 
monocytes - as it had a mean MFI of 181±11; however, SpA exhibited 
significantly higher binding to monocytes with a mean ± SD MFI of 678±129 
(figure 4.3A). When comparing monocyte binding levels from the blood to the 
bone marrow, a dramatic decrease in binding of SpA can be seen - with a 
dramatic decrease in the mean ± SD MFI value 2759 ± 450 to 678±129, 
respectively. It was also noted that in the bone marrow, but not in the blood, 
monocytes binding was bimodal. The bone marrow is the major site of 
haematopoiesis, thus there will be an array of monocytes at different 
developmental stages, exhibiting different surface receptor expression. This 
could explain the difference in SpA-488 binding between blood and bone marrow 
compartments, since in the bone marrow a wide spectrum of Fc receptor 
expression exists, whereas in the blood, Fc receptors are expressed at higher 
defined levels. Also, SpA-488 binding to neutrophils was assessed in the bone 
marrow where no binding was noted.   
Although SpA-488 binding to monocytes was lower in the BM compared to blood, 
the interaction of SpA-488 with monocyte subsets was investigated due to the 
bimodal distribution of binding seen in the total monocyte population (Figure 
4.3A), and because the bone marrow is an important site of monocyte 
maturation and differentiation (figure 4.3B). Furthermore, when Ly6Chi 
monocytes do not encounter an inflammatory signal in the blood stream they are 
believed to home back to the bone marrow and differentiate into Ly6Clow 
monocytes, which are then released into the blood stream to either patrol the 
vasculature or replace tissue-specific DC and macrophages in the steady-state. In 
accordance with the blood, SpA-488 showed significantly increased binding to 
the Ly6Chi monocyte subset in comparison to the control protein. However, 
unlike the blood, only a minor population of the Ly6Clow monocyte subset bound 
to SpA-488.  
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Figure 4.3 SpA-488 binding in monocytes and neutrophils in bone marrow.  
C57BL/6 mice received either 500µg of SpA-488 or OVA-488 i.p. After 2h mice were culled and 
bone marrow was harvested and prepared for flow cytometric analysis on the MACS Quant. Data 
were analysed by a two-tailed, unpaired t-test, ** = P<0.01; *** = P<0.001. (A) The mean ± SD MFI 
values for SpA-488 and OVA-488 binding for bone marrow monocytes T5= 4.30, P<0.0077 (left 
panels) and neutrophils T5= 0.52, P<0.620 (right panels) with representative histogram plots below; 
SpA – blue line, OVA – red line. (B) The mean ± SD MFI values for Ly6Chi T5= 4.54, P<0.0062 
(right panels) and Ly6Clow T5= 2.39, P<0.0621 (left panels) monocyte populations, binding with 
representative histogram plots below; SpA – blue line, OVA – red line. This experiment was carried 
out on two separate occasions; the data were then pooled together for purposes of statistical 
analysis. The two experiments had a total N of; SpA N=3 and OVA N=4.  
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4.2.2 SpA requires IgG to interact with myeloid cells in vivo 
It has been previously shown in vitro that SpA must be in complex with IgG at a 
2:4 ratio (two SpA molecules and four IgG molecules for one complex) for it to 
exert its immuno-modulatory effects 225. The inability of SpA to interact with 
monocytes in the absence of IgG in vivo was examined using µMT mice - as they 
lack mature B cells. This defect is due to a mutation in their µ C gene, which 
leads to a loss of membrane-bound heavy chain. Failure to express the heavy 
chain with the surrogate light chain results in arrestment of the cell at the large 
pre-B cell stage of development 283. µMT mice have no immunoglobulin due to 
their lack of mature B cells, making the µMT mice the perfect host to test the 
hypothesis that SpA must be bound to IgG to facilitate monocyte interaction.  
Mice were injected i.v. with either 6mg of purified murine IgG or PBS and left 
for 40min to equilibrate. The same mice were subsequently injected with either 
500µg of SpA-488 or OVA-488 i.p. and left for a further 2h before being culled 
and blood harvested. The control protein, OVA-488, did not interact with the 
monocyte population in the presence or absence of IgG (figure 4.4). Compared 
to controls, minimal binding of SpA-488 to monocytes was observed. However, 
this marginal binding could possible be attributed to SpA’s ability to interact 
with TNFR1 and von Willebrand factor 284 285. Importantly, SpA-488 in the 
presence of IgG binds the majority of the monocyte population to a far greater 
extent than SpA-488 in the absence of IgG (figure 4.4A). The dramatic difference 
in SpA’s ability to bind to the monocyte population in the presence or absence of 
IgG can be demonstrated further when looking at MFI values (figure 4.4B): SpA-
488 plus PBS has a mean ± SD MFI of 1540±590, but SpA-488 plus IgG has a mean 
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Figure 4.4. SpA requires IgG to interact with monocytes in vivo.  
μMT mice received either 500µg of SpA-488 or OVA-488 i.p and 6mg of IgG or PBS i.v. After 2h 
mice were culled and blood was harvested and prepared for flow cytometeric analysis. (A) 
Histograms illustrate SpA-488 and OVA-488 binding in the presence and absence of IgG binding 
profiles to monocytes in the blood. (B) The mean ± SD MFI values for SpA-488 and OVA-488 
binding in the presence and absence of IgG binding profiles to monocytes in the blood. This 
experiment was carried out on two separate occasions; the data were pooled together for purposes 
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4.2.3 SpA treatment for 24hrs under non-inflammatory conditions 
leads to a shift in the blood monocyte population 
Having established that SpA binds to monocytes in the blood and bone marrow in 
the presence of IgG, the next step was to examine if there was any effect on the 
monocyte population in vivo under steady-state conditions. C57BL/6 mice were 
treated with 600µg of SpA or OVA for 24h before they were euthanized, and 
blood (figure 4.5) and bone marrow (data not shown) harvested and prepared for 
flow cytometric analysis.  
Monocytes were defined as CD11b+, Gr1low/-, Ly6C+ and then sub-divided into 
CD11b+, Gr1low, Ly6Chi or CD11b+, Gr1-, Ly6Clow populations; and the two 
populations can be seen clearly in the representative histogram and FACS plots 
(figure 4.5A). It was observed that in comparison to the control group (OVA), SpA 
treatment resulted in a significant decrease in the Ly6Chi population with a 
concurrent increase in the Ly6Clow population (figure 4.5B). This suggests that 
SpA treatment could be promoting the differentiation of Ly6Chi monocytes into 
Ly6Clow monocytes. As discussed in the introduction to this chapter and in 
section 1.3.3, Ly6Chi monocytes are termed the inflammatory sub-set and have a 
short half-life in the blood. If they do not migrate to a site of inflammation 
where they can differentiate into a macrophage or DC, Ly6Chi monocytes will 
mature into Ly6Clow monocytes. The previous data would suggest that SpA 
accelerates this natural process. 
In addition to looking at the expression of Ly6C, other relevant cell surface 
markers were also investigated e.g. FcγRI, which is essential for SIC binding in 
BMDM (Section 3.2.6). Evaluation of CD64 (FcγRI) expression after SpA treatment 
demonstrated that it was significantly down-regulated on both monocyte subsets 
(figure 4.5C). Furthermore, Gr1 was also significantly down-regulated in the 
Ly6Chi SpA treatment group when compared to the OVA control group (figure 
4.5D). It is of interest to note that the Ly6Chi monocyte population starts to 
down-regulate its Gr1 expression in the presence of SpA - leading to the 
assumption that SpA is inducing the Ly6Chi monocyte to mature into a Ly6Clow-
like population - as Gr1 is not expressed on the latter population.  
 
  127 
 
Figure 4.5. SpA treatment for 24h under non-inflammatory conditions leads to a shift in the 
blood monocyte population.  
C57BL/6 mice received either 600µg of SpA or OVA i.p. After 24h mice were culled and blood was 
harvested and prepared for flow cytometric analysis. Data were analysed by a two-tailed, unpaired 
t-test, * =P<0.05; ** = P<0.01; *** = P<0.001. (A) A representative histogram (OVA - red line, SpA – 
blue line) and FACS plots of the Ly6Chi and Ly6Clow monocyte subsets in the blood from each 
treatment group. (B) The mean ± SD % for Ly6Chi T10= 4.69, P<0.0015 (left panels) and Ly6Clow 
T10= 4.53, P<0.0019 (right panels) monocyte populations in the blood. (C) The mean ± SD MFI 
values of CD64 for Ly6Chi T10= 12.39, P<0.0002 (left panels) and Ly6Clow T10= 4.76, P<0.01 (right 
panels) monocyte. (D) The mean ± SD MFI values for Gr1 for Ly6Chi T10= 2.98, P<0.041 (left 
panels) and Ly6Clow (right panels) monocyte populations. This experiment was carried out on two 
separate occasions; the data were then pooled together for purposes of statistical analysis. The 
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4.2.4 FcγRIII and SpA 
The binding studies performed in chapter three showed that SIC interacts with 
and operates via FcγRs - predominantly FcγRI - polarizing bone marrow-derived 
macrophages to an IL-10-producing anti-inflammatory phenotype. Unfortunately, 
FcγRI-/- mice could not be obtained to investigate SpAs interaction with FcγRI in 
an in vivo setting. However, FcγRIII-/- mice were available and these were used 
instead. Studies have shown that FcγRIII plays a role in the anti-inflammatory 
properties of IVIg in the resolution of inflammation. Bone marrow-derived 
macrophages exhibited reduced ROS production, endocytosis and phagocytosis 
via ITAMi activity, which is the inhibitory signalling component of the Fcγ 
receptor 203. Since FcγRIII has been implicated in the mechanism of IVIg, it was 
decided to investigate whether FcγRIII is one of the receptors responsible for the 
change in phenotype of the monocyte population after treatment with SpA.  
FcγRIII-/- mice were injected with 600µg of SpA or OVA for 24h before the mice 
were culled; blood was then harvested and prepared for flow cytometric 
analysis. The two-monocyte sub-populations were gated as described in section 
4.2.3. The same phenotypes present in blood monocytes of C57BL/6 mice (figure 
4.5) after SpA treatment for 24h were seen in the FcγRIII-/- with a shift in the 
Ly6Chi to Ly6Clow monocyte population (figure 4.6A&B). CD64 (figure 4.6C) and 
Gr1 (figure 4.6D) were also down-regulated in the FcγRIII-/- blood monocyte 
populations. This led to the conclusion that FcγRIII is not vital to the mechanism 
by which SpA regulates the change of Ly6Chi monocytes in the blood.  
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Figure 4.6. FcγRIII is not involved in SpAs ability to induce Ly6Chi monocytes maturation to 
Ly6Clow monocytes in the blood.  
FcγRIII-/- mice received either 600µg of SpA or OVA i.p. After 24h mice were culled and blood was 
harvested and prepared for flow cytometric analysis on the LSR II. Data were analysed by a two-
tailed, unpaired t-test, ** = P<0.01; *** = P<0.001. (A) Representative FACS plots of the Ly6Chi and 
Ly6Clow monocyte subsets in the blood from each treatment group. (B) The mean ± SD % for 
Ly6Chi (T5= 4.18, P<0.0086, left panels) and Ly6Clow (T5= 4.04, P<0.0099, right panels) monocyte 
populations in the blood. (C) The mean ± SD MFI values of CD64 for Ly6Chi T5= 6.97, P<0.0009 
(left panels) and Ly6Clow (T5= 5.35, P<0.0031, right panels) monocytes. (D) The mean ± SD MFI 
values of Gr1 for Ly6Chi (T5= 8.94, P<0.0003, left panels) and Ly6Clow T5= 6.01, P<0.0018 (right 
panels) monocyte populations. This experiment was carried out on two separate occasions that 
showed the same results: the data shown is a representative figure of one of these experiments. 
The experiment shown has an N of; SpA N=5 and OVA N=6. The two experiments had a combined 
total N of; SpA N=10 and OVA N=11.  
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4.2.5 SpA-488 cannot penetrate the blood-brain barrier and 
interact with cells in the undamaged spinal cord 
The data thus far suggest that SpA induces the differentiation of the Ly6Chi 
inflammatory monocyte subset to the Ly6Clow patrolling/anti-inflammatory 
subset in the steady-state. The ability of SpA to modulate cells of the myeloid 
lineage in an inflammatory environment was now investigated. To do this, the 
impact of SpA-mediated monocyte modulation in SCI was examined - as high 
levels of infiltration by monocytes are seen in the early stages of SCI. It was 
hypothesized that if the balance of inflammatory monocytes could be shifted to 
a regulatory phenotype this might reduce the amount of neuronal death that is 
attributed to the secondary death phenomenon seen after SCI.   
The first questions to be addressed was whether SpA could pass-through the 
blood-brain barrier in an undamaged spinal cord and thereafter interact with 
cells in this microenvironment. To examine this, the same technique used in 
section 4.2.1 was employed here. In brief, 500µg of SpA-488 or OVA-488 were 
injected i.p into C57BL/6 mice and left for 2h; mice were culled, exsanguinated 
and perfused with PBS. This method was employed to make sure minimal blood 
cell contamination occurred in the spinal cord. The spinal cords were then 
harvested and prepared for flow cytometric analysis.  
DAPI was used to gate out dead cells (not shown), and CD45 used to locate the 
leukocyte population in the spinal cord (figure 4.7A). The majority of the CD45+ 
cells present in the un-damaged cord were microglia (92.5% ±1.4) - defined as 
CD45int CD11b+. When the CD45hi and CD45int population were gated, in both the 
control and SpA-488 group, there were only background levels of fluorescent 
binding (figure 4.6B). Thus, it can be concluded that SpA-488 cannot enter an 
un-damaged spinal cord due to the presence of the blood-brain barrier.  
  131 
 
Figure 4.7. SpA cannot cross the intact blood-brain barrier to interact with cells within the 
spinal cord.  
C57BL/6 mice received either 500µg of SpA-488 or OVA-488 i.p. After a further 2h mice were 
culled and spinal cord was harvested and prepared for flow cytometric analysis. (A) Gating strategy 
for un-damaged spinal cord, live/dead cell exclusion is performed first on samples (not shown), 
followed by CD45+ selection. Microglia are then distinguished as CD45int and all other leukocytes 
are gated as CD45hi. (B) Representative leukocyte and microglia histograms of SpA-488 (blue line) 
and OVA-488 (red line) binding. This experiment was carried out on three separate occasions. The 
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4.2.6 SpA-488 interactions in the damaged spinal cord 
When the blood-brain barrier is intact, SpA is unable to bind to cells within the 
spinal cord (Figure 4.7).  However, physical disruption to the barrier should 
facilitate entry of SpA and allow interaction with myeloid cells in the spinal cord 
microenvironment. To generate SCI, mice received a contusion injury of 100Kdyn 
to the C5/C6 border of the spinal cord (see methods section 2.10); 24h later 
mice were injected i.p with 500µg of SpA-488 or OVA-488 and left for a further 
2h. Mice were euthanized and the damaged spinal cord sections (figure 4.8) 
were then harvested along with blood (figure 4.9) and prepared for flow 
cytometric analysis to look at the SpA-488 binding profile in comparison to the 
binding profile of SpA-488 in the non-injured mice (figure 4.7). 
Gating of the damaged spinal cord cells was carried out as described in the 
undamaged spinal cord (section 4.2.5). The proportion of the CD45+ population 
found in the damaged spinal cord was vastly different from the undamaged 
spinal cord with 58.4% ± 6.8 being CD45hi cells- in comparison to the undamaged 
cord of only 7.4% ± 1.4 cells, which is a very statistically significant change 
(P<0.0001). The CD45hi cell population was analysed further to determine 
composition (figure 4.8A). This revealed that, as expected, both neutrophils 
(CD11bhi, Gr1+ and Ly6C-) and monocytes (CD11bhi, Gr1+ and Ly 6C+) were present 
in the spinal cord. 
Evaluation of SpA-488 binding in the monocyte, neutrophil and microglial 
populations (CD45int, CD11bint and Ly6C-) were determined (Figure 4.8B&C) - 
concluding that monocytes and microglia showed significantly higher binding of 
SpA-488 than the control protein OVA-488. In the microglia population, MFI 
values demonstrated that SpA-488 had a mean ±SD of 670 ±81 compared to just 
231 ±22 in the OVA-488 group. Microglia are a branch of the myeloid cell lineage 
and as such are said to be the “macrophages of the CNS”, so it was to be 
expected that these cells would interact with SpA-488. Monocyte MFI mean ± SD 
for SpA-488 binding was 1547 ± 341 in comparison to that of the control protein 
of 256 ± 48. With regard to the neutrophils, although we saw significant binding 
of SpA-488 in comparison with the OVA-488 control (Figure 4.8C), as can be seen 
in the histogram (Figure 4.8B), this represented a small population skewing the 
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MFI value. It is possible that this was due to a very small proportion of 
monocytes being present in the neutrophil gate.  
The SpA-488 binding profile in blood of the injured mice was also examined 
(figure 4.9) and interestingly, this confirmed previous findings shown in the 
blood of the uninjured mice (figure 4.2). SpA-488 binds significantly more than 
control protein (OVA-488) to the total monocyte population as well as to the two 
sub-populations (Figure 4.9B) and the neutrophil population (Figure 4.9B). In the 
neutrophil population, the mean ±SD MFI of SpA-488 is 280±27, which is a 10-fold 
decrease in comparison to monocytes’ ability to bind to SpA-488, which have an 
mean ±SD MFI of 3574±609. A detailed analysis of SpA-488 binding (mean ±SD 
MFI) to a variety of myeloid cells within the damaged portion of the spinal cord, 
blood and bone marrow after SCI is presented in Appendix 3. It can be concluded 
therefore that SpA-488 can bind to microglia and monocytes in the spinal cord 










  134 
 
Figure 4.8. SpA-488 can bind to cells within a damaged spinal cord.  
C57BL/6 mice received SCI at the C5/6 border. 24h after injury mice received either 500µg of SpA-
488 or OVA-488 i.p. After a further 2h mice were culled and spinal cords were harvested and 
prepared for flow cytometric analysis. Data were analysed by a two-tailed, unpaired t-test, ** = 
P<0.01; *** = P<0.001. (A) Gating strategy for the damaged spinal cord. (B) Representative 
histograms depicting SpA-488 (blue) and OVA-488 (red) binding to monocytes, microglia and 
neutrophils. (C) The mean ± SD MFI values for SpA-488 and OVA-488 binding to monocytes (T8= 
3.41, P<0.01), microglia (T8= 5.24, P<0.0008) and neutrophils (T8= 8.94, P<0.0003). This 
experiment was carried out on two separate occasions; the data were then pooled together for 






  135 
 
Figure 4.9. SpA-488 binding profile in blood monocytes and neutrophils after SCI.  
C57BL/6 mice received SCI at the C5/6 border. 24h after injury mice received either 500µg of SpA-
488 or OVA-488 i.p. After a further 2h mice were culled and blood was harvested and prepared for 
flow cytometric analysis on the MACS Quant. Data were analysed by a two-tailed, unpaired t-test, 
** = P<0.01; *** = P<0.001. (A) The mean ± SD MFI values for SpA-488 and OVA-488 binding for 
blood monocytes (T8= 5.27, P<0.0008, left panels) and neutrophils (T8= 7.13, P<0.0001, right 
panels) with representative histogram plots below; SpA – blue line, OVA – red line. (B) The mean ± 
SD MFI values for Ly6Chi (T8= 8.24, P<0.0001, right panels) and Ly6Clow (T8= 4.08, P<0.0035, left 
panels) monocyte populations, binding with representative histogram plots below; SpA – blue line, 
OVA – red line. This experiment was carried out on two separate occasions; the data were then 
pooled together for purposes of statistical analysis. The two experiments had a total N of; SpA N=5 
and OVA N=5.  
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4.2.7 24hr treatment with SpA has an effect on the infiltrating 
monocyte populations after SCI 
 It has already been established that SpA can bind to cells in the damaged spinal 
cord. The next task was to examine if SpA treatment had an effect on the 
myeloid cell populations found in the damaged spinal cord after treatment. To 
do this, mice received 100Kdyn contusion injuries at the C5/6 border of the 
spinal cord. After a recovery period of 24h, mice then received 600µg of either 
SpA or OVA by i.p injection. After a further 24h, mice were euthanized and 
blood (figure 4.11), bone marrow (data not shown) and the damaged portion of 
the spinal cord (figure 4.10) were harvested and prepared for flow cytometric 
analysis. 
The monocyte population showed an altered phenotype after 24h treatment with 
SpA, and this included changes in the sub-populations Ly6Chi and Ly6Clow, which 
make up the total monocyte population. Analysis demonstrated that the Ly6Chi 
inflammatory monocyte subset was significantly decreased after SpA treatment 
(figure 4.10A&B) – whereas, the Ly 6Clow monocyte subset was significantly 
increased (figure 4.10A&B). Further investigation of CD64 (figure 4.10C) and Gr1 
(figure 4.10D), in a subsequent experiment, showed a substantial down-
regulation of both markers after SpA treatment. It should be appreciated, 
however, that due to fatalities in surgery and time restraints, only 2 mice pre-
group were evaluated and therefore statistical tests could not be performed. In 
support of this finding, the results showed a similar phenotype to those 
exhibited in the blood of uninjured mice that were treated with SpA for 24h 
(figure 4.5). However, the microglial and neutrophil populations within the 
damaged spinal cord exhibited no observable phenotypic variations after 24h 
treatment with SpA - in comparison to the control treated group (data not 
shown). 
 
Furthermore, evaluation of the circulating monocytes in the blood of SCI mice 
(Figure 4.11) confirmed the altered phenotype in the myeloid compartment. SpA 
treatment significantly decreased the Ly6Chi monocyte population while 
significantly increasing the Ly6Clow monocytes (figure 4.11 A&B). This outcome 
was also associated with the down-regulation of CD64 (figure 4.11C) and Gr1 
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(figure 4.11D). Once again, statistical analysis could not be performed on CD64 
and Gr1 levels because, as previously described, only two mice could be 
evaluated. These data therefore suggest that SpA treatment 24h after SCI is 
inducing the maturation of the Ly6Chi inflammatory monocytes to the Ly6Clow 
monocytes, which are assumed to be of an anti-inflammatory or regulatory 
nature.  
4.2.8 IL-10, SCI and SpA 
SpA treatment for 24h has been shown in section 4.2.7 to modify the monocyte 
population within the damaged spinal cord to a predominately Ly6Clow 
monocytes population. This is an interesting finding as Ly6Clow monocytes are 
said to differentiate into regulatory or tissue-repair macrophages within an 
inflammatory environment. SpA has also been shown to promote bone marrow-
derived macrophages to an anti-inflammatory phenotype when stimulated in 
conjunction with LPS, with significantly higher IL-10 (one of the main immune-
modulatory cytokines of the immune system) and significantly decreased IL-12 
(pro-inflammatory cytokine) production when compared to controls. Hence, it 
was of interest to examine if SpA treatment after SCI would induce the 
infiltrating monocyte population to produce IL-10 and be truly polarized to a 
regulatory or tissue-repair phenotype after SpA treatment - as well as having 
decreased Ly6C surface expression.  
Vert-X mice are IL-10 reporter mice, and have a GFP (green fluorescent protein) 
reporter gene linked to the IL-10 promoter - leading to the production of GFP 
when the cell is induced to produce IL-10. This allows the quantification of IL-10 
production at an individual cell level by the correlation of the amount of 
fluorescence each cell exhibits. SCI was induced in the Vert-X mice and after 24h 
of recovery, mice were i.p. injected with SpA or OVA. Twenty-four hours later 
mice were euthanized and blood and the damaged portion of the SC were 
removed and prepared for flow cytometric analysis.  
The same monocyte phenotype that was noted previously in the damaged SC 
(figure 4.10A) after SpA treatment was also seen in the Vert-X mice, with the 
consequential reduction of Ly6Chi monocyte population and an increase in the 
Ly6Clow monocyte subset (figure 4.12A).  
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In the OVA treatment group, 49.7% of the population of monocytes in the 
damaged spinal cord produced IL-10, which concurs with recent literature that 
there will be 50% of inflammatory and regulatory macrophages/monocytes 
present 3-4 days post-injury 133; after this point the authors saw an exponential 
increase in inflammatory macrophages. In the SpA treatment group, 68.5% of the 
population expressed IL-10. The Ly6Chi monocytes population predominantly 
seen in the control group did not produce any IL-10, corroborating their status as 
being the inflammatory subset of monocytes. The entire population of Ly6Clow 
monocytes, which were the predominant population in the damaged spinal cord 
of the SpA treatment group, produced IL-10, confirming their status as the 
regulatory subset. It is interesting to note that monocytes in the blood in both 
treatment groups did not express any IL-10. This finding is most likely due to a 
lack of tissue-specific signal to induce the production of IL-10. 
Again, due to technical issues with the contusion surgery there was only N=1 per 
group for this experiment. Furthermore, there was an outbreak of pseudomonas 
in the facility that breeds the Vert-X mice colonies, resulting in the colony 
having to be culled. The Vert-X mouse line has not yet been re-derived, 
therefore, as a consequence this experiment has not been repeated. The above 
result has been added here only as an interesting observation, and will have to 
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Figure 4.10, 24h treatment with SpA alters the infiltrating monocyte populations after SCI.  
C57BL/6 mice received contusion at the C5/6 border. 24h post-injury mice received either 600µg of 
SpA or OVA i.p. After a further 24h mice were culled and spinal cords were harvested and 
prepared for flow cytometric analysis. Data were analysed by a two-tailed, unpaired t-test, *** = 
P<0.001. (A) Representative image of the monocyte population within the damaged spinal cord of 
a SpA and control group. (B) The mean ± SD % for Ly6Chi (T10= 5.29, P<0.0004, left panels) and 
Ly6Clow (T10= 5.33, P<0.0003, right panels) monocyte populations in the damaged spinal cord. (C) 
The mean ± SD MFI values of CD64 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte. 
(D) The mean ± SD MFI values of Gr1 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte 
populations. This experiment was carried out on two separate occasions; the data were then 
pooled together for purposes of statistical analysis. The two experiments had a total N of; SpA N=6 
and OVA N=6. CD64 & Gr1 were not introduced until the second experiment; due to fatalities in 
surgery sample size was too small to perform statistical analysis (SpA N=2, OVA N=2).  
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Figure 4.11, 24h treatment with SpA alters the blood monocyte populations after SCI.  
C57BL/6 mice received a contusion injury at the C5/6 border. 24h post-injury mice received either 
600µg of SpA or OVA i.p. After a further 24h, mice were culled and spinal cords were harvested 
and prepared for flow cytometric analysis. Data were analysed by a two-tailed, unpaired t-test, *** = 
P<0.001. (A) Representative FACS plots of the Ly6Chi and Ly6Clow monocyte subsets in the blood 
from each treatment group. (B) The mean ± SD % for Ly6Chi (T10= 4.71, P<0.0008, left panels) and 
Ly6Clow (T10= 4.66, P<0.0009, right panels) monocyte populations in the blood after SCI. (C) The 
mean ± SD MFI values of CD64 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte. (D) 
The mean ± SD MFI values of Gr1 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte 
populations. This experiment was carried out on two separate occasions; the data were then 
pooled together for purposes of statistical analysis. The two experiments had a total N of; SpA N=6 
and OVA N=6. CD64 & Gr1 were not introduced until the second experiment; due to fatalities in 
surgery sample size was too small to perform statistical analysis (SpA N=2, OVA N=2).  
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To validate if SpA was in fact inducing IL-10 production in these mice, BMDM 
were generated from Vert-X mice (as described in section 2.2). On day 6, the 
BMDM were plated out at a concentration of 1.5x106 cells in 3ml of complete 
media in 6 well plates and left overnight to adhere. On day 7, the macrophages 
were treated with SIC or IgG at 25µg/ml with or without 100ng/ml of LPS for 6h. 
Only enough cells were generated to have 1 well per condition. Medium was 
removed and cells scraped off the plates; flow cytometric analysis was carried 
out to look at GFP expression, which correlates to IL-10 production in the cells. 
The treatment of SIC and LPS in combination leads to superior IL-10 production 
from the Vert-X macrophages in comparison to the controls (figure 4.13A), which 
was also shown in chapter 3 by IL-10 ELISA when this experiment was performed 
with C57BL/6 mice. CD64, another marker that has been shown in previous 
experiments to be down-regulated with SpA treatment in vivo, was also down-
regulated with SIC treatment. Unlike IL-10, this occurred in the presence or 
absence of LPS. In chapter 3 it was demonstrated that CD64, also known as 
FcγRI, was essential for SIC’s ability to polarize BMDM to an anti-inflammatory 
phenotype. The observations made in figures 4.12 and 4.13 are extremely 
interesting and indicate that SpA is inducing monocytes to differentiate and 
mature into a regulatory or anti-inflammatory macrophage population that has 
the ability to produce IL-10. However, the results are only of an observational 
nature due to the small ‘n’ and must be repeated so statistical analysis can be 
preformed before any definitive conclusions are drawn from this data set. 
 
 
  142 
 
Figure 4.12, Does SpA treatment induce monocytes to become polarized to an IL-10 
producing phenotype in the context of SCI?  
Vert-X mice received SCI at the C5/6 border; 24h later mice received either 600µg of SpA or OVA 
i.p. After a further 24h mice were culled and blood and spinal cord were harvested and prepared for 
FACS analysis. (A) Shows Ly6Chigh and Ly6Clow monocyte subsets in the damaged spinal cords of 
an OVA and a SpA treated mouse. (B) Shows the total spinal cord and blood monocyte populations 
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Figure 4.13, Does SIC have the ability to induce BMDM from Vert-X mice to produce IL-10 in 
vitro? 
Bone marrow was taken from Vert-X mouse and BMDM were generated using L929 supernatant 
containing M-CSF. On day 6, BMDM were re-seeded in 3ml in 6 well plates at a concentration of 
0.5x106/1ml and left to adhere overnight. On day 7, cells were treated with SIC or IgG, with or 
without LPS (100ng/ml) for 6hrs. BMDM were then scraped off the plate and stained for FACS 
analysis. (A) Shows IL-10 GFP MFI and (B) Shows CD64 MFI. This experiment was only carried 
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4.2.9 SpA is inducing Ly6Chi monocytes to differentiate into 
Ly6Clow monocytes 
SpA treatment for 24h under steady-state or inflammatory conditions leads to a 
shift in the circulating monocyte population - whereby a decrease in the Ly6Chi 
subset and an increase in the Ly6Clow subset is observed. It has been 
hypothesised that this shift is due to the Ly6Chi monocyte population down-
regulating its Ly6C expression. The differentiation of Ly6Chi monocytes into 
Ly6Clow monocytes has been previously described and involves the homing of 
circulating Ly6Chi monocytes back to the bone marrow, due to a lack of 
encounter with an inflammatory signal in the periphery. The newly-
differentiated Ly6Clow monocytes are then released back into the circulation as 
patrolling monocytes 48.  
In this model of SpA treatment, the ratio of Ly6Chi monocytes to Ly6Clow 
monocytes was altered in the blood and in the damaged spinal cord (which is a 
highly inflammatory site). The hypothesis is that this is due to monocyte 
differentiation but an alternative possibility is that the change in monocyte 
subsets after SpA treatment is due to the trafficking of Ly6Chi cells into other 
compartments, which artificially increases the Ly6Clow population in the blood 
and the damaged spinal cord. The aim of this series of studies was to test the 
hypothesis that SpA treatment induces the differentiation of Ly6Chi monocytes 
into Ly6Clow monocytes.  
CX3CR1 is the membrane-bound receptor of the chemokine Fractalkine; it is one 
of the key markers for defining the monocyte population subsets (along with 
Ly6C). Ly6Chi monocytes express intermediate levels of CX3CR1, whereas Ly6Clow 
monocytes express high levels of CX3CR1. CX3CR1GFP transgenic mice have 
already been generated. In these mice, one allele of the Fractalkine receptor 
was removed and replaced with the gene for GFP 40. To test the above-
mentioned hypothesis, an adoptive transfer system was employed with the use 
of the CX3CR1 GFP mice. 20 of these mice were euthanized. The hind legs were 
removed and bone marrow cells were flushed out. Bone marrow cells were then 
filtered through nitex and stained with the phenotypic markers Ly6C, Gr1, CD11b 
and C-kit. This combination of antibodies allows the isolation of Ly6Chi 
monocytes by flow cytometric cell sorting (figure 4.14).  
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Figure 4.14, Gating strategy for isolation of Ly6Chi GFPint monocytes from the bone marrow 
cells of CX3CR1 mice.  
To obtain Ly6Chi GFPint monocytes, cells were sorted based on (A) Single doublet exclusion, (B) 
CD11b+ cells, (C) C-Kit- (to exclude precursor of monocytes), (D) Ly6Glow (to exclude neutrophils) 
and (E) Ly 6C and GFP expression to split the monocytes into two populations of Ly6Chi or Ly6Clow 
monocytes subsets. The Ly6Chi populations were collected and adoptively transferred by i.v. 
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1.5 million purified Ly6Chi monocytes were injected i.v into C57BL/6 mice, and 
600µg of SpA or OVA was subsequently injected i.p. Twenty-two hours later the 
mice were culled and blood, spleen and bone marrow harvested for flow 
cytometric analysis. However, on the first occasion, due to technical limitations 
with sorting of cells, only enough cells were collected for an N=4 experiment. 
The experiment was repeated a second time with N=5. 
It was seen that GFP+ cells were present in the blood and peripheral organs, such 
as the bone marrow and the spleen, 24h after their injection (figure 4.15). This 
demonstrates that GFP monocytes are surviving after the adoptive transfer 
procedure and are trafficking into other organs as well as circulating within the 
blood. When absolute numbers of GFP+ monocytes were examined within the 
blood, bone marrow and spleen, there were a greater number of GFP+ 
monocytes found in the SpA-treated mice in both experiments in comparison to 
the control group (figure 4.16). This suggests that SpA may provide a survival 
signal to monocytes after adoptive transfer, but further experiments are needed 
to test this theory. 
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Figure 4.15, GFP+ monocytes were present 22h after adoptive transfer.  
1.5x106 GFP+ Ly6Chi monocytes were adoptively transferred by iv injection into C57BL/6 mice. 
600μg of either SpA or OVA were administered i.p at the same time as the GFP+ cells. 22h later 
mice were euthanized and blood, bone marrow and spleen were harvested and analysed by flow 
cytometry. (A) Gating strategy for locating the GFP monocytes in the blood. (B) Gating strategy for 
locating the GFP monocytes in the spleen. (C) Gating strategy for locating the GFP monocytes in 
the bone marrow.  
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Figure 4.16, SpA-treated mice have a higher number of GFP+ cells present 22h after 
adoptive transfer.  
1.5x106 GFP+ Ly6Chi monocytes were adoptively transferred by iv injection into C57BL/6 mice. 
600μg of either SpA or OVA was administered i.p at the same time as the GFP+ cells. 22h later 
mice were euthanized and blood, bone marrow and spleen were harvested and analysed by flow 
cytometery. (A) Absolute number of GFP+ monocytes in the blood. (B) Absolute number of GFP+ 
monocytes in the bone marrow. (C) Absolute number of GFP+ monocytes in the spleen. This 
experiment was carried out on two separate occasions (SpA N=2, OVA N=2 for the first experiment 
and SpA N=3, OVA N=2 for the second experiment) that showed the same results: the data 
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The Ly6Chi GFP+ monocyte population found in the blood of adoptively-
transferred mice that were treated with SpA for 24h, showed a down-regulation 
of their Ly6C marker in comparison to the controls (figure 4.17A). A 
representative histogram and contour plots of the GFP+ monocyte population 
within the blood of OVA and SpA treatment groups demonstrate the down-
regulation of Ly6C that the monocyte population underwent when it was treated 
with SpA. When the total GFP+ monocyte population was sub-divided into two 
populations of Ly6Chi and Ly6Clow the difference in percentage of each 
population seen between the two treatment groups showed a significant 
increase in the percentage of GFP+ Ly6Clow monocytes in the SpA-treated group 
in comparison to the control group (figure 4.17B). Importantly, the GFP+ Ly6Clow 
monocytes could only have differentiated from the adoptively-transferred GFP+ 
Ly6Chi monocytes.  
Furthermore, examination of CD64 expression (figure 4.17C) demonstrated that 
it was significantly down-regulated in both monocyte subset populations in the 
SpA treatment group in comparison to the OVA group. This is consistent with all 
previous experiments. CX3CR1 MFI was looked at in the two monocyte 
populations; unfortunately, due to a difference in the MFI values seen across the 
two experiments, the two sets of results could not be pooled together to allow 
statistical analysis. However, in both experiments the Ly6Chi monocytes had 
increased expression (MFI mean ± SD 20000±1000) of CX3CR1 after SpA treatment 
when compared to the control group (MFI mean ± SD 14500±500) (figure 4.17D). 
It was noted that Ly6Clow monocytes express higher levels of CX3CR1 than Ly6Chi 
monocytes. Therefore, it is reasonable to speculate that this increase may be 
due to the Ly6Chi monocyte population readying themselves to differentiate into 
Ly6Clow monocytes, which express a MFI mean ± SD of 21500±500. There was only 
a very minimal change detected in CX3CR1 expression in the Ly6Clow population 
between the SpA-treated group and the OVA treated group.  
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Figure 4.17. SpA treatment for 22h leads Ly6Chi monocytes to differentiate into Ly6Clow 
monocytes in the blood.  
1.5x106 GFP+ Ly6Chi monocytes were adoptively transferred by i.v. injection into C57BL/6 mice. 
600μg of SpA or OVA was administered i.p. at the same time as the GFP+ cells. 22h later mice 
were euthanized and blood, bone marrow and spleen were harvested and analysed by flow 
cytometry. Data were analysed by a two-tailed, unpaired t-test, *** = P<0.001. (A) Representative 
histogram and contour plot showing the division of the total monocyte population into Ly6Chi and 
Ly6Clow GFP+ monocytes sub-populations in the blood. (B) The mean ± SD % for Ly6Chi GFP+ (T7= 
6.01, P<0.0005, left panels) and Ly6Clow GFP+ (T7= 6.16, P<0.0005, right panels) monocyte 
populations in the blood. (C) The mean ± SD MFI values of CD64 for Ly6Chi (T7= 17.87, P<0.0001, 
left panels) and Ly6Clow (T7= 10.15, P<0.0001, right panels) monocyte. (D) The mean ± SD MFI 
values of CX3CR1 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte. This experiment 
was carried out on two separate occasions; the data were then pooled together for the purposes of 
statistical analysis. The two experiments had a total N of; SpA N=5 and OVA N=4. Due to 
differences in voltage, CX3CR1 values could not be pooled together for statistical purposes. 
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Monocytes migrate into the peripheral organs, such as the spleen, where they 
can differentiate into macrophages. For this reason, the spleen was examined 
for GFP+ cells (figure 4.15B); and it was found that GFP+ cells were present 22h 
after adoptive transfer. Furthermore, the GFP+ cells present in the spleen 
showed a significant increase in the macrophage linage marker F4/80. 
Nevertheless, the population of GFP+ cells still expressed high levels of Ly6C and 
have the same FSC and SSC characteristics as blood monocytes. Therefore, the 
GFP+ cells present in the spleen will be defined as “monocytes/macrophages” as 
they could not be defined to any greater extent with the panel of antibodies 
used in this experiment. The representative histogram of the total GFP+ 
monocyte/macrophage population within the spleen shows the SpA-treated 
group (Blue line) and the control group (red line); the decrease in Ly6C 
expression can be seen clearly on the histogram within the SpA treatment group 
compared to the OVA group (figure 4.18A). The contour-plots show the gates 
that have been drawn to divide up the two Ly6C monocyte populations. The 
percentage of Ly6Chi population that is found in the spleen is significantly 
reduced in the SpA-treated group, along with a significant increase in the Ly6Clow 
monocyte population - compared to the OVA treatment group (figure 4.18B).  
The same significant down-regulation of CD64 that was seen in the peripheral 
blood was seen again in both of the monocyte subsets in the spleen (figure 
4.18C). Also, in the SpA treated group CX3CR1 was up-regulated on the Ly6Chi 
monocyte subset isolated from the spleen (figure 4.18D); as with the peripheral 
blood, no statistical analysis could be performed as the values between the 
experiments were too different (figure 4.17D). It is interesting to note that 
adoptively-transferred Ly6Chi monocytes traffic to the spleen and are 
differentiating to Ly6Clow monocytes in this compartment when, in point of fact, 
the literature states that they must traffic back to the bone marrow before 
differentiation can occur.  
Therefore, further analysis of the bone marrow would be beneficial after 
monocyte adoptive transfer. As mentioned above, this is the compartment that 
the literature states Ly6Chi monocytes must traffic back to in order to 
differentiate into Ly6Clow monocytes prior to subsequent release back into the 
circulation 286. The bone marrow findings were consistent with what was seen 
within the blood and spleen examinations. SpA treatment for 22h induces the 
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differentiation of the adoptively-transferred Ly6Chi GFP+ monocytes to Ly6Clow 
GFP+ monocytes in the bone marrow (figure 4.19). This can be observed when 
gates are drawn to divide up the monocyte population into two separate groups 
(figure 4.19A); there is a significant down-regulation of the percentage of Ly6Chi 
monocyte population and a significant increase in the percentage of the Ly6Clow 
population resulting from this (figure 4.19B). There was also a significant down-
regulation in CD64 expression (figure 4.19C) in both the Ly 6Chigh and Ly 6Clow 
populations. CX3CR1 also appeared to have increased in both of these 
populations but, as previously stated, statistical tests could not be performed 
due to differences in values between the two experiments (figure 4.19D). 
These data demonstrate that GFP+ Ly6Chi monocytes can be adoptively-
transferred and isolated 22h later in the blood, spleen and bone marrow. 
Interestingly, when these mice are treated with a control protein, OVA, a small 
proportion of the adoptively-transferred Ly6Chi monocytes differentiate into 
Ly6Clow monocytes. However, when the mice were treated with SpA for 22h 
there was a significantly higher rate of differentiation of the GFP+ Ly6Chi 
monocytes in the peripheral blood (and the two tissues that were also 
examined). SpA not only increased the rate of Ly6C down-regulation, but also 
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Figure 4.18. SpA treatment for 22h leads Ly6Chi monocytes to differentiate into Ly6Clow 
monocytes in the spleen.  
1.5x106 GFP+ Ly 6Chi monocytes were adoptively transferred by i.v. injection into C57BL/6 mice. 
600μg of SpA or OVA was administered i.p. at the same time as the GFP+ cells. 22h later mice 
were euthanized and the spleen was harvested and analysed by flow cytometry. Data were 
analysed by a two-tailed, unpaired t-test, **=P<0.01; *** = P<0.001. (A) Representative histogram 
and contour plot showing the arbitrary division of the total monocyte population into Ly6Chi and 
Ly6Clow GFP+ monocytes sub-populations in the spleen. (B) The mean ± SD % for Ly6Chi GFP+ 
(T7= 4.26, P<0.0036, left panels) and Ly6Clow GFP+ (T7= 3.93, P<0.0057, right panels) monocyte 
populations in the spleen. (C) The mean ± SD MFI values of CD64 for Ly6Chi (T7= 15.01, 
P<0.0001, left panels) and Ly6Clow (T7= 4.85, P<0.0019, right panels) monocyte. (D) The mean ± 
SD MFI values of CX3CR1 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte. This 
experiment was carried out on two separate occasions; the data were then pooled together for 
purposes of statistical analysis. The two experiments had a total N of; SpA N=5 and OVA N=4. Due 
to differences in voltage, CX3CR1 values could not be pooled together for statistical purposes.  
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Figure 4.19. SpA treatment for 22h leads Ly6Chi monocytes to differentiate into Ly6Clow 
monocytes in the bone marrow.  
1.5x106 GFP+ Ly 6Chi monocytes were adoptively transferred by i.v. injection into C57BL/6 mice. 
600μg of SpA or OVA was administered i.p. at the same time as the GFP+ cells. 22h later mice 
were euthanized and the bone marrow was harvested and analysed by flow cytometry. Data were 
analysed by a two-tailed, unpaired t-test, **=P<0.01; *** = P<0.001. (A) Representative histogram 
and contour plot showing the arbitrary division of the total monocyte population into Ly6Chi and 
Ly6Clow GFP+ monocytes sub-populations in the bone marrow. (B) The mean ± SD % for Ly6Chi 
GFP+ (T7= 4.24, P<0.0038, left panels) and Ly6Clow GFP+ (T7= 4.32, P<0.0035, right panels) 
monocyte populations in the bone marrow. (C) The mean ± SD MFI values of CD64 for Ly6Chi (T7= 
3.94, P<0.0056, left panels) and Ly6Clow (T7= 6.01, P<0.0005, right panels) monocyte. (D) The 
mean ± SD MFI values of CX3CR1 for Ly6Chi (left panels) and Ly6Clow (right panels) monocyte. 
This experiment was carried out on two separate occasions; the data were then pooled together for 
purposes of statistical analysis. The two experiments had a total N of; SpA N=5 and OVA N=4. Due 
to differences in voltage, CX3CR1 values could not be pooled together for statistical purposes.  
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4.3 Discussion 
In this chapter it has been demonstrated that SpA can interact with monocytes 
in the blood and bone marrow of mice under steady-state conditions, inducing 
the maturation of Ly6Chi monocytes to Ly6Clow monocytes. Moreover, in the 
inflammatory setting of SCI, SpA treatment can interact with monocytes in the 
blood and the damaged spinal cord. Furthermore, SpA can also interact with the 
resident microglial population. Consistent with homeostatic conditions, SpA 
treatment induced a maturation of the spinal cord infiltrating Ly6Chi monocyte 
subset into Ly6Clow monocytes. It was further demonstrated that treatment with 
SpA after SCI induced the Ly6Clow monocyte population to increase its production 
of IL-10. The ability of SpA to induce the maturation of the inflammatory Ly6Chi 
monocyte population into an IL-10-producing Ly6Clow anti-inflammatory 
monocyte in the vastly inflammatory environment of SCI is an intriguing prospect 
for a therapeutic approach for a cells-specific modification of the inflammatory 
environment to a far less inflammatory setting, which would possibly result in 
increased functional recovery for patients. 
One of the primary aims of this chapter was to assess the in vivo binding 
capacity of SpA to cells of the myeloid lineage. Under steady-state, SpA 
interacted with monocytes in the blood and bone marrow. Moreover, it was also 
able to interact with neutrophils; however, the level of binding was 10-fold 
lower than that observed with monocytes. In explanation, neutrophils and 
monocytes express different Fcγ receptors. In the blood under steady-state 
conditions, neutrophils are known to express FcγRIII and FcγRIV, but only very 
low levels of FcγRI or FcγRIIb, while monocytes express all four FcγRs at higher 
levels than neutrophils 287. The reduced level of FcγR expression on the cell 
surface of neutrophils is responsible for the decreased levels of SpA binding. In 
support of this it has been shown in chapter 3 that FcγRI is responsible for SIC’s 
ability to bind to and polarize BMDMs to an anti-inflammatory phenotype. 
Neutrophils express FcγRI only very weakly 288, whereas monocytes and 
macrophages express high levels of FγRI constitutively. Interestingly, when 
considering circulating monocytes, it is important to note that Ly6Chi monocytes 
express higher levels of FcγRI than the Ly6Clow subset 287. This in part explains 
why SpA has an increased degree of interaction with Ly6Chi monocytes (Figure 
4.2).  
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It has been demonstrated in the literature that the two different monocyte 
subsets have different roles in homeostasis and inflammation. As discussed in the 
introduction to this chapter, Ly6Chi monocytes are the inflammatory subset and 
have a short half-life in blood. Ly6Clow monocytes, patrol the blood vessels and 
are involved in the resolution of inflammation and the initiation of wound-
healing processes when they migrate into tissue 274  48 46. When the effects of 
SpA binding on the monocyte population in steady-state was investigated 
further, a curious skewing of the monocyte compartment to an increased 
presence of the Ly6Clow monocyte subset was revealed, even though it had been 
shown that SpA preferentially binds to the Ly6Chi subset of monocytes. The 
mechanism by which this anomaly could be explained is that if Ly6Chi monocytes 
do not migrate from the blood to a site of inflammation, where they 
differentiate into a macrophage or a DC, Ly6Chi monocytes will traffic back to 
the bone marrow and mature into Ly6Clow monocytes 47. The data present 
suggests that SpA accelerates the differentiation of Ly6Chi into Ly6Clow 
monocytes. Importantly, it also suggests that the Ly6Chi monocytes do not need 
to home back to the bone marrow to under go this transformation. 
Another indicator showing that SpA is inducing the maturation of Ly6Chi 
monocytes is that the SpA-treated Ly6Chi monocytes have decreased Gr1 (Ly6G) 
expression -conventionally used as a neutrophil marker. However, this has 
recently been shown to be expressed at low levels on the Ly6Chi subset (but is 
not expressed on the Ly6Clow monocyte subset 289), indicating that the SpA-
treated Ly6Chi population is down-regulating this marker in preparation for 
maturing into a Ly6Clow monocyte. The SpA-treated Ly6Chi population 
additionally down-regulated their CD64 (FcγRI) expression in comparison to the 
Ly6Chi monocytes of the control group, suggesting further changes in their 
maturation state are taking place as CD64 is expressed at decreased levels on 
Ly6Clow monocyte population compared to Ly6Chi monocytes 287.  
On the other hand, the change in the balance of the monocyte compartment 
after SpA treatment could be attributed to the Ly6Chi population dying off or 
migrating to another site and/or more Ly6Clow cells migrating into the blood, and 
may not in fact be a change in maturation status of the Ly6Chi monocytes at all. 
An adoptive transfer experiment was set up to address the following question: is 
SpA inducing Ly6Chi monocytes to mature into Ly6Clow monocytes?  
  157 
To answer this, Ly6Chi GFP+ monocytes were adoptively-transferred into WT 
mice, which were then treated with SpA or the control protein OVA, and 22h 
later the GFP+ cells’ phenotype was interrogated. The results showed that GFP+ 
monocytes in the SpA-treated group, compared to the control group, had 
significantly lower surface expression of Ly6C. This demonstrates that SpA is 
inducing Ly6Chi monocytes to differentiate into Ly6Clow cells and that this is at a 
higher rate than exhibited in homeostasis. As was seen in previous experiments 
(figure 4.5), Ly6C was not the only surface phenotype that was changed on the 
Ly6Chi SpA-treated group; CD64 and Gr1 were also significantly down-regulated. 
Another monocyte subset-specific marker that was examined after SpA 
treatment was CX3CR1, which is expressed at higher levels on the Ly6Clow 
monocyte sub-set compared to the Ly6Chi monocyte sub-set 40. The Ly6Chi 
monocytes of the SpA-treated group had higher levels of CX3CR1, further 
suggesting they are readying themselves for differentiation into Ly6Clow 
monocytes.  
After adoptive transfer, GFP+ cells were not only discovered in the blood, but 
were also detected in the spleen and the bone marrow. GFP+ monocytes in these 
tissues exhibited the same phenotype after SpA treatment as the blood 
monocytes. It is interesting to note that although it has previously been reported 
that Ly6Chi monocytes must migrate back to the bone marrow before 
differentiation can occur 47,67, it was also found that adoptively-transferred 
Ly6Chi monocytes trafficked to the spleen and differentiated to Ly6Clow 
monocytes. Another interesting and somewhat unexpected observation was that 
SpA not only altered the phenotype of Ly6Chi monocytes to Ly6Clow monocytes, 
but there was also a higher number of GFP monocytes recovered in the SpA-
treated group after both adoptive transfer experiments. No statistical analysis 
could be performed on this phenomenon, as recovery of cells was different in 
both experiments. The question that needs to be addressed in future work is: 
Can SpA induce monocytes to proliferate, even though literature states 
otherwise, and is this outcome specific to a certain sub-set, or alternatively is 
SpA acting as a survival agent for the monocytes?  
The ability of SpA to induce maturation of Ly6Chi monocytes to Ly6Clow 
monocytes was recognised to be a very promising therapeutic approach to the 
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amelioration of inflammation and therefore secondary death after SCI; Ly6Clow 
monocytes have been shown in many inflammation models to induce the 
resolution of inflammation and play a vital role in tissue remodelling 58 55 290. To 
evaluate the ability of SpA to modulate the inflammatory monocyte 
compartment in the absence of an overt auto-reactive adaptive immune 
response, a contusion model of spinal cord injury was used - driven by a 
traumatic event - resulting in significant inflammation at the site of injury 132 291 
292. Ly6Chi monocytes have already been targeted as a method for the 
modulation of CNS inflammation in neurodegenerative diseases such as 
Amyotophic Lateral Sclerosis (ALS). ALS results from progressive muscle 
weakness associated with degeneration of motor neurons in the brain and spinal 
cord 293. The disease pathology is perpetrated by activated microglia and 
infiltrating pro-inflammatory Ly6Chi monocytes in the spinal cord, an outcome 
that is very similar to the pathogeneses of secondary death in SCI. Interestingly, 
the administration of an anti-Ly6C monoclonal antibody to mice prone to ALS, 
significantly increased survival and neurological scoring in the treatment group 
compared to the control group (which received an isotype control antibody). 
This result was due to decreased recruitment of Ly6Chi monocytes into the spinal 
cord, which correlated with an increase in neuronal survival and a decrease of 
pro-inflammatory cytokine production 294. Although this is not SCI, it is 
nevertheless a neuro-inflammatory disease - which illustrates that inflammation 
is decreased by minimizing the presence of Ly6Chi monocytes in the spinal cord, 
resulting in a decreased neuronal death and an increased level of survival. 
The depletion of monocytes/macrophages has been previously investigated in 
the experimental treatment of SCI. Scientists have used clodronate liposomes 
when seeking to deplete monocytes or macrophages from a model system 295. 
However, this is not a very specific or elegant method as it also depletes any 
cells that can phagocytosis the toxic liposomes. When clodronate has been used 
to “selectively” deplete monocytes/macrophages in SCI studies, varying results 
were noted, prompting much debate in the past as to whether 
macrophages/monocytes played a protective or determinate role in SCI 296 94.  
It has become much clearer in recent years that macrophages and monocytes are 
heterogeneous populations, and the sub-sets within these cell types play both 
beneficial and detrimental roles in the recovery from diseases or tissue injuries. 
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A new and more sophisticated experimental strategy designed to specifically 
modulate the inflammatory Ly6Chi component of the monocyte population uses   
siRNA against CCR2. CCR2 is the chemokine receptor that the inflammatory 
Ly6Chi monocytes utilise to egress from the bone marrow and travel to sites of 
inflammation 69. Firstly, Leuschner et al demonstrated that Ly6Chi monocytes 
take up the highest level of the CCR2 siRNA, showing a significant decrease in 
the amount of CCR2 mRNA that these Ly6Chi cells were producing. Leuschner et 
al went on to demonstrate that in several models of inflammation (myocardial 
infarction, pancreatic islet transplantation and atherosclerosis), which are all 
characterized by large infiltrates of inflammatory monocytes, reduced Ly6Chi 
monocytes were recruited to the site of inflammation, correlating with improved 
recovery after CCR2 siRNA treatment. 1.  
The use of siRNA or Ly6C blocking antibodies are two methods that have been 
shown to reduce the infiltration of Ly6Chi monocytes into sites of inflammation, 
correlating with better outcomes. However, the potential benefit of using SpA 
instead of either of these two strategies is evidenced by the fact that SpA 
treatment has been shown to induce the maturation of Ly6Chi inflammatory 
monocyte into Ly6Clow anti-inflammatory monocytes. The increase in Ly6Clow 
monocytes at the site of inflammation theoretically could have an additional 
benefit by resolving inflammation over just blocking the inflammatory subsets 
infiltration. It is also noteworthy to mention that previous studies have shown 
that CNS regeneration after SCI is greatly increased when the overt 
inflammatory immune response is down-regulated with the modulation of 
residual monocyte/macrophages 297 133 and results from chapter 3 demonstrated 
the ability of SpA to polarize macrophages to an anti-inflammatory phenotype 
when it is in complex with IgG. Taking into consideration the evidence that (a) 
anti-inflammatory macrophages are less toxic to neurons and can induce growth 
of axon 133, and (b) that reducing the Ly6Chi infiltrating monocyte population 
results in increased recovery in numerous models of inflammatory conditions, 
justifies SpA’s potential as a molecule that can modulate monocyte populations.  
To further investigate SpA’s potential for use as a therapeutic in SCI, it was vital 
to prove that SpA could not only bind to myeloid populations in the blood and 
bone marrow, but could also bind to myeloid cells in the spinal cord. To 
substantiate this, it was important to examine SpA’s binding potential in the 
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spinal cord of injured and non-injured states. In the non-injured spinal cord, 
microglia dominated the CD45+ population and did not bind any SpA (figure 4.7). 
Conversely, the injured spinal cord had a vastly different cellular profile after 
injury; there was a massive increase in the inflammatory infiltrate of 
monocyte/macrophages and neutrophils, in conjunction with the resident 
microglia adopting an activated phenotype (figure 4.8). The 
monocyte/macrophage population found in the injured spinal cord bound SpA-
488 at a significantly higher level than the control protein. Microglia showed the 
ability to bind to SpA, though this was at a reduced level compared to the level 
of monocyte/macrophage population. However, it is noteworthy to mention that 
a recent discovery has established that microglia do not develop from HSC-like 
monocyte-derived macrophages but derive from a primitive yolk sac progenitor 
cell at embryonic day 8 39 38. This is possibly the reason why there is reduced 
binding in the microglial population in comparison to the monocyte/macrophage 
population. The discovery therefore highlights a major caveat to the collective 
term “CNS macrophages” used regularly in SCI literature to refer to 
monocytes/macrophages and microglia as the same population. And because of 
the fact that microglia are not derived from HSC, the umbrella term “CNS 
macrophage” will not be used to define these two separate populations in this 
body of work.  
Now that it has been shown that SpA can interact with cells in the damaged 
spinal cord, SpA’s ability to induce the maturation of Ly6Chi monocytes to a 
Ly6Clow phenotype was examined in the inflammatory setting of SCI.  
It was found that SpA exhibited the ability to alter the phenotype of the 
infiltrating Ly6Chi monocyte population, leading to a preferential Ly6Clow 
monocyte population in the damaged spinal cord of the SpA treated group 
compared to the control group. The skewing of the monocyte population was 
also noted in the peripheral blood of the SpA-treated SCI group. This result 
further supports the potential of SpA as a cell-specific therapeutic strategy to 
combat the aberrant inflammatory immune response displayed after SCI.  
Contrary to current literature, Shechter et al published a paper in 2009 which 
states that the Ly6Chi monocytes are important for recovery after SCI as they 
localise to the lesion margin and are induced to produce IL-10, which they 
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suggest leads to a small recovery in hind limb function, assessed via the Basso 
mouse score (BMS) 298. However, it should be noted that the authors immunised 
the mice a week before injury with a MOG peptide T cell vaccine, which they 
stated boosts the monocyte population that infiltrates into the spinal cord after 
injury, and justify the use of the vaccination strategy by inferring that the 
monocyte population would be otherwise undetectable in the damaged spinal 
cord after injury, which is quite contradictory to literature 101 and the finding in 
this body of work. Moreover, the authors did not address how this vaccination 
strategy affected the phenotype of the infiltrating monocytes. It is highly likely 
that vaccination polarized the infiltrating monocytes to an anti-inflammatory 
phenotype prior to their entery into the spinal cord. This phenomenon did not 
occur in the un-vaccinated SCI model.  
In light of the Shechter et al paper 298, it was vital to show that the Ly6Clow 
population of monocytes within the spinal cord does have the ability to produce 
IL-10 and be anti-inflammatory given the right stimuli. The ability of both the 
Ly6Chi and Ly6Clow monocyte subsets were, therefore, examined for their 
potential to produce IL-10 after SCI with and without SpA treatment.  
SCI was performed in Vert-X mice, which are GFP IL-10 reporter mice; 
unfortunately, due to technical issues in surgery only an N=1 for each condition 
could be performed in this experiment, and it must therefore be repeated to 
statistically significant levels to validate the finding. However, the findings that 
were gathered showed that the SpA-treated mouse had a higher percentage of 
monocytes that were producing IL-10 in the damaged spinal cord than the OVA 
control mouse did. In the control mouse, 49% of cells expressed IL-10, which is 
consistent with findings from a study that revealed there was a 50:50 ratio in 
mRNA levels of M1 (pro-inflammatory macrophages) and M2 (regulatory/anti-
inflammatory) macrophages present in the damaged spinal cord until day 3 post-
injury133. Furthermore, in the spinal cord of the control mouse, there was a 
distinct Ly6Chi population that was IL-10 negative, contrary to the Shechter et al 
findings. The SpA-treated mouse had a reduced Ly6Chi monocyte compartment 
within the damaged spinal cord, with a corresponding increase in the Ly6Clow 
monocyte (69%) population, which were all positive for IL-10 production. The 
blood of the SCI mice was examined to determine whether SpA also induced the 
production of IL-10 in the Ly6Clow monocyte population in this compartment. 
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However, no production of IL-10 was exhibited in either of the two treatment 
groups. This was an interesting observation as Ly6Clow monocytes produced IL-10 
at the site of inflammation (damaged spinal cord) but did not produce it 
systemically, leading to the assumption that there must be tissue-specific signals 
that govern the production of IL-10 in the Ly6Clow population. The tissue-specific 
regulation of IL-10 permits the regulation of inflammation in one compartment 
of the body but still allows the immune system to stay primed in case of 
secondary infection at another site. The ability to combat secondary infections is 
a major concern in the design of a therapeutic for SCI patients given the 
potentially long recovery period spent in hospital.  
To elucidate the mode of action that SpA was working through to induce the 
maturation of Ly6Chi monocytes to Ly6Clow monocytes in vivo, the function of 
SpA was investigated in FγRIII knock-out mice. The rationale for a role of FcγRIII 
in the process was based on the fact that its expression on accessory cells was 
required for SpA-induced apoptosis of B cells in vivo, via VH3 BCR engagement 
(unpublished data, Goodyear). FcγRIII has furthermore been shown to be 
involved in the anti-inflammatory mechanism of IVIg, via ITAMi signalling that 
leads to the up-regulation of FcγRIIb on macrophages 203. 
From this investigation, data presented conclusively demonstrated that the 
ability of SpA to modulate the Ly6Chi monocyte population to the Ly6Clow 
monocyte population was not dependent on the expression of FcγRIII. Taken 
together with the findings in Chapter 3, this indicates that the most likely 
candidate is FcγRI. 
In summary, the data so far support the concept that SpA treatment after SCI (or 
in steady-state) can induce the maturation of the Ly6Chi inflammatory monocyte 
to the Ly6Clow anti-inflammatory IL-10 producing phenotype. This finding is of 
particular interest in the setting of SCI, as SpA could in the future be used as a 
cell-specific method for modulating the massive inflammatory response 
contributing to the secondary death of neurons days to possibly months after the 
initial trauma; a detrimental response that, without modulation, results in 
substantially impaired functional recovery for SCI patients.  
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5 Optimisation of behavioural testing for murine 
spinal cord injury 
5.1 Introduction 
The spinal cord comprises only 2% of the total human central nervous system 
however, if damaged, it can result in disruption to essential functions such as 
the replay of sensory, motor and autonomic signals. There are many types of 
injury that can occur to the spinal cord, some of which are lacerations, 
contusions and compression injuries; the most common of these is a contusion 
injury. This form of injury occurs when a substantial force comes into contact 
with the spinal cord vertebra causing movement of the vertebra, injuring the 
normally protected spinal cord, which can lead to haemorrhaging and bruising.   
Almost half of all spinal cord injuries occur at the cervical level in humans, the 
level that controls both the upper and lower extremities. Injury at this area can 
therefore leave patients as quadriplegics. Due to its prevalence, this level of 
contusion was chosen as the injury site for the optimisation of murine spinal 
cord injury. It should be appreciated that in order to recreate a spinal cord 
contusion injury model in mice, the device used for measurement had to be 
reliable and produce consistent injury severities throughout the experimental 
run.  
5.1.1 Experimental methods for SCI induction 
The first experimental system for spinal cord injury was the weight drop 
technique of Allen 299. This was used to create contusion injuries in rats and it 
relied on distance, weight and any resistance experienced as the weight fell, to 
determine the severity of the injury. However, this method showed huge 
variations in data and had a lack of consistency between specimens; therefore 
the technique underwent modifications to become the contemporary basis of 
techniques now used today to create spinal cord contusion injury. 
Contusion injuries are now typically produced by using one of three devices; the 
New York University impactor (NYUi), the Ohio State University device (OSUd) or 
the Infinite Horizon device (IH). All of these devices provide measurements of 
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biomechanical parameters, including force on the spinal cord, impact 
displacement, and velocity of the impact tip. The first of these devices involves 
releasing its impactor tip at a set height onto an exposed spinal cord. The 
severity of the injury can be adjusted by changing the height at which the 
impactor tip is dropped. The NYUi can measure such force feedback parameters 
as velocity and tissue compression depth 300. The OSUd uses a computer-driven 
probe to measure displacement from the dura to the cord. Different injury 
severities were created by changing the distance of displacement 301. This device 
is yet to be produced commercially but has been used in a variety of studies 302. 
The commercially-available IH device is a standardised means of replicating 
contusion injuries, reliably producing contusion injuries of a user-defined force 
that displaces the exposed spinal cord of the specimen by means of a computer-
driven steel impounder tip with a force sensor attached. The sensor measures 
the force applied to the spinal cord in kilodynes (Kdyn) 303. The IH device allows 
a more controlled and repeatable method of creating contusion injuries and 
minimises the variability of severity between specimens. As the force can be 
defined it can be used to produce graded severities of these injuries. This was 
one of the main reasons the IH was the device of choice for this project. 
Although each of three devices was originally created for injuring rats, they have 
all been adapted for experiments on mice.  
Once a reliable and reproducible model of injury induction can be guaranteed it 
was realised that when evaluating a therapeutic, such as SpAs, potential to 
reduce inflammation at the site of trauma in SCI and hopefully improve recovery 
outcome, it was clear that a functional read out as well as cellular analysis 
would have to be employed to determine this goal.  
5.1.2 Behavioural testing methods for SCI assessment   
There are four main types of categories of behavioural assessments: locomotor, 
sensory, motor or sensory-motor. The behavioural assessments that have been 
used in this study were motor-based.  
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5.1.2.1 Baso mouse scale 
The Basso, Beattie and Bresnahan (BBB) Scale for rats is a modified open-field-
gait test designed to standardise locomotor testing 304. It grades hind limb 
movement on a scale of 0-21. Zero represents no spontaneous locomotor activity 
while 21 denotes normal locomotory movement with co-ordinated gait.  The 
Basso Mouse Scale (BMS) test was adapted from the BBB Scale as it was thought 
that the rat-scoring system was not applicable or sensitive enough for mice - it 
being a 9-point scale for testing hind limb function of mice 305. BMS works on the 
same principles as the BBB scale in that the animals are allowed to roam freely 
in a pen for 4 minutes, and two examiners grade hind limb locomotor function.  
Three key features that had to be modified between the BBB and the BMS were: 
joint movement during periods of paresis, frequency of coordination and toe 
clearance. There was great difficulty in discerning movements of the hip and 
knee joint from each other in the mice compared to the rats, since in the mice 
these movements were very slight and they were quite often obscured by the fur 
or folds of the skin. Ankle movement was easily observed in the mice and this is 
what is focused on in the BMS score.  
Mouse locomotion follows a repetitive pattern of fore-limb-stepping coinciding 
with a stepping of the contralateral hind limb - unlike with larger quadrupeds 
such as rats. Mice also move more rapidly than rats, and it was shown to be too 
difficult to discriminate whether mice were walking with co-ordination in three 
consistent body lengths at the same pace, therefore, in the BMS there is only 
one category for ‘if the mouse is walking with co-ordination’ unlike in the BBB 
where there are four categories of co-ordination. 
Due to the small size of mice it was not possible to see whether toe clearance 
was occurring. If this could not be seen with rats when conducting the BBB scale 
the examiner would listen out for dragging of the toe, but this could not be 
reliably heard over ambient noise on a consistent basis due to the small size of 
mice so this category was removed from the BMS scale. Table 5.1 shows the 
scoring characteristics used in the BMS.   
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5.1.2.2 Grip strength test 
Another motor assessment technique that was employed in this study to evaluate 
long-term recovery after SCI in mice was the grip-strength test. This is where 
the maximal peak force development by a mouse is determined when an 
operator tries to pull the rodent off of a specifically designed bar attached to a 
force meter. The amount of force a mouse uses, gripping with its front paws, is 
measured before and periodically after SCI to see if the injury has led to changes 
in gripping potential and, if so, whether the grip spontaneously recover or not.  
5.1.2.3 Digital Gait analysis techniques  
Gait analysis is an invaluable tool for assessing SCI as it can be used to assess 
recovery progression. By understanding a normal gait it can then be used to 
compare any subtle changes seen after SCI or in other neurological defects. 
There are several methods that have been employed to look at gait analysis: one 
such method is the ‘Footprint Analysis’ test. This consists of rodents walking 
along a papered runway with painted paws. Using different colours for the 
individual paws allows different parameters of gait to be evaluated such as paw 
angle, stance width and stride length. This technique is laborious and can lack 
sensitivity as the speed of walking cannot be controlled, which can affect gait 
read outs.  
Another technique used widely to evaluate gait is the ‘Catwalk’, it was 
developed to increase the number of gait indices that could be measured 306. 
Essentially, it works by having a transparent conveyor belt with a chamber over 
it that restricts the movement of a mouse, resulting in a consistent forward 
motion. The bottom of the chamber has a glass plate, the catwalk, with an LED 
light emitting from inside it. The light is completely internally reflected, except 
from the area the mouse had stepped on, which is captured by the high-speed 
camera underneath the glass plate. This footage is then analysed by specific 
software that scrutinizes paw angle, swing stride and has the ability to tell how 
heavily an animal is bearing on one or more of its paws. This is achieved by the 
correlation of intensity from the fluorescent footprint captured by the camera.  
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Table 5.1: BMS scoring definitions. 
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Another gait analysis system is the ‘DigiGait’. This was the favoured method of 
video-gait analysis due to the vast number of parameters it can assess, and was 
the system employed in the present study. This method involves videoing 
sequential images of the animal walking for a defined length of time on a 
transparent treadmill. Once the data have been collected it is input into DigiGait 
analysis software, which examines individual paw-steps from each run. The 
DigiGait imaging system generates 20 different indices of gait dynamics and 
posture, some of which can be seen in table 5.2. Indices generated by the 
DigiGait system convey information about sensory and motor outputs of gait and 
gait variability before and after injury or disease in rodents. Figure 5.1 shows a 
typical paw contact with the belt - along with the different phases of walking 
that could be expected in a healthy rodent. 
The DigiGait imaging system has been used in a number of injury and disease 
models such as CIA (Collagen Induced Arthritis) 307; Parkinson’s 308 and 
Huntington’s 309 disease.  It has never before been used as a measure of SCI-
outcome in mice, although it has been successfully used to evaluate SCI in rats, 
where it has been shown to be sensitive enough to determine drug efficacy in 
the treatment of SCI 310. Neu2000, which is a derivative of Acetylsalicylic acid 
and salicylic acid, has been shown indirectly to prevent excitotoxicity, which is a 
major contributor in the pathogenesis of secondary death in SCI. The authors 
showed that parameters such as stride-duration spent in swing-phase and stance-
phase, swing-to-stance ratio and hind-limb-paw-angle, all significantly changed 
in comparison to the vehicle-group-treated group. The high number of 
parameters that DigiGait can assess in conjunction with the successful 
application in a drug regime in SCI analysis with rats is why the DigiGait was used 
in this study instead of other gait-analysis systems.  
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Table 5.2: Parameters measured by the DigiGait Imaging System.  
Table adapted from Mouse Inc data sheet on DigiGait Imaging System 311 
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Figure 5.1. Healthy paw placement on the DigiGait in a healthy rodent and the different 
phases of walking they go through.  
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5.2 Aims 
The object of the research carried out within this chapter was to identify and 
critically assess different methods of behavioural testing and histological 
staining after murine SCI that could be used in the future to evaluate the 
potential outcome of a therapeutic strategy, such as SpA. This was carried out 
by: 
• Assessing the potential of BMS, grip strength and DigiGait for use as 
appropriate behavioural tests after contusive cervical SCI with the IH 
device. 
• The first objective was to identify if any of the parameters measured by 
the behavioural tests showed changes that did not recover over the 6 
weeks of post-injury testing 
• Four different injury severities of 50Kdyn, 80Kdyn, 100Kdyn and 120Kdyn 
were trialled to evaluate the sensitivity of each of the behavioural tests. 
This was done by examining the limit of detection of each parameter 
within each of the tests measured to see which, if any, of the behaviour 
tests were sensitive enough to show differences between the injury 
groups. This was important, as the test used must be sensitive enough to 
identify subtle changes in recovery after therapeutic intervention.   
• Tract tracing of the cortico-spinal tract was also evaluated as an 
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5.3 Results  
5.3.1 BMS 
Twenty C57BL/6 mice underwent SCI contusion surgeries with the Infinite 
Horizon (IH) device. Four different severities were performed, with 5 mice per 
group. The impactor tip of the IH delivered a force of 50Kdyn, 80Kdyn, 100Kdyn 
or 120Kdyn. The 4 different injury groups were tested for hind limb function 
using the BMS for 6 weeks post-operatively. Mice were allowed to run around a 
meter pen for four minutes once a day for 5 days prior to the surgery. This 
acclimatised the mice to the test/apparatus prior to surgery. After surgery the 
mice were left for a week to recover before the testing commenced. Mice were 
placed in the same pen and allowed to roam freely while two investigators 
observed and scored each of the animals back legs separately using the BMS 9 
point-scoring system (Table 5.1).   
Pre-operatively it was assumed that all mice started with a score of 9 for both 
limb functions. At the end of testing, mice in the 50Kdyn injury group had 
recovered full left hind limb function with a score of 9 (figure 5.2A) and almost 
completely recovered right hind limb function with a score of 7.7±1.2 (figure 
5.2B). The 80Kdyn injury group had an average score of 8.2±1.1 for both hind 
limbs by completion of testing. The 100Kdyn injury group had an average score 
of 7±0 for both limbs, which meant that they had frequent or occasional planter 
stepping that is mostly coordinated, and did not show any change from post-
operatively 1 to the final testing session.  
The 50Kdyn, 80Kdyn and 100Kdyn injury group showed a predominately fore limb 
phenotype and almost normal movement of hind limbs, whereas, the 120Kdyn 
injury group scored 4, which correlates to only occasional planter stepping, at 
post-operatively week 1. These mice exhibited a small steady recovery of hind 
limb function until plateauing at post-operatively week 4 with a final score of 
5.8±0.5 for both hind limbs (figure 5.2). From the data collected for the period 
of BMS testing and the observed phenotype that the animals exhibited, it was 
concluded that the BMS was not the most suitable test for a mild to medium 
cervical contusion injury as it solely focused on the hind limbs function and the 
mice predominately exhibited fore limb ataxia with little impairment to their 
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hind limbs. With the most severe injury group, this test was deemed to be 
applicable as this group displayed ataxia in both fore and hind limbs.  
5.3.2 Grip Strength  
The BMS locomotor test predominantly detects defects in hind limb 
function.  The SCI model, as discussed above, primarily affects fore limbs and 
not hind limbs. Therefore an alternative test, the grip strength test, was 
utilized. Importantly, the grip strength test was thought to be a more suitable 
behavioural test for the injury phenotype induced in this model because it 
specifically measures fore limb function.  
Mice were allowed to acclimatize to the force meter for a week prior to surgery. 
At the end of this week, baseline data were taken, which consists of allowing 
the mouse to grab the bar that protrudes from the end of the force meter and 
then pulling the mouse back by its tail until it releases the bar; the 
corresponding value is registered on the force meter. This was performed five 
times per session with each mouse. Mice received an 80Kdyn, 100Kdyn injury or 
no injury. One-week post-surgery data were collected as described for the 
acquisition of baseline data. Data were collected once per week from the 
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Figure 5.2. BMS hind limb motor assessment after SCI over 6 weeks post-operatively.  
Mice received contusion injury to their C5-C6 vertebrae. (A) left hind limb data (B) right hind limb 
data. The number of mice within each of the injury severity group; 50Kdyn: n=3, 80Kdyn: n=5, 
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When the raw data from the 3 groups of animals were examined, there was a 
clear difference in the maximal muscle strength of injured and non-injured mice 
(figure 5.3). Following further examination of the data, a similar pattern was 
seen in all three groups: the amount of grip strength would increase and 
decrease in harmony until the end of testing (Figure 5.3A). This was true for the 
uninjured animals as well, which leads to the conclusion that an external factor 
was influencing the amount of force the animals were able to pull from week to 
week as the same pattern was displayed in the uninjured group as well as the 
injured groups. Animals that undergo behavioural testing are very sensitive to 
external factors such as heat, draught, light and one of these factors could 
easily account for the difference in the level of force being registered. 
For the above reason, the data for the injured animals were normalised against 
the uninjured animals’ scores to show a reduction in the force of the injured 
mice in comparison to non-injured controls to eliminate external variation 
(figure 5.3B). When the data were normalised it gave a much clearer picture of 
the effect of injury. Essentially, animals that are injured dramatically lose 
maximal muscle strength by comparison with those in the non-injured group. 
One week after injury the 80Kdyn injury group displayed a significant decrease 
(P<0.001) in grip strength of 42.7g±12.4g. They showed a steady rate of recovery 
until post-operation week 5, where they had a reduction in normal force of 
23.5g±5.2g in comparison to the non-injured animals. By post-operative week 6 
they still showed a significant decrease (P<0.001) in the amount of force they 
could pull (32.5g±7.4g) (figure 5.3C). When the 80Kdyn injury group’s reduction 
in the amount of force the animals could pull was compared to the non-injured 
group, there was a statistically significant reduction (P<0.001) at every time 
point (figure 5.3C).  
The 100Kdyn injury group showed an initial drop of 54.5g±6.7g and also 
exhibited a steady recovery patterns, and by post-operative week 5, the group’s 
decrease of gripping force had increased to 40.3g±10.1g less than the uninjured 
group. By the completion of testing, the 100Kdyn showed a grip strength 
reduction to post-operative week 1 levels of 54.4g±10.7g (figure 5.3D). When the 
100Kdyn injury group’s reduction in the amount of force the animals could pull 
was compared to the non-injured group, there was a statistically significant 
reduction (P<0.001) at every time point (figure 5.3D). The 100Kdyn injury group 
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displayed the same dip in performance at post-operative week 6 as the 80Kdyn 
injury group leading to the conclusion that the mice could have become 
habituated to the test and 6 weeks may be too long for this particular 
behavioural test. Nevertheless, the grip strength test has shown promising 
results, which makes it a very good candidate for studies in the future as it is 
specifically tailored to the fore limb injury phenotype. There were no 
statistically significant differences between the two injury severities when 
comparing their reduction in maximal muscle strength after injury at any of the 
time points (figure 5.3E). This suggests that the grip strength test is not sensitive 
enough to show subtle differences between the injury groups; however this 
could be an artefact of too small a sample size and warrants further 
investigation to see if this issue could be resolved with a bigger sample group to 
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Figure 5.3. Assessment of grip strength in the fore-paws pre-operatively and for 6 weeks 
post-operatively, following SCI surgery.  
Thirteen male C57BL/6 mice were acclimatized to the grip-strength meter and then pre-operative 
data were recorded. Mice received SCI at differing forces (80Kdyn: n=3 and 100Kdyn: n=4), and 
three were left as uninjured controls. Mice were left for 1 week to recover and then data collection 
followed for 6 weeks post-operatively. (A) Raw data from non-lesioned, 80Kdyn and 100Kdyn 
groups F2, 60=42.18, P<0.0001. (B) The 80Kdyn and 100Kdyn injury groups were normalised 
against the uninjured group so that the graph shows the reduction in grip strength of the injury 
group in comparison to non-injured animals F2, 60=42.05, P<0.0001. Statistical analysis was 
conducted on figure A and B using a repeated measures two-way ANOVA, significant differences 
between groups were determined using a post-hoc Bonferroni test, which compared all groups to 
each other. For illustrative purposes figure C, D and E were generated from figure B and statistical 
annotation was added. *** = P<0.001 
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5.3.3 DigiGait 
The grip-strength test has been shown to be a potentially useful assessment of 
fore limb recovery after SCI but it is only 1 parameter. In comparison, DigiGait 
examines 20 different indices of gait in both the fore and hind limbs and was 
therefore employed as an additional test to give a more complete measure of 
recovery from SCI. 
 Pre-operatively, mice were acclimatised to the DigiGait for one week before 
data were collected. This consisted of mice being taken one at a time and 
placed inside the DigiGait perspex box, which surrounds a portion of the 
transparent treadmill, and trained to walk.  When the treadmill is activated 
electronic “footprints” of the mouse that is ambulating are collected by a high-
speed video camera mounted underneath the treadmill shown in figure 5.4. Data 
were collected during ambulation at two different speeds of 15 and 20 cm/sec. 
Three runs of 4 sec were collected per speed pre-operatively and then for 6 
weeks post-operatively. The segments of data that were collected provided 
enough strides to determine characteristic gait parameters (e.g. stride length, 
width and angle) of the mouse for each time-point and speed. 
 
 
Figure 5.4. DigiGait apparatus.  
This consists of a high-speed camera mounted underneath a transparent treadmill. A perspex box 
covers a segment of the treadmill where the animal is confined. 
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Of an initial 50 mice that were tested on the DigiGait, only 34 of these mice 
could be trained to walk on the apparatus and pre-operative data were only 
gathered for these mice. Of the 34 mice which underwent surgery, only 14 would 
walk on the DigiGait post-operatively at the speed of 15cm/sec (50Kdyn: n=3, 
80Kdyn: n=6 and 100Kdyn: n=5) and 8 mice would run at 20cm/sec (50Kdyn: n=3, 
80Kdyn: n=4 and 100Kdyn: n=1) for the entirety of the experiment. Due to the 
small sample number of mice that would run at the higher speed of 20cm/sec, 
the results have not been shown. After injury the 50Kdyn mice had no issues in 
participating in testing from post-operatively week 1; the 80Kdyn mice could 
participate in testing from post-operatively week 2 and the 100Kdyn could start 
participating from post-operatively week 4. However, the 120Kdyn mice were 
too severely injured to take part in this method of behavioural assessment.  
Some of the parameters that were analysed by the DigiGait after injury did not 
change, examples being swing stride % (figure 5.5), brake stride % and propel 
stride (data not shown). These three parameters are all interlinked as they make 
up the complete movement of the stride, defined as the time the foot takes 
from leaving the belt to touching it again. Propel is the point at which the foot is 
leaving the belt; swing is where it is off the belt entirely and brake is where it 
makes contact with the belt until it is completely flat. As such, these 
parameters are of limited utility for further analysis. 
Some of the parameters the DigiGait analysed showed initial change from the 
baseline pre-operative data but returned to normal by the end of the testing 
period. This was most evident with the 50Kdyn injury group as it was noted that 
they had only a very transient injury phenotype and by post-operatively week 4 
appeared to be fully recovered. An example of this is in the brake stance (figure 
5.6A) where the fore-limb shows initial change, reaches a significant change at 
post-operatively week 3, but has returned to baseline by post-operative week 4. 
The parameter brake stance also showed inherent fluctuations and variability 
within each of the groups - having very large variations throughout all of the 
injury groups. This is most evident in the 80Kdyn and 100Kdyn groups where it 
looks as if there is a change in this parameter compared to pre-operative 
testing, however, the spread of data is so wide it is not statistically relevant. 
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The DigiGait analysis did reveal some parameters that changed from the baseline 
to the end of post-operatively week 6. The parameter ‘stride frequency’, which 
measures the number of strides a mouse takes per second, was statistically 
significant at post-operatively week 6 in comparison to pre-operative data within 
fore (figure 5.7) and hind limbs (data not shown) in all three of the injury 
severities. Nonetheless, when the data from each of the injury severities was 
combined together to examine if the DigiGait was sensitive enough to be able to 
show significant differences in the injury severities at individual time points 
(figure 5.7D), it revealed that the most statistically significant time-point 
between the 50Kdyn and 80Kdyn was in fact the pre-operative data (figure 
5.7E). This was also seen between the 50Kdyn and the 100Kdyn injury groups 
(figure 5.7E). The result reveals the high variability and inherent insensitivity of 
using this method for behavioural testing, as these are genetically inbred mice, 
which you would expect to have the same pre-operative levels of stride 
frequency. The 80Kdyn and 100Kdyn groups showed no significant difference at 
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Figure 5.5. Assessment of swing stride percentage in the fore and hind limbs pre-
operatively and 6 weeks post-operatively, following SCI surgery.  
14 C57BL/6 mice were trained on the DigiGait to walk and then pre-operative data were recorded. 
Mice received SCI at differing forces (50Kdyn: n=3, 80Kdyn: n=6 and 100Kdyn: n=5). The mice 
were left for 1 week to recover and then data collection followed for 6 weeks post-operatively. Data 
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Figure 5.6. Assessment of percentage brake stance in the fore and hind limbs pre-
operatively and 6 weeks post-operatively, following SCI surgery.  
14 C57BL/6 mice were trained on the DigiGait to walk and then pre-operative data were recorded. 
Mice received SCI at differing forces (50Kdyn: n=3, 80Kdyn: n=6 and 100Kdyn: n=5). Mice were 
left for 1 week to recover and then data collection followed for 6 weeks post-operatively. Data were 
analysed on the DigiGait ‘mouse-specific’ computer programme. (A) Fore-limb 50Kdyn. (B) Hind-
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Two parameters that are also examined in the DigiGait system and are 
intertwined with stride frequency are steps per second (figure 5.8) and stride 
length (figure 5.9). Both of these parameters show significant differences in 
their pre-operative levels in comparison to post-operative week 6, which fulfils 
one of the aims of this chapter. Nevertheless, when the sensitivity of these 
parameters was examined further the same level of inconsistency in pre-
operative test data was demonstrated in both steps per second (figure 5.8E) and 
stride length (figure 5.9E). The data-spread within each of the post-operative 
weeks is extremely wide for the parameter ‘steps per second’ and again 
demonstrates the substantial levels of variability within the system. 
Another limitation of this behavioural test was that due to the fore-paws of the 
100Kdyn injury group exhibiting spastic clenching, fore-paw angle could not be 
looked at. Hind-paw angle showed no significant change in 50Kdyn (figure 5.10A) 
and 100Kdyn (figure 5.10C) injury groups at the end of testing. This was due to 
massive amounts of variation in the data recorded for each of the time points. 
The 80Kdyn groups did show a statistically significant difference in paw angle 
(figure 5.10B), showing a decrease in rotation by the end of testing. When the 
data from the three injury groups were combined together no statistical 
difference was seen amongst the pre-operative injury groups. The 80Kdyn group 
showed a statistical difference in paw rotation from the 50Kdyn injury group at 
the end of testing - but not compared to the 100Kdyn injury (figure 5.10D). 
However, due to the massive variation within each of the injury group’s data-
sets, at each time point, it made the finding somewhat irrelevant.  Thus the 
data suggests that the DigiGait is not sensitive or reliable enough for use in the 
testing of therapeutic intervention in mice. However, it has given us a small 
insight into the phenotype of the injury that the contusion injury induces. This 
insight reveals that the mice decrease the number and frequency of steps and 
strides they take per second, but that they compensate by increasing the length 
of the strides that they do take.  
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Figure 5.7. Assessment of stride frequency per second in the fore limbs pre-operatively and 
6 weeks post-operatively, following SCI surgery.  
14 C57BL/6 mice were trained on the DigiGait to walk and then pre-operative data were recorded. 
Mice received SCI at differing forces (50Kdyn: n=3, 80Kdyn: n=6 and 100Kdyn: n=5). Mice were 
left for 1 week to recover and then data collection followed for 6 weeks post-operatively. Data were 
analysed on the DigiGait ‘mouse specific’ computer programme. Statistical analysis was conducted 
using a repeated measures one-way ANOVA, significant differences between groups were 
determined using a post-hoc Bonferroni test, which compared all post-operative week 6 data to 
pre-operative data, apart from in figure E which used a Bonferroni post-hoc test that compared all 
groups to each other. *= P<0.05, **= P<0.01, *** = P<0.001. (A) Fore limb 50Kdyn F6, 41=5.656, 
P<0.0005. (B) Fore limb 80Kdyn F5, 71 =10.41, P<0.0001. (C) Fore limb 100Kdyn F3, 39 =7.14, 
P<0.0011. (D) Combined 50Kdyn, 80Kdyn and 100Kdyn fore limb data. (E) Pre-operative 
combined data F2, 27 =13.32, P<0.0001  
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Figure 5.8. Assessment of the number of steps taken within a second in the fore limbs pre-
operatively and 6 weeks post-operatively, following SCI surgery.  
14 C57BL/6 mice were trained on the DigiGait to walk and then pre-operative data were recorded. 
Mice received SCI at differing forces (50Kdyn: n=3, 80Kdyn: n=6 and 100Kdyn: n=5), and were left 
for 1 week to recover; then data collection followed for 6 weeks post-operatively. Data were 
analysed on the DigiGait ‘mouse specific’ computer programme. Statistical analysis was conducted 
using a repeated measures one-way ANOVA, significant differences between groups were 
determined using a post-hoc Bonferroni test, which compared all post-operative week 6 data to 
pre-operative data, apart from in figure E which used a Bonferroni post-hoc test that compared all 
groups to each other. **= P<0.01, *** = P<0.001. (A) Fore limb 50Kdyn F6, 41=11.72, P<0.0001. (B) 
Fore limb 80Kdyn F5, 71 =7.46, P<0.0001. (C) Fore limb 100Kdyn F3, 39 =12.36, P<0.0001. (D) 
Combined 50Kdyn, 80Kdyn and 100Kdyn fore limb data. (E) Pre-operative combined data F2, 27 
=5.73, P<0.0089  
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Figure 5.9. Assessment of stride length in the fore limbs pre-operatively and 6 weeks post-
operatively, following SCI surgery.  
14 C57BL/6 mice were trained to walk on the DigiGait, and then pre-operative data were recorded. 
Mice received SCI at differing forces (50Kdyn: n=3, 80Kdyn: n=6 and 100Kdyn: n=5), and were left 
for 1 week to recover; then data collection followed for 6 weeks post-operatively. Data were 
analysed on the DigiGait ‘mouse specific’ computer programme. Statistical analysis was conducted 
using a repeated measures one-way ANOVA, significant differences between groups were 
determined using a post-hoc Bonferroni test, which compared all post-operative week 6 to pre-
operative data, apart from in figure E which used a Bonferroni post-hoc test that compared all 
groups to each other. *= P<0.05, **= P<0.01, *** = P<0.001. (A) Fore limb 50Kdyn F6, 41=4.771, 
P<0.0016. (B) Fore limb 80Kdyn F5, 71 =14.19, P<0.0001. (C) Fore limb 100Kdyn F3, 39 =7.88, 
P<0.0006. (D) Combined 50Kdyn, 80Kdyn and 100Kdyn fore limb data. (E) Pre-operative 
combined data F2, 27 =8.496, P<0.0015 
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Figure 5.10. Assessment of paw angle in the hind limbs pre-operatively and 6 weeks post-
operatively, following SCI surgery.  
14 C57BL/6 mice were trained to walk on the DigiGait and then pre-operative data were recorded. 
Mice received SCI at differing forces (50Kdyn: n=3, 80Kdyn: n=6 and 100Kdyn: n=5), and were left 
for 1 week to recover; then data collection followed for 6 weeks post-operatively. Data were 
analysed on the DigiGait ‘mouse specific’ computer programme. Statistical analysis was conducted 
using a repeated measures one-way ANOVA, significant differences between groups were 
determined using a post-hoc Bonferroni test, which compared all post-operative week 6 to pre-
operative data. *** = P<0.001.  (A) Hind limb 50Kdyn. (B) Hind limb 80Kdyn F5, 71 =6.099, 
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5.3.4 BDA tract tracing  
Another avenue with which to investigate SCI and therapeutic efficacy is BDA 
tract tracing of axonal tracks. BDA track tracing labels axons of a given neuronal 
track. This is relevant for the assessment of therapeutic efficacy as damage to 
individual neural pathways can be quantified with the amount of BDA tracer 
present rostral and caudal of the lesion. BDA track tracing of the cortico-spinal 
tract is already an established technique for assessing axonal regeneration, and 
examining levels of Wallerian degeneration. It has also been used recently to 
test the efficacy of a T-cell based therapy in a rat SCI model - showing that 
when treated rats had a decrease in the level of ’die back’ of axons from the 
lesion site compared to the control treated group 146. The cortico-spinal tract 
was chosen for BDA tracing because it is a tract that contains mostly motor 
neurons - which underlie our voluntary movements - and runs from the brain 
along the spinal cord. In humans the tract controls fine, complex movements 
such as hand and finger dexterity.  
Twenty mice from a range of injury severities underwent the BDA tract tracing 
procedure. However, a full investigation could not be performed due to both 
time constraints and access to the microscope. In brief, mice were allowed a 
week to recover from SCI surgery before they underwent surgery for BDA tract 
tracing (performed by Dr John Riddell and assisted by Andrew Toft). This was 
performed by making a small incision in the scalp of the mouse with a 
subsequent small window being drilled into the skull over the left sensorimotor 
cortex. Using the bregma as an anatomical reference point, injections of BDA 
were made at four sites. The scalp incision was sutured closed; the mice were 
allowed to recover for 14 days before being perfused, and the damaged section 
of the cord being removed. Sections were cut on a freezing microtome, first in a 
horizontal section caudally to the lesion to examine if the BDA track tracing 
targeted the correct tract. The remaining section was cut in sagittal cross-
section to look at the longitudinal staining of the tract (sectioning and staining 
was performed by myself under the tutelage of Andrew Toft, who also 
supervised with the imaging of sections).  
In the only sections that were imaged, it can be observed that in the horizontal 
sections of the spinal cord, above the injury site, staining is mainly observed in 
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the dorsal cortico-spinal tract (figure 5.11A). In the longitudinal section a large 
lesion can be seen in the centre of the picture with reactive astrocytes (GFPA: 
blue) forming the glial scar round the outside of the lesion epicenter. BDA 
(green) stained neurons can be identified rostral to the lesion site - but caudally 
there was no staining (figure 5.11B). This reveals that the dorsal cortico-spinal 
tract in 100Kdyn SCI mice is totally ablated by the injury and BDA tract tracing 
may be a possible technique to use to determine if there is sparing of any of the 
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Figure 5.11. BDA staining of the cortico-spinal tract in a 100Kdyn SCI mouse.  
(A) Horizontal cross sections of the damaged spinal cord rostral to the lesion and a schematic 
diagram of the same section of the spinal cord identifying the location of the dorsal cortico-spinal 
tract. (B) Sagittal sections of the damaged portion of the spinal cord. In both sections staining 
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5.4 Discussion Conclusion  
The aim of this chapter was to discover the most sensitive and appropriate single 
or multiple readouts for the possible future experimental treatment of SCI with 
SpA as a mode of modulating the inflammatory response seen after SCI.  
At the outset, it was determined that the method of assessment must be 
sensitive enough to show subtle improvements in anatomical structure or 
functional recovery that the therapeutic might impart. BDA tract tracing of the 
cortico-spinal tract was inspected to determine if it was suitable for use as an 
indicator of anatomical change following the treatment of SpA after SCI. Three 
different behavioural tests were also considered when it came to assessing hind 
limb function, fore limb function and gait parameters. The tests not only had to 
identify a functional read-out/parameter that was changed after SCI - and 
remained changed for the length of the testing period - but also had to be 
sensitive enough to detect minor oscillations in these parameters after 
treatment of a therapeutic. This was the reason four different injury severities 
were used to scrutinize the sensitivity each of the tests was able to offer – and 
in the tests’ ability to detect differences between the various injury-severity 
groups.  
Unfortunately, a full and proper examination of the BDA tract tracing method 
was not possible due to time constraints operating the microscope used to 
generate images from sections of damaged spinal cord that had their cortico-
spinal tract traced with BDA. Two complete images of 100Kdyn animals were 
generated and these showed the complete ablation of the cortico-spinal cord 
with only axons rostral, but not caudal, of the lesion being labelled with BDA. 
This type of tract tracing has been used in many experiments in conjunction with 
behavioural testing to assess therapeutic regimes 312 146. It is therefore a method 
that warrants further investigation as it has been shown to be an appropriate 
method of examining the damaged spinal cord as there was no spontaneous 
regeneration of the cortico-spinal tract in either of the sections scrutinized; 
however the sensitivity level of this technique must be investigated further to 
establish its overall suitability.  
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Looking at the first possible behavioural test measure, BMS, the data suggests 
that this is not an appropriate test for cervical contusion injury of 100Kdyn or 
less as the injury has a predominately fore limb phenotype and the BMS is a hind 
limb only locomotor gait scoring system 305. The only injury group that this test 
had potential utility in was the 120Kdyn injury group as this injury severity 
exhibited a hind limb, as well as a fore limb, phenotype. Nevertheless, even 
though the BMS did recognise the hind limb phenotype in the 120Kdyn group, the 
group had a far more pronounced deficiency in their fore than hind limbs that 
this measure did not take account of. The BMS did not exhibit any notable 
differences between the scoring of the 50Kdyn, 80Kdyn and 100Kdyn injury 
phenotypes - leading to the conclusion that the BMS is not a sufficiently sensitive 
assessment of injury, and will thus not be used in the future.  
Next to be considered was the DigiGait, which examines the gait of mice when 
ambulating, encompassing both hind and fore limbs, and giving a readout of over 
20 different parameters for analysis. Some of the parameters such as number of 
steps taken per second, stride length and stride frequency did show significant 
statistical changes from pre-operative to post-operative week 6. Nevertheless, 
this test was not sensitive, stringent or reliable enough for use in the future to 
evaluate the ability of a therapeutic agent such as SpA.  
One of the major draw-backs of using the DigiGait compared to the other two 
methods of behavioural testing was that not all injury groups could participate in 
testing from post-operative week 1 - or, indeed, at any stage in the process; the 
most telling reason for this being the fact that the most severe injury group 
(120Kdyn) were unable to walk on the DigiGait at any time-point during the 
whole testing period. The 100Kdyn mice did not all walk until post-operative 
week 4; the 80Kdyn mice walked from post-operative week 2 onwards and the 
50Kdyn injury group was the only group that could take part in every week of 
testing.  
Due to these limitations, this test did not give a good indication of the varying 
degrees in injury phenotypes of these mice at different injury severities. The 
50Kdyn mice showed very little permanent adverse effects, and exhibited 
normal behaviour such as hanging upside down from the roof of their cages from 
post-operative week 4 onwards. This was substantially different to the 100Kdyn 
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mice as they showed significant injury phenotypes until the end of the study 
with no sign of resolution. One such phenotype was the spastic clenching of fore-
paws in at least one, if not both, of the paws. The 100Kdyn mice also exhibited 
hair loss on the inside of their fore limbs and thorax, which was suspected by the 
vet to be a consequence of over grooming or rubbing of these areas due to 
partial or full loss of sensation as a consequence of the injury. The clenched paw 
and hair loss was not evident in the 80Kdyn groups.  
The DigiGait results did not adequately capture the visible differences observed 
between the 80Kdyn and the 100Kdyn injury groups in any of the parameters 
that showed a significant difference after the 6 weeks of testing from the pre-
operative data. This highlights the lack of sensitivity of this technique - that a 
distinctive set of injury phenotypes can be seen in the different groups but could 
not be picked up by the behavioural test. The DigiGait did show statistically 
significant differences in post-operative week 6 phenotypes between 50Kdyn 
versus 80Kdyn and 50Kdyn versus 100Kdyn in parameters of stride length and 
stride frequency. However, on closer examination of these results it was 
revealed that there was not only a statistically significant difference in post-
operative data between the 50Kdyn versus 80Kdyn and 50Kdyn versus 100Kdyn, 
but there were also statistically significant differences in the pre-operative 
data.  This is very concerning and identifies a worrying lack of reliability and 
sensitivity in the DigiGait system: the pre-operative data for the cohort of a 
genetically identical inbred mouse strain should not be significantly different.  
Another problem with the DigiGait system was the very high drop-out rate: 72% 
of the starting cohort failed to complete. 50 mice were initially earmarked for 
testing with the DigiGait but only 14 finished the study. This was for the most 
part due to mice being unwilling to walk on the DigiGait at the time of testing; 
only 3 of the drop-outs were due to fatalities in surgery. Mice would simply not 
move when the treadmill started or they would avoid the treadmill by climbing 
up the walls of the Perspex box in which they were housed when testing began. 
At other times they would “bunny hop” with their hind legs, which was not an 
accurate representation of their walking ability and many runs had to be 
excluded based on this. If three runs could not be collected over a three-day 
period of the post-operative week, the mice had to be excluded from the study.  
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Furthermore, large variation was seen within each of the injury groups; 
percentage brake stride being a good example of this: results from the post-
operative week 4 for the fore-paw 80Kdyn group ranged from 20% to almost 70% 
of a spread in values for what was the same group. This is a substantial degree 
of fluctuation and may be due to limitations/deficiencies within the analysis 
software (DigiGait systems). It was noted that mice would become habituated to 
running on the DigiGate and “bunny hop”, as discussed above. These runs were 
excluded from the test if they were noticed; however, it is possible that not all 
of these types of movement were caught before the raw data were analysed and 
therefore it I possible that a true representation of the animals’ gait was not 
always portrayed.  
Another source of variability that could have been introduced at the analysis 
level is in relation to the ‘snout and tail blocker’. In this test, there must be a 
snout and tail blocker manually added by the investigator within the analysis 
software. The reason for this requirement is that as the software tracks the 
footprints of the mouse by their pink colour, it can therefore inadvertently 
mistake a nose or tail for a paw if these have not been blocked out completely. 
This normally causes a problem if the mouse runs in a side-to-side motion on the 
treadmill resulting in the blockers being ineffective. Thus, the DigiGait may not 
be sensitive, suitable or reliable enough as a test for use in the future for 
examining the benefits of therapeutic strategies in mice.  
The most suitable form of behaviour testing was the grip strength test. This was 
due to the predominant fore limb injury phenotype that was induced by the SCI 
contusion model used in this study, and the grip strength being a behavioural 
test that is specifically designed to test for deficiencies in forelimb function 87. 
The grip strength is also a well-established behavioural test that has been used 
by many other groups to assess recovery after SCI in both mice and rats 313 302. 
The grip strength test showed a statistically significant decrease in the maximal 
muscle force the injured animal could grip with their fore-paws throughout the 
test period, and showed a significant difference at all time points between the 
non-injured group versus the 80Kdyn and 100Kdyn injury groups. A trend was 
observed in the data, showing that the 100Kdyn injury group lost a greater 
degree of maximal muscle strength than the 80Kdyn injury group. Nevertheless, 
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there was no significant difference between the two injury groups, indicating 
that the test lacks a finer level of sensitivity. However, it should be appreciated 
that this aspect of the study was only carried out with N=3 for the 80Kdyn and 
N=4 for the 100Kdyn injury group, which may be too small a sample size. 
Statistical significance may be achieved if the sample size is increased.  
Two major advantages of the grip strength over the DigiGait test emerged: there 
were no drop-outs from the grip strength over the testing period and all animals 
could take part in the testing from week 1; unlike the DigiGait, where 100Kdyn 
animals could not take part in testing until post-operative week 4 and 72% of the 
initial 50 animals designated to take part in the DigiGait study failed to 
complete the testing period. Secondly, whilst the DigiGait does examine fore 
limb function like the grip strength test, it is very dependent on the training and 
cooperation of the animals taking part in the study, whereas the grip strength 
takes advantage of the inherent trait that mice will grab onto the closest object 
to them when held by the tail - and little training is therefore needed. 
Thus, in conclusion, future studies will be needed to evaluate the potential of 
the grip strength test and BDA tracing of the cortico-spinal tract to determine if 
they are sensitive enough methods of assessment in detecting subtle 
improvements in recovery in the setting of SCI after treatment with an 
experimental therapeutic, such as SpA. 
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6 Discussion, conclusion and future experiments 
6.1 Discussion  
In this thesis, it has been shown that SpA in the presence of IgG (SIC) has the 
ability to polarize macrophages to an anti-inflammatory phenotype in vitro in 
conjunction with LPS.  The phenotype of SIC-treated macrophage is 
characterized by the induction of IL-10 and inhibition of IL-12 cytokine 
production. The macrophages also show MHC II down-regulated via an IL-10-
independent pathway. However, SIC-treated macrophages show no alteration in 
their ability to produce NO and IL-6 compared to LPS-only treated macrophages. 
This phenotype was dependent on the formation of SIC with polyclonal IgG or 
complexes generated with a 1:1 ratio of IgG1/2a and to a lesser extent with 
IgG2a and their ability to signal through FcγRI.  
When SpA’s ability to interact with and polarize the myeloid compartment to an 
anti-inflammatory phenotype was examined in vivo, it was demonstrated that 
SpA can bind to monocytes, and preferentially to the Ly6Chi monocyte sub-
population. It was also revealed that SpA induced the maturation of the Ly6Chi 
(pro-inflammatory) monocyte population into a Ly6Clow (anti-inflammatory) 
monocyte in steady-state conditions in the blood. It should be appreciated, 
however, that monocyte phenotype is a controversial issue. Studies have stated 
that Ly6Clow cells are anti-inflammatory/patrolling and Ly6Chi cells are pro-
inflammatory 40; while others have provided evidence that Ly6Clow monocytes 
can induce inflammatory responses and Ly6Chi cells can be anti-inflammatory 62. 
In the steady-state, it would seem that the classification of Ly6Chi and Ly6Clow 
specific subsets by Geissman et.al. is the evolutionarily conserved default 
phenotype. Nevertheless, there is growing recognition that monocyte and 
macrophage function can be modified by their local environment to become 
either pro or anti-inflammatory no matter what they were pre-disposed to do 
before they entered the tissue 63. A good example of an environment that 
induces phenotypic modifications in monocytes is the intestine, where newly-
arrived inflammatory monocytes (Ly6Chi) differentiate into IL10-producing anti-
inflammatory CX3CR1hi tissue macrophages 64.  
  197 
To examine the ability of SpA to induce the maturation of Ly6Chi monocytes into 
Ly6Clow monocytes in inflammation without the complication of environmental 
modification (for example, what happens in the intestine), SCI was chosen as a 
model because of its large inflammatory infiltrate, which is predominantly 
myeloid in nature. One caveat that has recently been discovered is that the glial 
scar may have some immune-modulating properties. Fourteen days after SCI, it 
was shown that microglia and infiltrating blood monocytes co-localized in the 
margins of the lesion where copious amounts of CSPG are produced. This results 
in the production of high levels of IGF-1, which has been shown to be a neuronal 
survival factor 110. Inhibition of CSPG via Xyloside (a pharmalogical inhibitor of 
CSPG) treatment attenuates IGF-1 production and increases TNFα production via 
the monocyte and microglial populations that surround the margins of the lesion. 
This leads to an increase in lesion size and decrease in functional recovery 111. 
More interestingly, at 7 days post-injury, IL-10-producing macrophages were 
seen at the site of the margin where CSPG was present; the macrophages were 
also shown to have up-regulated MMP-13, which in turn leads to the degradation 
of the glial scar. This data suggests a unique regulatory feedback loop that not 
only alters the immune response but also changes glial scar degradation. 
However, this work was performed in the context of a T cell-specific MOG-
activating vaccine, which was administered a week before injury and may have 
skewed the results 112. Having stated this concern, it should be appreciated that 
it was shown that isolated CD115+ monocytes, when cultured in the presence of 
LPS and CSPG, produce IL-10 in an in vitro setting and therefore may be of 
physiological relevance. 
This previous work shows that IL-10 is a vital mechanism for immune 
regeneration in the spinal cord, though it might be initiated too late to have an 
effect on the harmful pro-inflammatory immune response which begins within 
hours of injury. For this reason, the time-point of 24h post-injury was chosen to 
administer SpA as it was recognized that elimination of the inflammatory 
immune response would lead to inefficient clearing of cellular debris and would 
not initiate a wound-healing program. Thus 24h would allow the infiltration of 
neutrophils and some monocytes to initiate the clean-up and repair program. 
However, after the administration of SpA at 24h post injury this would allow the 
generation of anti-inflammatory monocytes. This, in turn, would shut off the 
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uncontrolled inflammatory feedback loop that is established within the spinal 
cord after injury. 
When SpA treatment was examined in the inflammatory setting of SCI, it was 
seen to have the ability to increase the Ly6Clow monocyte population within the 
damaged cord and also in the peripheral blood. CD64 and Gr1 were both down-
regulated on the Ly6Chi monocytes after SpA treatment. These markers are 
expressed at lower level (CD64) or are absent (Gr1) on Ly6Clow monocytes when 
compared to the Ly6Chi population. Interestingly, there was no down-regulation 
of MHC II on the monocyte populations found in blood after SpA treatment, 
which was a feature of SIC-treated BMDMs in vitro. However, it is known that 
MHC II is not constitutively expressed by all monocytes - being present on the 
Ly6Clow monocytes but not on the Ly6Chi monocyte subpopulation. Therefore, 
this difference in monocyte and BMDM phenotypes may explain the anomaly in 
results. Another reason could be the cytokine milieu of the blood in homeostasis 
- and after SCI may not exhibit the right environmental cues to induce the up-
regulation of MHC II from their constitutive baseline levels, therefore masking 
the effect SpA could potentially have on MHC II levels. MHC II could not be 
examined on the monocytes in the damaged spinal cord due to technical issues 
with the number of flourochromes being available on the FACS machine being 
used to carry out this set of experiments. In future experiments it would be 
interesting to examine monocyte MHC II expression in the injured spinal cord 
after SpA treatment to determine if MHC II is expressed at higher levels on these 
infiltrating monocytes than their peripheral blood counterparts and, if so, can 
treatment induce the down-regulation of MHC II on monocytes found in the 
spinal cord after injury. 
Due to some differences with SpA’s effects on monocytes and BMDM, along with 
the findings from Shechter et al that Ly6Chi monocytes were actually the subset 
that produced IL-10 in the damaged spinal cord 298, it was sought to confirm in 
vivo the in vitro observation that SIC (in the presence of LPS - an inflammatory 
surrogate) could induce IL-10 up-regulation in BMDCs. To do this, we examined 
the ability of SpA to induce the up-regulation of IL-10 in the Ly6Chi & low 
monocyte populations that are present in the damaged cord after injury. Vert-X 
mice, which are GFP IL-10 reporter mice, were used due to the technical 
difficulties of carrying out intracellular cytokine staining in whole spinal cord 
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preps. It was demonstrated that the SpA-treated group showed more IL-10 
production in the damaged spinal cord compared to the control group. Of 
interest, in the control group, the Ly6Chi monocytes in the cord were IL-10-
negative, but 70% of the Ly6Clow cells in the SpA-treated mouse were IL-10-
positive. This shows that in this model of SCI, Ly6Chi monocytes do not produce 
IL-10 and SpA can induce the increased production of IL-10 in the monocyte 
population present in the spinal cord compared to the control group. The data 
also suggests that SpA induces the maturation of Ly6Chi monocytes to Ly6Clow 
monocytes, and that there is an increased presence of these IL-10 producing 
cells in the damaged spinal cord of SpA-treated mouse compared to the control. 
However, these studies do not categorically prove that SpA is changing Ly6Chi 
into Ly6Clow monocytes that are subsequently induced to produce IL-10. It is still 
a possibility that the Ly6Clow monocyte population is increased via a pre-existing 
circulating pool of Ly6Clow monocytes. The former interpretation is still an 
interesting and relevant finding but it would be interesting to investigate if the 
monocytes that SpA induced to mature into the anti-inflammatory subset were 
the cells producing IL-10. A way of investigating this would be to use an adoptive 
transfer system. Ly6Chi monocytes from vert-X mice, which are CD45.1, could be 
adoptively transferred into a CD45.2 congenic mouse 24h after SCI and treated 
with SpA - 24h later the adoptively transferred cells could be examined via flow 
cytometry. This system would allow the tracking of Ly6Chi monocytes maturation 
into Ly6Clow monocytes and their subsequent ability to produce IL-10. 
Interestingly, there was no IL-10 production from any of the monocytes in the 
blood, even though there was an increase in the Ly6Clow monocyte population 
after SpA treatment. In vitro it was determined that IL-10 was up-regulated by 
SIC alone, however, the production of IL-10 was increased further if there was 
LPS also present. This in vitro phenomenon could be mimicking what is 
happening in vivo in the setting of SCI and SpA treatment. Monocytes infiltrating 
into the damaged cord are encountering danger signals; these could include heat 
shock proteins, dsDNA and RNA which are all recognised by TLRs, and this could 
be stimulating the monocytes within the damaged spinal cord to produce high 
levels of IL-10. Although monocytes in the blood encounter SpA, which is known 
to induce a phenotypic change in Ly6Chi monocytes under non-inflammatory 
conditions, they do not receive the second TLR signal while in the peripheral 
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blood that would induce them to up-regulate their IL-10 production. It should be 
appreciated that this experiment was only carried out with one mouse per group 
and needs to be repeated to validate the results - but it does show a very 
interesting result for SpA as a modulator of inflammation in SCI. 
Thus far in chapters 3 and 4 of this thesis, it has been demonstrated that SpA 
induces an anti-inflammatory phenotype in monocytes and macrophages under 
inflammatory conditions - both in vitro and in vivo. Nevertheless, a functional 
read-out to assess if this modulation of the inflammatory response is actually 
having a beneficial effect on recovery after SCI would be essential. To answer 
this question, BDA tract-tracing of the cortico-spinal tract was examined as a 
potential measure of neuronal survival and regeneration. A full study of this 
technique could not be undertaken because of constraints on microscope time, 
and therefore not all of the sections could be imaged. Two animals that were 
BDA tract-traced, which had received 100Kdyn injuries, showed that the cortico-
spinal tract could be detected by BDA-tracking and that the cortico-spinal tract 
was ablated by the contusion injury.  
A variety of behavioural techniques were also tested to identify a suitable 
method to scrutinize the potential functional recovery in mice after the use of 
SpA in SCI. The test chosen to produce these results had to be sensitive, reliable 
and reproducible.  Different severities of SCI (50Kdyn, 80Kdyn, 100Kdyn and 
120Kdyn) were induced to see if the behavioural tests could sufficiently detect 
differences between each of the injury groups and therefore would be sensitive 
enough to detect subtle changes in recovery between treated and non-treated 
groups. The BMS was deemed not to be a suitable assessment of recovery as it is 
a hind limb locomotor test, and the cervical contusion injury induced a fore limb 
injury phenotype. Using the BMS test, no differences were seen between the 
50Kdyn, 80Kdyn and 100Kdyn injury groups, even though there was very 
noticeable differences in fore limb function. The DigiGait analyses gait, can give 
a read-out of over 20 parameters that are attributed to gait, and assesses both 
forelimb and hind-limb functions. Unfortunately, this method of behavioural 
testing had a very high drop-out rate, with only 25% of all animals completing 
the 6 weeks post-operation testing routine. Additionally, there was a very wide 
data spread within each of the injury groups at specific time points. More 
worrying still was that there was found to be an unacceptably wide, statistically 
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significant variation between mice groups in the pre-operative data. To avoid 
external factors interfering with the results and to ensure consistency of 
measurement, all mice in the study were ordered in from the same supplier and 
were all age and sex-matched. Due to these performance issues, the DigiGait 
was deemed to be unreliable and insufficiently sensitive for assessing the ability 
of SpA to improve recovery after SCI. The final behavioural testing method that 
was examined was the grip strength test, which showed the most promising 
results for future use as a functional read-out, as it is a dedicated fore limb-
specific test. All mice at both the 100Kdyn and 80Kdyn injury level could take 
part in this form of behavioural test from post-operative week 1, with no drop-
outs. The only issue that arose with the test was its level of sensitivity: there 
was a statistically significant difference in each of the injury severities 
compared to the non-injured control group at all time points. There was also a 
visible difference between the two injury groups - though this was not 
statistically significant due to variation within each of the injury groups. 
However, this study was carried out with only 3 mice in the 80Kdyn injury group 
and 4 mice in the 100Kdyn injury group and further investigation is warranted 
with a bigger study group to establish if SpA can cause a functionally relevant 
improvement in recovery after SCI by modulating the inflammatory immune 
response. 
6.2 Conclusion 
In summary, it has been demonstrated in chapter 3 of this thesis that SpA, when 
in complex with IgG, can polarize BMDM to an anti-inflammatory phenotype, 
which consists of increased IL-10 and reduced ability to produce IL-12. IFNγ-
primed macrophages that are treated with SIC and LPS also show down-regulated 
MHC II surface expression; interestingly they still exhibited normal levels of co-
stimulatory molecule CD86 compared to classically-activated macrophage. In 
chapter 4 it was demonstrated that SpA can bind to monocytes in vivo and this 
was preferentially to the Ly6Chi monocyte sub-population. Additionally, SpA was 
shown to induce the maturation of the Ly6Chi monocyte population into Ly6Clow 
monocytes in steady state and in the inflammatory setting of SCI. SpA treatment 
also induced monocytes within the damaged cord to produce increased levels of 
IL-10 compared to the control. 
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Taken together, these observations indicate that when SpA and IgG form SIC and 
interact with macrophages and monocytes in vitro or in vivo the cells can be 
polarized to an anti-inflammatory phenotype, which has the potential to down-
regulate the massive inflammatory response after SCI. While several methods of 
functional assessment were examined for their ability to measure discernable 
changes in the recovery of mice after SCI, none of the behavioural tests assessed 
met all the requirements for a functional read-out that would be effective in the 
assessment of SpA’s ability to induce greater recovery than controls. However, 
more investigation of the grip strength and the BDA track tracking techniques 
are warranted and did show promising potential.  
In conclusion, it has been shown in this thesis that SpA has the potential to be 
used as a cell-specific method for modulating the massive inflammatory 
response that contributes to the secondary death of neurons days to weeks after 
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1.Buffer and solutions: 
10x PBS: 80 g NaCl, 2 g KCl, 11.5g Na2HPO47H2O and 2g KH2PO4 to 1 litre distilled 
water (pH 7.4) 10x stock. 
FACS Buffer: 1% (v/v) FCS, 5mM EDTA, 0.02 Sodium azide in 1X PBS 
Complete media: 1% (v/v) Pen/Strep, 1% (v/v) L-Glut, 10% (v/v) FCS in 500ml 
RPMI 
Separation media: 2.5% (v/v) FCS 2mM EDTA 1X PBS 
2.Immunohistochemistry antibodies  
Primary antibody: 
1) Neurofilament-200 (NF200), mouse IgG1, Sigma #N0412, dilution: 1:1000 
2) Glial fibrillary acidic protein (GFAP), rabbit IgG1, DAKO #Z0334, dilution: 
1:1000 
Secondary antibody: 
1) Donkey anti-mouse IgG, Rhodamine conjugate, Jackson Immunoresearch #715-
025-150, dilution: 1:100 
2) Donkey anti-rabbit IgG, DyLight 649 conjugate, BioLegend #406406, dilution: 
1:500 
Streptavidin: 




3.Flow Cytometery Antibodies  
APC 
Marker  Dilution Manufacturer 
 
Catalogue   
Number 
CD45 1:200 ebioscience 17-0451 
CD19 1:200 BD Pharmingen  550992 
CD64/FcγR I 1:200 BD Pharmingen  558539 
F4/80 1:300 ebioscience  17-4801-82 
MR/CD206 1:100 Biolegend  123010 
CD45R/B220 1:300 Biolegend  103226 
Streptavidin 1:400 ebioscience  17-4317-82 
Gr1/Ly-6C G 1:100 BD Pharmingen  553129 
 
APC cy7 
Marker  Dilution Manufacturer 
 
Catalogue   
Number 
CD11b 1:200 BD Pharmingen 557657 
CD45 1:300 BD Pharmingen 557659 
 
FITC/Alexa-488  
Marker  Dilution Manufacturer 
 
Catalogue   
Number 
CD11B 1:100-200 Biolegend   101205 
CD80 1:100 - 200 BD Pharmingen  553768 
CD86 1:100 - 200 BD Pharmingen  553691 
CD45 1:100 ebioscience   11-0451 
MHC II I-A(B) 1:100 BD Pharmingen  553605 




1:100 BD Pharmingen  553456 
IgG2a (iso 
Alexa-488) 
1:100 Ebioscience  53-4724-80 
 
PE cy7 
Marker  Dilution Manufacturer 
 
Catalogue   
Number 




Marker  Dilution Manufacturer 
 
Catalogue   
Number 
CD3 1:300 BD Pharmingen  553064 
CD11b 1:500 ebioscience   12-0112-83 
CD40 1:300 BD Pharmingen  553791 
CD45 1:500 Biolegend   103106 
CD69 1:300 ebioscience   12-0691-82 
CD86 1:300 BD Pharmingen  553692 
Streptavidin 1:1000 ebioscience   12-4317-87 
IgG2a (iso) 1:300 BD Pharmingen  551799 
F4/80 1:400 Biolegend 123109 
 
 
PerCP-cy5.5/PE cy 5.5 
Marker  Dilution Manufacturer 
 
Catalogue   
Number 
B220 PE cy 5.5 1:300 BD Pharmingen  551001 
Ly-6C PerCP-
cy5.5 




Marker  Dilution Manufacturer 
 
Catalogue   
Number 
IL-10R/CD210  BD Pharmingen  550012 
 
AF700 
Marker  Dilution Manufacturer 
 
Catalogue   
Number 
Ly6G 1:200 ebioscience  56-5931 
CD45 1:400 ebioscience  56-0451 
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Co-Opting Endogenous Immunoglobulin for the Regulation of
Inflammation and Osteoclastogenesis in Humans and Mice
Lindsay M. MacLellan,1 Jennifer Montgomery,1 Fujimi Sugiyama,1 Susan M. Kitson,1
Katja Thu¨mmler,1 Gregg J. Silverman,2 Stephen A. Beers,3 Robert J. B. Nibbs,1
Iain B. McInnes,1 and Carl S. Goodyear1
Objective. Cells of the monocytic lineage play
fundamental roles in the regulation of health, ranging
from the initiation and resolution of inflammation to
bone homeostasis. In rheumatoid arthritis (RA), the
inflamed synovium exhibits characteristic infiltration of
macrophages along with local osteoclast maturation,
which, together, drive chronic inflammation and down-
stream articular destruction. The aim of this study was
to explore an entirely novel route of immunoglobulin-
mediated regulation, involving simultaneous suppres-
sion of the inflammatory and erosive processes in the
synovium.
Methods. Using in vivo and in vitro studies of
human cells and a murine model of RA, the ability of
staphylococcal protein A (SPA) to interact with and
modulate cells of the monocytic lineage was tested. In
addition, the efficacy of SPA as a therapeutic agent was
evaluated in murine collagen-induced arthritis (CIA).
Results. SPA showed a capacity to appropriate
circulating IgG, by generating small immunoglobulin
complexes that interacted with monocytes, macro-
phages, and preosteoclasts. Formation of these com-
plexes resulted in Fc! receptor type I–dependent polar-
ization of macrophages to a regulatory phenotype,
rendering them unresponsive to activators such as
interferon-!. The antiinflammatory complexes also had
the capacity to directly inhibit differentiation of pre-
osteoclasts into osteoclasts in humans. Moreover, ad-
ministration of SPA in the early stages of disease
substantially alleviated the clinical and histologic ero-
sive features of CIA in mice.
Conclusion. These findings demonstrate the over-
arching utility of immunoglobulin complexes for the
prevention and treatment of inflammatory diseases. The
results shed light on the interface between immunoglob-
ulin complex–mediated pathways, osteoclastogenesis,
and associated pathologic processes. Thus, therapeutic
agents designed to harness all of these properties may
be an effective treatment for arthritis, by targeting both
the innate inflammatory response and prodestructive
pathways.
Monocytes differentiate into either macrophages
or osteoclasts depending on their response to specific
intra- and extracellular signals (1,2). These cells play
pivotal roles in the generation of adaptive immune
responses, initiation and resolution of inflammation, and
bone homeostasis (3). In chronic inflammatory condi-
tions such as rheumatoid arthritis (RA), these cells have
crucial roles in perpetuating disease pathogenesis.
Monocytes and macrophages are the primary source of
the inflammatory cytokines and chemokines that drive
the chronicity of the synovial lesion (4,5), while the
increased differentiation of osteoclasts from cells pres-
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ent in the joint (6,7) is considered critical for the
development of the major erosive lesion.
The local environment has a dramatic influence
on macrophage maturation and can drive the develop-
ment of a spectrum of functionally diverse phenotypes
(8). Two of the functional extremes are the antiinflam-
matory “regulatory” macrophages and the proinflamma-
tory “classically” activated macrophages. The regulatory
phenotype is characterized by increased expression of
interleukin-10 (IL-10) but decreased expression of IL-
12. In contrast, the proinflammatory phenotype is de-
fined as Th1-driven (interferon-! [IFN!]–primed) and
characterized by increased expression of IL-12 and
inducible nitric oxide synthase (8). Therapeutic strate-
gies with the potential to polarize macrophages to a
regulatory phenotype are of intense interest in the
generation of new approaches to treat patients during
the chronic self-perpetuation phase of RA (5).
One potential therapeutic approach for inflam-
matory diseases comes from an understanding of im-
mune complexes (ICs) and their interactions with macro-
phages. It has been recognized for several decades that
ICs play a central role in the pathogenesis of RA (9),
being responsible for driving inflammation and, indi-
rectly, joint erosion, via Fc! receptor (Fc!R)–mediated
interactions (10). In the right context, ICs can have
antiinflammatory properties (8), and this is partly due to
their ability to contribute to the generation of regulatory
macrophages (11). Recent studies have demonstrated
that small, preformed ICs (12), intravenous immuno-
globulin (IVIG) complexes (13,14), and antibodies to
soluble serum proteins (15) can be used to ameliorate
arthritis in passive transfer autoimmune models such as
K/BxN serum–induced inflammatory arthritis. However,
such unoptimized therapies as IVIG have little clinical
benefit in RA.
Staphylococcal protein A (SPA), a microbial pro-
tein widely used for therapeutic antibody purification
and formerly used as a column-bound apheresis therapy
for severe RA (16), has the ability to co-opt circulating
IgG and exclusively form small, defined hexameric com-
plexes, or (IgG2SPA)2 (17–19). Exploiting the ability of
SPA to hijack endogenous IgG may facilitate a novel
macrophage-targeting approach, aimed at driving Fc!R-
mediated signaling toward regulatory pathways that can
modify autoimmune inflammatory diseases.
In this study, we show that SPA–IgG immune
complexes (SICs) have the ability to ameliorate antigen-
induced arthritis, by inhibiting both the clinical and
pathologic aspects of murine collagen-induced arthritis
(CIA). Mechanistically, SICs modulate macrophage re-
sponsiveness to proinflammatory cytokines via Fc!R,
and thus alter the phenotype of these cells. Further-
more, we show, for the first time, that specific ICs can
interact with preosteoclasts, can dramatically inhibit
osteoclastogenesis, and can substantially reduce oste-
oclast abundance in the joint. We conclude that co-
opting endogenous IgG into ICs may provide an alter-
native therapy for RA and other autoimmune/
inflammatory diseases, by targeting both inflammatory
and erosive aspects of the disease process.
MATERIALS AND METHODS
Mice. DBA/1J and C57BL/6 mice (ages 7–10 weeks)
were purchased from Charles River. Mice of the "MT strain
were bred and maintained at the University of Glasgow, UK.
FcR!!/!, Fc!RI!/!, and Fc!RII!/! mice (C57BL/6 back-
ground) were bred and maintained at the University of South-
ampton, UK. The Ethical Review Process Committee and the
UK Home Office approved all experimental procedures.
In vivo tracking of SPA. Recombinant SPA (rSPA;
Repligen), or ovalbumin (OVA) as a control, was conjugated
to Alexa Fluor 488–labeled N-hydroxysuccinimide (Molecular
Probes), as previously described (20). In "MT mice, 6 mg of
mouse IgG (Jackson Immunochemicals) in phosphate buffered
saline (PBS) was injected intravenously. Labeled protein (300–
500 "g of SPA-488 or OVA-488) was then injected intraperi-
toneally (IP), and 2 hours later, the blood and spleens were
harvested and erythrocyte-free single cell suspensions were
prepared.
Flow cytometry. Cells were preincubated with or with-
out Fc Block and stained with specific antibodies or isotype
controls. Data were acquired on a FACSCaliber LSRII
(Becton-Dickinson) or MACSQuant (Miltenyi) flow cytome-
ter, and results were analyzed with FlowJo software (Tree
Star).
Generation of immune complexes. To generate the
SICs, rSPA (SPA-488) at a concentration of 37.5 "M was
mixed with 150 "M human or mouse IgG in PBS at 37°C for
1 hour. To generate the OVA plus polyclonal IgG (OpIg)
control, 37.5 "M of OVA (OVA-488) was mixed with 150 "M
of mouse IgG in PBS at 37°C for 1 hour. Prior to being used in
these experiments, the IgG was centrifuged at 13,000 revolu-
tions per minute for 5 minutes, to remove large IgG complexes.
Generation and stimulation of murine bone marrow–
derived macrophages (BMMs) and preosteoclasts. Cells were
flushed from the mouse femurs and tibiae. In some studies,
monocytes were enriched by magnetic negative selection
(StemCell Technologies). Bone marrow monocytes or en-
riched monocytes were cultured in complete RPMI with 20%
L929-conditioned medium or 30 ng/ml recombinant macro-
phage colony-stimulating factor (M-CSF) for 5–6 days to
generate BMMs, or with 30 ng/ml M-CSF and 50 ng/ml
RANKL for 5 days to generate preosteoclasts. On days 5–6,
the BMMs and preosteoclasts were removed and either used
directly in flow cytometry or washed, reseeded, and left to
adhere overnight prior to stimulation.
BMMs were stimulated for 6–24 hours with lipopoly-
saccharide (LPS) (100 ng/ml Escherichia coli O127:B8; Sigma-
Aldrich) in the presence or absence of SICs, SPA, or IgG.
In some instances, BMMs were prestimulated overnight with
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IFN! (100 units/ml) prior to these other treatments. To
analyze the macrophage response to OVA ICs (designated
M!-II in Figure 3), after prestimulation of the BMMs with
IFN!, the cells were treated with LPS and 150 "g/ml ICs
consisting of OVA and rabbit anti-OVA IgG, as previously
described (21).
Enzyme-linked immunosorbent assay (ELISA). Cyto-
kine and anticollagen antibody levels were assayed by ELISA,
using appropriately diluted sera or culture supernatants.
Mouse IL-10 and IL-12p40 (BD Biosciences), and human
IL-10, IL-12, and tumor necrosis factor # (TNF#; Biosource)
were assayed in accordance with the manufacturers’ instruc-
tions. Anti–type II collagen (anti-CII) antibody titers in
individual sera were evaluated using ELISA-grade collagen
(Chondrex) and detected with horseradish peroxidase (HRP)–
conjugated anti-mouse IgG1 or IgG2a (Southern Biotechnol-
ogy). Total IgG was determined using an unlabeled anti-mouse
IgG capture antibody and detected with HRP-conjugated
anti-mouse IgG1 or IgG2a. Antibody ELISAs were developed
using OPD substrate (Sigma).
Induction and assessment of arthritis. CIA was in-
duced in DBA/1J mice with 100 "g of bovine CII emulsified in
Freund’s complete adjuvant (MD Biosciences) on day 0, and
boosted on day 21 with an IP injection of CII in PBS (22).
Starting on day 21, mice were scored by a treatment-blinded
researcher (LMM) for clinical signs of arthritis, as previously
described (23). On day 25, mice were randomized to receive an
IP injection of 100 "g rSPA or vehicle control (pyrogen-free
PBS). Treatment was continued every other day.
The hind paws were histologically scored by treatment-
blinded researchers (LMM and CSG) for inflammation and
joint damage (24), in which 0 " healthy, 1 " mild, 2 "
moderate, and 3 " severe. The researchers scored 3 sections
per knee, and the mean score per treatment group was
calculated.
In addition, the hind paws were assessed by immuno-
histochemistry for the presence of osteoclasts. Sections were
deparaffinized, and antigen retrieval was performed. Slides
were blocked in 3% horse serum/Tris buffered saline and
stained with a rabbit polyclonal IgG against cathepsin K
(ProteinTech Group) or normal rabbit IgG. Slides were devel-
oped using the ImmPRESS Anti-Rabbit Ig (peroxidase) sub-
strate kit (Vector), and counterstained with hematoxylin. The
bone surface area and the numbers of cathepsin K–positive
cells per section were determined for each knee joint, and the
number of cells per mm2 of bone was calculated.
Restimulation of lymph node (LN) cells. Single cell
suspensions were prepared from inguinal LNs. Cells were
cultured in triplicate in 96-well plates at 6 # 105 cells/well in
complete RPMI. Cells were restimulated with medium, 30
"g/ml CB11 peptide (optimal concentration; Chondrex), or 30
"g/ml of the irrelevant peptide MOG35–55. Proliferation was
analyzed 88 hours thereafter by assessing 3H-thymidine incor-
poration (GE Healthcare) for the last 16 hours of culture.
Real-time quantitative polymerase chain reaction
(PCR). Cell and tissue RNA was isolated using Qiagen Mini
and Micro kits in accordance with the manufacturer’s instruc-
tions. Tissue samples were disrupted in liquid nitrogen using a
pestle and mortar. To quantify RNA transcripts, complemen-
tary DNA (cDNA) was prepared using the Stratagene Affinity
Script Multiple Temperature cDNA Synthesis Kit. Real-time
quantitative PCR using SYBR Green (Applied Biosystems)
was carried out using the Applied Biosystems 7900HT Fast
Real-Time PCR System. Specific transcript levels were nor-
malized to those for GAPDH, and the $$Ct calculation
method was used to determine gene expression, as previously
described (25).
Generation and stimulation of human peripheral
blood monocyte–derived macrophages. Buffy coats of healthy
human blood were obtained from the Scottish Blood Transfu-
sion Service, and their use was approved by the Glasgow East
Ethics Committee. Peripheral blood mononuclear cells were
separated on Histopaque (Sigma-Aldrich), and monocytes
were purified using the CD14-positive selection EasySep kit
(StemCell Technologies). The monocytes were cultured in
complete RPMI with 10 ng/ml human M-CSF (PeproTech) for
7 days in the presence or absence of SICs, SPA, or IgG. On day
7, cultures were stimulated with LPS (100 ng/ml) and super-
natants were harvested for analysis of cytokine content. For the
investigation of IFN!-mediated signaling, monocytes were
cultured for 6 days with M-CSF, washed, and treated with
either SICs, SPA, or IgG for 48 hours. These cultures were
then stimulated with 10 units/ml of IFN! (PeproTech) for 10
minutes and immediately used for immunoblotting or imaging.
Immunoblotting. Whole cell extracts were obtained by
lysing cells in radioimmunoprecipitation assay extraction buf-
fer with protease and phosphatase inhibitors. Protein amounts
were quantified with the BCA Protein Assay (Pierce), accord-
ing to the manufacturer’s instructions. Twenty micrograms of
cell lysate was fractionated on 4–12% Bis-Tris Gels, trans-
ferred to PVDF membranes (Invitrogen), and incubated with
antibodies specific for phosphorylated STAT-1 tyrosine 701,
total STAT-1, or $-actin (Abcam). Membranes were washed
and incubated with HRP-labeled anti-IgG antibodies and
developed with SuperSignal West Pico substrate (Pierce).
Immunofluorescence imaging. Chamber slide cultures
were fixed with 4% paraformaldehyde for 10 minutes at room
temperature. Phosphorylated STAT-1 was visualized in cells by
permeabilizing with 90% ethanol in PBS and staining with a
biotinylated anti–phosphorylated STAT-1 antibody. This was
followed by staining with streptavidin–HRP, biotinylated tyra-
mide (Invtirogen), and, finally, streptavidin–Alexa Fluor 647.
The sections were also stained with DAPI and mounted in
Vectashield (Vector). Fluorescence imaging was conducted
using an LSC fluorescence microscope (Compucyte) with a
Hamamatsu Orca ER digital camera and Openlab digital
imaging program (Improvision).
Generation of human peripheral blood monocyte–
derived osteoclasts. Monocytes (1 # 106) were cultured in
#-minimum essential medium (10% fetal bovine serum, 2 mM
L-glutamine, 100 "g/ml penicillin, 100 "g/ml streptomycin)
with 30 ng/ml M-CSF and 100 ng/ml RANKL (PeproTech) in
the presence or absence of SICs, SPA, OpIg, or IgG. The
medium was changed every 3 days, and on day 7, the cultures
were evaluated for osteoclast differentiation. Slides were
stained for tartrate-resistant acid phosphatase (TRAP) using a
leukocyte acid phosphatase kit (Sigma-Aldrich). Osteoclasts
were identified under light microscopy by the presence of %3
nuclei (identified as purple staining); osteoclast precursor cells
were identified as TRAP-positive cells with 1 or 2 nuclei.
Statistical analysis. GraphPad Prism was used for all
statistical analyses: t-tests, Mann-Whitney U tests, one-way
analysis of variance (ANOVA) with post hoc tests, or two-way
ANOVA with repeated measures, as appropriate. Data are
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expressed as the mean ! SD, except for clinical scores of CIA,
which are given as the mean ! SEM. P values less than or
equal to 0.05 were considered significant, and all tests were
2-sided.
RESULTS
Binding of SPA–IgG complexes to monocytes,
macrophages, and preosteoclasts via Fc!RI. SPA binds
to B cells in a B cell receptor (BCR)–dependent man-
ner. However, it can also interact with non–B cell and
non–T cell populations in vivo (20). We analyzed the
non–B cell binding of fluorescently labeled SPA in vivo.
In the blood of mice injected with SPA-488, we observed
considerable binding to monocytes but minimal binding
to neutrophils (Figures 1A and B). SPA-488 also inter-
actedwithdifferentiatedmonocytes, i.e.,CD11b"macro-
phages, in the spleen (Figure 1C).
In B cell/immunoglobulin–deficient !MT mice,
SPA was able to interact with circulating monocytes only
if the mice had been reconstituted with IgG (Figure 1D).
To further investigate the interaction of SPA and IgG
Figure 1. Staphylococcal protein A (SPA) binds to circulating mono-
cytes and tissue macrophages in mice with collagen-induced arthritis.
Mice were injected with 500 !g of Alexa Fluor 488–labeled SPA
(SPA-488) or ovalbumin (OVA-488), and 2 hours later, the blood and
spleens were harvested for cell analyses. A, Representative results of flow
cytometry are shown. Monocytes and neutrophils from the blood were
initially gated based on their forward light-scatter (FSc) versus side
light-scatter (SSc) patterns (top left panel), and then gated by lymphocyte
antigen (Ly-6C versus Ly-6G/C) expression (top right panels). The lower
panels show binding of OVA-488 or SPA-488 to CD11b"monocytes and
neutrophils. Values in the boxed areas (same as boxed areas in the top
panels) are the percentage of positive cells in each population. B and C,
The extent of OVA-488 or SPA-488 binding was determined in mono-
cytes and neutrophils (B) and in splenic CD11b"macrophages (C). Bars
show the mean ! SD representative results from 1 of 3 independent
experiments, expressed as the mean fluorescence intensity (MFI) in 3
mice per group. !!! # P $ 0.001 versus OVA-488, by t-test. NS # not
significant. D, Mice of the !MT strain were injected intravenously with
phosphate buffered saline (PBS) or mouse polyclonal IgG. Mice were
then injected intraperitoneally with 300 !g SPA-488 or OVA-488, and 2
hours later, the blood was collected to determine the extent of binding of
OVA-488 or SpA-488 to monocytes. Bars show the mean ! SD repre-
sentative results from 1 of 2 independent experiments, expressed as the
MFI in 2 mice per group.
Figure 2. Formation of staphylococcal protein A (SPA)–IgG immune
complexes (SICs) and the presence of Fc" receptor type I (Fc"RI) are
required for binding to macrophages and preosteoclasts. Bone marrow
cells from C57BL/6 and Fc"RI%/% mice were enriched for monocytes
and cultured with recombinant macrophage colony-stimulating factor
(M-CSF) or M-CSF plus RANKL for 5 days to generate bone
marrow–derived macrophages (BMMs) or preosteoclasts, respectively.
These cells were incubated with Alexa Fluor 488–labeled ICs (ovalbu-
min plus polyclonal IgG [OpIg-488], SPA-488, SIC-488, or ovalbumin-
488 [not shown]) to evaluate binding. Representative images show the
binding of each complex to CD11b" BMMs and preosteoclasts.
Values over the boxed populations are the percentage of positive cells.
The data shown are representative flow cytometry results, tested in
duplicate, from 1 of 3 independent experiments.
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with monocytes, macrophages, or preosteoclasts, we
generated SPA-488–IgG immune complexes (SIC-488)
(data not shown) at a molar ratio that is consistent with
what would be formed in the circulation when excess
IgG, or (IgG2SPA)2 (17–19), is present. SIC-488 showed
significant binding both to BMMs and to preosteoclasts,
while SPA-488, OVA-488 (data not shown), or OpIg-488
were unable to bind to these cells (Figure 2).
As was indicated in Figure 1, SPA-488 showed
substantial binding only to monocytes. Importantly,
whereas both monocytes and neutrophils express
Fc!RIIb, Fc!RIII, and Fc!RIV, only monocytes express
Fc!RI (26) (data not shown). Thus, as anticipated,
SIC-488 was unable to bind to BMMs or to preoste-
oclasts that were deficient in their expression of Fc!RI
(Figure 2).
Skewing of macrophages to a regulatory pheno-
type by SICs. The aforementioned findings and those
from previous studies using experimental ICs (refs. 21,
27, and data not shown) raised the possibility that SICs
would interact with, and polarize, macrophages toward a
regulatory phenotype. The addition of SICs, and not
SPA or IgG alone, in the absence of a Toll-like receptor
4 agonist (LPS) was able to induce significant produc-
tion of IL-10 (Figure 3A and data not shown), a phe-
nomenon not noted previously with other experimental
ICs (21,27). Moreover, the addition of SICs along with
stimulation with LPS resulted in a significant inhibition
of IL-12 secretion (Figure 3A). Levels of TNF" and
nitric oxide were unchanged, and transforming growth
factor # was not detectable (data not shown). The
induction of IL-10 was also confirmed at a transcrip-
tional level, in which SICs induced an 8-fold increase in
IL-10 transcripts (data not shown). Crucially, mannose
receptor expression did not change (data not shown),
suggesting that SPA does not induce a formal regulatory
phenotype.
To further define this apparently novel regula-
tory macrophage lineage, BMMs from DBA/1J and
C57BL/6 mice were primed with IFN!, and 16 hours
Figure 3. Treatment of mice with staphylococcal protein A (SPA)–IgG immune complexes (SICs) alters the cytokine profile and activation state
of macrophages in an Fc! receptor type I (Fc!RI)–dependent manner. A, Bone marrow–derived macrophages (BMMs) from DBA1/J mice were
stimulated for 6 hours without or with lipopolysaccharide (LPS) in the absence or presence of SICs, and levels of interleukin-10 (IL-10) and
IL-12p40 were determined. Stimulation with IgG did not yield results significantly different from those with either medium alone or SPA, and
therefore IgG is not shown. B and C, BMMs from C57BL/6 mice were primed with interferon-!, and 16 hours later, the cells were stimulated with
LPS (Ca-M!), SICs " LPS (SIC-M!), or ovalbumin ICs (M!-II) (21) or left unstimulated (Uns-M!). Six hours later, the BMMs were analyzed
by flow cytometry for the expression of class II major histocompatibility complex (MHC II) and CD86, as shown in representative histograms (B)
and shown as the mean fluorescence intensity (MFI) (C). Incubations over 24 hours (not shown) resulted in the same expression profiles. D, BMMs
from C57BL/6 and Fc!RI#/# mice were stimulated for 6 hours with LPS in the absence or presence of SICs. Results with IgG " LPS and SPA "
LPS did not differ significantly from those with LPS alone, and therefore these are not shown. Bars show the mean $ SD representative results
from 1 of 3 independent experiments, determined in samples from triplicate wells, measured in triplicate. !% P& 0.05; !!!% P& 0.001, by analysis
of variance with post hoc test.
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later, the cells were stimulated with LPS in the presence
or absence of SICs. As a result, upon stimulation of the
cells with SICs and LPS, the levels of CD86 were
up-regulated, which was also observed with SICs alone
(data not shown), whereas there was an abrogation of
the up-regulated expression of class II major histocom-
patibility complex (MHC) (Figures 3B and C and data
not shown). This is distinct from the observations made
with other experimental ICs, which, in general, up-
regulated class II MHC and CD86 (Figures 3B and C)
(21,27). In addition, neither LIGHT nor CCL-1 tran-
script levels, both of which are known to be associated
with the regulatory phenotype, were altered by stimula-
tion with SICs plus LPS when compared to LPS alone
(data not shown).
Polarization of macrophages by SICs via Fc!RI
interactions. Studies on the mechanisms of experimental
ICs have demonstrated that these complexes impart
their effects through ligation of Fc!RI (11). Based on
these studies and our own findings (as shown in Figure
2), we hypothesized that SICs would interact with macro-
phages in a similar way. To determine whether Fc!RI or
an alternative Fc receptor was the main mechanism of
interaction, we generated BMMs from C57BL/6,
FcR!!/!, Fc!RI!/!, and Fc!RII!/!mice. When BMMs
from C57BL/6 mice were treated with SICs, regulatory
macrophages were generated (Figure 3D). However, in
the absence of either the FcR! chain, i.e., lack of the Fc
receptors Fc!RI, Fc!RIII, and Fc!RIV (data not
shown), or in the absence of Fc!RI alone (Figure 3D),
SICs were unable to modify the effect of LPS and skew
BMMs toward a regulatory phenotype. Interestingly,
SICs were still effective at inducing regulatory macro-
phages in the absence of Fc!RII (data not shown).
Amelioration of murine arthritis by treatment
with SPA. Given the ability of SICs to interact with
monocytes, macrophages, preosteoclasts, and B cells,
and, more specifically, their ability to polarize macro-
phages to a regulatory phenotype, we investigated the
potential of treatment with SPA to ameliorate disease
in the early phase of inflammatory arthritis. Treatment
of mice with SPA significantly decreased the severity
and incidence of disease (Figures 4A and B). Histomor-
phometric evaluation revealed that, compared with
vehicle-treated mice, SPA-treated mice had significantly
fewer features of inflammatory disease and displayed
Figure 4. Treatment of mice with staphylococcal protein A (SPA) at disease onset inhibits the development of arthritis. Mice with
collagen-induced arthritis were treated on day 25 after induction of arthritis and every other day thereafter with either vehicle or SPA. A and B,
The severity (A) and incidence (B) of arthritis were assessed in each group. Bars in A and B show the mean " SEM results (pooled from 2
experiments) in 16–17 mice per group. ! # P # 0.02 versus vehicle, by two-way repeated-measures analysis of variance (ANOVA) in A or by
log-rank test in B. C and D, Representative histologic images of hematoxylin and eosin (H&E)–stained knees from vehicle-treated (C) and
SPA-treated (D) mice on day 42 after arthritis induction are shown. E, Histologic features of arthritis (assessed as hyperplasia, infiltration, and
erosion in H&E-stained knees, and cartilage destruction, as measured by proteoglycan [PG] depletion, in Safranin O–stained sections) were scored
in a blinded manner. Bars show the mean " SD of 9 mice per group. !! # P $ 0.01; !!! # P $ 0.001 versus vehicle, by ANOVA with post hoc
test. F and G, Knees from vehicle-treated (F) and SPA-treated (G) mice were stained for cathepsin K–positive cells (osteoclasts) (indicated by the
red arrow) on day 42 after arthritis induction. Representative images are shown. H, Sections stained for cathepsin K were measured for bone area
and the number of osteoclasts (cathepsin K–positive cells) per mm2 of bone was determined. Bars show the mean " SD of 5–8 mice per group.
!!! " P $ 0.001 versus vehicle, by t-test.
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markedly less hyperplasia, infiltration, and cartilage and
bone erosion (Figures 4C–E).
In addition, the evaluation of osteoclast numbers
in the joints illustrated that SPA-treated mice had
substantially fewer osteoclasts present in the joints (Fig-
ures 4F–H). This latter finding could arise from a
suppression of macrophages or a reduction in inflamma-
tion, which thus would decrease RANKL, IL-1, or
M-CSF release, or alternatively could reflect a direct,
and unidentified, effect of SPA/SICs upon preoste-
oclasts and the resulting osteoclastogenesis.
Skewed anti-CII antibody response and in-
creased serum IL-10 levels following SPA treatment. In
vivo administration of SPA results in the depletion of
VH3 BCR–encoded B cells (28). In the murine CIA
model, this depletion occurs (data not shown); however,
susceptible B cells only represent!3% of the repertoire.
Total B cell depletion late in CIA has no effect on
clinical disease (29), and although we cannot conclu-
sively rule out the impact of this small level of depletion,
it is unlikely to be the main contributing factor to such a
dramatic clinical effect.
To identify alternative factors for the clinical
effect of SPA, we investigated the established adaptive
immune response. Surprisingly, treatment with SPA
resulted in increased ex vivo lymphocyte proliferative
responses to collagen peptide (Figure 5A). Moreover,
the levels of CII-specific IgG2a antibodies were unaf-
fected, whereas anti-CII IgG1 titers were elevated by
SPA treatment (Figures 5B and C), thus demonstrating
that in SPA-treated mice, the capacity to generate and
maintain a class-switched antibody response with T cell
help, albeit skewed to the IgG1 subclass, is retained. In
addition, we also observed a significant increase in
serum IL-10 levels with SPA treatment (Figure 5D).
Activation of macrophages with skewing to a
regulatory phenotype can lead to an increase in IgG1
antibodies and an increase in the secretion of IL-10 (30),
and SPA, in the form of SICs, can lead to a regulatory
macrophage phenotype (Figure 3). Therefore, we con-
sidered the possibility that SPA-mediated disease sup-
pression may occur via the modulation of macrophage
function.
Alteration of macrophage responsiveness to
IFN! by SPA.Although IFN!"/"mice have exacerbated
disease in the CIA model, treatment with IFN! in the
early stages of disease can exacerbate the clinical fea-
tures even further (31). To address the capacity of SPA
to alter macrophages in vivo, mice with CIA were
treated with SPA or vehicle control, and on day 42, the
mice received an IP injection of IFN!. Three hours later,
peritoneal macrophages were harvested and RNA was
extracted for gene expression analyses. As expected, the
addition of IFN! in the vehicle treatment group resulted
in a significant increase in the expression of the IFN!-
Figure 5. Treatment of mice with staphylococcal protein A (SPA)
enhances the proliferative responses to CB11 peptide, increases
collagen-specific IgG1 antibodies, and renders macrophages unrespon-
sive to interferon-! (IFN!). Mice with established collagen-induced
arthritis (CIA) were treated on day 25 with intraperitoneal (IP)
injections of either vehicle alone or 0.1 mg of SPA every other day. A,
Inguinal lymph nodes collected on day 42 were cultured in medium
alone or with 30 "g/ml CB11 peptide. The recall response to CB11
peptide was calculated as the counts per minute of 3H-thymidine
(3H-TdR) incorporation in medium alone subtracted from the
peptide-specific counts. Bars show the mean # SEM of 7 mice per
group. B–D, Serum levels of anticollagen (anti-CII) mouse IgG2a (B)
and IgG1 (C), expressed as relative units (RU), and serum levels of
interleukin-10 (IL-10) and IL-12 (D) were determined on the day of
harvest (day 42). There were no significant differences in the total
levels of IgG (data not shown). In B and C, results are shown as box
plots, where the boxes represent the 25th to 75th percentiles, the lines
within the boxes represent the median, and the lines outside the boxes
represent the 10th and 90th percentiles, for 9–10 mice per group. In D,
results are the mean # SD of 5 mice per group. E, Mice with
established CIA in each treatment group were treated on day 42 with
an IP injection of IFN! or vehicle (v). Peritoneal macrophages were
harvested 3 hours later, RNA was extracted, and quantitative polymer-
ase chain reaction was performed to determine the expression of IP10
and IRF1. Values for the target genes were normalized to those for
GAPDH, with results expressed as the mean# SD fold change in gene
expression compared to vehicle in 7–9 mice per group. ! $ P % 0.05
versus vehicle, by t-test; !! $ P % 0.01 and !!! $ P % 0.001 versus
vehicle, by analysis of variance with post hoc test.
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inducible genes IP10 and IRF1. In contrast, macro-
phages from the SPA-treated mice were completely
unresponsive to IFN! (Figure 5E).
Inhibition of inflammatory cytokine production
and reduction in responsiveness to IFN! by SICs in
human macrophages. To confirm that SIC modulation
was not a species-specific phenomenon, we investigated
whether human monocyte polarization could be affected
by SIC treatment. Human blood monocyte–derived
macrophages were treated with SICs and stimulated
with LPS. The addition of SICs resulted in a 46%
decrease in the secretion of IL-12 (P ! 0.05), and the
levels of IL-10 were undetectable in the cultures (data
not shown). Unlike in mouse BMMs (data not shown),
SICs were able to decrease the production of TNF" in
human macrophages by 76% (P ! 0.001) (Figure 6A).
To extend our studies to demonstrate that SICs
can also impair the capacity of proinflammatory cyto-
kines to “classically” activate human macrophages, we
cultured human blood–derived macrophages with SPA,
IgG, or SICs for 48 hours prior to stimulation with IFN!.
The addition of either SPA or IgG alone was unable to
inhibit the ability of IFN! to activate STAT-1 (Figures
6B and C). The presence of SICs, however, considerably
inhibited the phosphorylation of STAT-1 in response to
IFN! (Figures 6B–D).
Inhibition of osteoclastogenesis by SICs. SICs
can interact with preosteoclasts (as shown in Figure 2)
and these cells express Fc!RI (data not shown). Further-
more, in vivo treatment is associated with a decrease in
osteoclast abundance in the mouse joint (Figures 4F and
H). To investigate whether SICs can alter the differen-
tiation of preosteoclasts, human CD14" monocytes
were cultured in the presence of RANKL and M-CSF.
The addition of SICs on day 1 resulted in the down-
regulation of CD115 (c-Fms), the M-CSF receptor, 6
hours posttreatment (Figure 6E).
To investigate whether this decrease in the level
of CD115 was associated with a decrease in the subse-
quent ability of preosteoclasts to differentiate into osteo-
clasts, the number of multinucleated (#3 nuclei)
TRAP" cells was assessed on day 7 (Figures 6F and G).
We observed a near complete inhibition of human
osteoclast differentiation. Commensurate with this,
there was no significant difference in the total number of
viable cells in the cultures on day 7 (data not shown).
Crucially, delaying the addition of SICs until day 5 (a
time firmly associated with the initiation of osteoclast
differentiation and emergence of cells capable of bone
resorption [32,33]), led to the suppression of cell matu-
ration (data not shown).
DISCUSSION
In this study, we evaluated the ability of SPA to
ameliorate inflammatory arthritis in the early stages of
disease and investigated the underlying mechanism of
action. Although it remains to be determined whether
Figure 6. Staphylococcal protein A (SPA)–IgG immune complexes
(SICs) alter the activation state of human macrophages and inhibit
human preosteoclast differentiation into osteoclasts. A, Human
CD14" monocytes were cultured with macrophage colony-stimulating
factor (M-CSF) without or with SICs, and on day 7, the cells were
stimulated with lipopolysaccharide (LPS). Levels of tumor necrosis
factor " (TNF") and interleukin-12 (IL-12) were determined at 6
hours and 24 hours, respectively. The level of secretion with LPS alone
(medium) was defined as 100%. The results in cultures with SPA were
not significantly different from those with IgG or medium alone, and
therefore SPA is not shown. Bars show the mean # SD results from
triplicate wells (n$ 4 per group). !$ P! 0.05; !!!$ P! 0.001 versus
IgG, by analysis of variance with post hoc test. B,Differentiated human
macrophages were treated on day 6 with either medium, SPA, IgG, or
SICs at 25 $g/ml for 48 hours. Cultures were left unstimulated or
stimulated with 10 units/ml of interferon-! (IFN!) 10 minutes prior to
lysis. Relative values of phosphorylated STAT-1 (pY-STAT-1) were
normalized to those for the total STAT-1 signal by densitometric
quantitation (non–IFN! treated $ 1); normalized values are shown
below the blots. %-actin was used as a control. C and D, Human
macrophages were incubated with either medium (C) or SICs (D) for
48 hours, followed by 10 units/ml of IFN! 10 minutes prior to fixation,
and the cells were stained for phosphorylated STAT-1 (pY-STAT-1)
(in red) and nuclei (in blue). No pY-STAT-1 staining was observable
in cells that did not receive IFN!. Images show representative results
from 1 of 3 separate experiments. E, Human CD14" monocytes (n $
6) were cultured with RANKL and M-CSF overnight and treated with
SICs for 6 hours. Expression of CD115 was assessed as the mean
fluorescence intensity (MFI). !!$ P! 0.01 by paired t-test. F,Human
CD14" monocytes (n $ 7) were cultured with RANKL and M-CSF in
the presence of medium, IgG, ovalbumin plus polyclonal IgG (OpIg),
SPA, or SICs starting on day 1. On day 7, cells were counted to
determine the number of tartrate-resistant acid phosphatase–positive
multinucleated cells (TRAP" MNC) (defined as #3 nuclei). Bars
show the mean # SD. !! $ P ! 0.01 versus vehicle, by Mann-Whitney
U test. G, Representative images of osteoclast cultures on day 7 after
treatment with medium, IgG, OpIg, or SIC are shown.
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this form of therapy is efficacious in established disease,
the results of our study show that SPA is a strong
inhibitor of the inflammatory and erosive aspects of
CIA. We show that these effects are due to the forma-
tion of immunoglobulin complexes, which are able to
engage Fc!RI, polarizing macrophages to a regulatory
phenotype. We further demonstrate that SICs are a
potent inhibitor of IFN!-mediated macrophage activa-
tion, and we predict that this occurs via Fc!RIII-
mediated suppression of IFN!RII expression (13). Fur-
thermore, SICs can interact with preosteoclasts and
inhibit their differentiation into mature osteoclasts.
SPA binds the Fc and variable heavy chains
(VH3) of immunoglobulin (28). These interactions do
not inhibit the ability of IgG to engage Fc receptors (34).
The ability of SPA to interact with the VH3 BCR
expressed on B cells leads to the induction of apoptosis
(20,35–38) via an Fc!RIII-dependent mechanism
(Goodyear CS and Silverman GJ: unpublished data). In
addition, SPA was the active component of a discontin-
ued US Food and Drug Administration–approved
apheresis therapy for inflammatory and autoimmune
diseases, including severe RA (39). There has been
longstanding controversy over the mechanism of action
and unpredictable efficacy of the therapy for inflamma-
tory and autoimmune diseases. Several hypotheses have
been proposed, including removal of immunoglobulin
and/or ICs, modification of small circulating ICs, and B
cell depletion (40). A salient finding was that during
each treatment, SPA could be proteolytically cleaved
and enter the patient’s circulation (41). The quantity of
SPA entering was significantly less than the amount of
circulating immunoglobulin, and Hanson and colleagues
demonstrated that, when excess immunoglobulin is pres-
ent, SPA will form only one type of immunoglobulin
complex (17,42). Our findings (as shown in Figures 1 and
2) show that these homogeneous complexes can interact
with monocytes, macrophages, and preosteoclasts via an
Fc!RI-mediated interaction. It is interesting to specu-
late that the administration of SPA would be of greater
benefit than the suboptimal administration via uncon-
trollable proteolytic cleavage.
To put the potential of SICs in some perspective,
several studies have shown that ICs present in IVIG
(13,14) or generated in alternative ways (12,15) have the
ability to inhibit inflammatory responses. Unlike our
findings with SPA (Figure 4), these ICs have never been
shown to be efficacious in active-immunization murine
models of RA or in patients with RA. The formation of
ICs in IVIG is a heterogeneous process, due to the
diverse binding interactions, and is therefore nonstan-
darized for size and content, suggesting that IVIG is far
from an optimized therapy. An alternative way to emu-
late IVIG ICs is the use of antibodies to immunologi-
cally inert serum protein, which can ameliorate arthritis
in passive transfer autoimmune models. Unlike the
findings in the present study (Figure 3), these complexes
are dependent on the presence of Fc!RIIb (15).
It is interesting to speculate that these differences
may be attributable to the nature of the immunoglobulin
used. The majority of previous studies have utilized
xenogenic immunoglobulin, primarily rabbit IgG, to
generate ICs (15,43). The interaction of rabbit IgG with
murine Fc receptors has never been specifically investi-
gated; however, results would suggest that rabbit IgG
has a certain order-of-magnitude lower affinity for
mouse Fc receptors compared to mouse IgG (44–47). It
is feasible to envisage that rabbit IgG ICs will have
altered binding activity to mouse Fc receptors that could
result in dramatically different outcomes when com-
pared to mouse IgG ICs. In this study, with the use of
SPA, we were able to directly overcome any xenogenic-
mediated differences and generate optimal homoge-
neous complexes with endogenous IgG, and it is this
entity that contains immunomodulatory potential.
The alteration of monocytes and macrophages by
ICs has been studied intensively, demonstrating that
macrophages stimulated with ICs can be polarized to a
regulatory phenotype (21). Macrophage plasticity, a
recently described phenomenon (8), would suggest that
phenotypes are not definitive but part of a spectrum.
Our data suggest that SIC-stimulated macrophages are
in the regulatory area of the spectrum and may have the
capacity to regulate the inflammatory response by being
unresponsive to inflammatory cytokines (Figures 5 and
6), producing antiinflammatory cytokines (i.e., IL-10 in
Figure 3) and by altered antigen presentation via class II
MHC (Figure 3 and currently under investigation). We
postulate that the difference with our SICs when com-
pared to experimental ICs in previous studies is based on
the affinity of autogenic IgG to Fc receptors compared
to that of xenogenic IgG.
Monocyte-derived osteoclastogenesis is consid-
ered critical to the erosive RA process (48), and it has
been suggested that in RA, circulating monocytes are
primed prior to their arrival in the joint. Maturation of
these monocytes is driven by M-CSF, via CD115, and
RANKL (2). In juxtaposition to earlier studies illustrat-
ing the induction of bone loss and osteoclast accumula-
tion via heat-aggregated IgG (49), our findings demon-
strate that SICs not only are capable of directly
interacting with monocytes and preosteoclasts via an
Fc!RI-mediated interaction (Figure 2), but also have
the ability to down-regulate CD115 and inhibit osteo-
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clastogeneis (Figure 6). The mechanisms underlying this
SIC-mediated inhibition of osteoclastogeneis remain to
be determined (currently under investigation). However,
it is interesting to speculate that the interaction of SICs
with Fc receptors on circulating monocytes, or even
those that have entered the joint, might alter the thresh-
old for initiation of M-CSF and RANKL signaling,
thereby inhibiting the ability of monocytes and preoste-
oclasts to mature into fully functional osteoclasts.
In conclusion, monocyte/macrophage-targeting
therapeutic approaches offer a rich potential for the
treatment of human inflammatory diseases. We herein
provide a novel approach that utilizes the ability of SPA
to co-opt endogenous IgG, forming highly regulated
complexes with defined size and shape (17,18). SPA,
which presumably arose in Staphylococcus aureus to
interfere with the host inflammatory responses required
for immunogenicity of microbial antigens, can also serve
as a potent inhibitor of autoimmune inflammatory dis-
ease. The antiinflammatory mode of action appears to
operate via the modification of macrophage responsive-
ness to inflammatory signals and the generation of a
regulatory macrophage that is characterized by IL-10
production but without the conventional regulatory phe-
notype. Finally, we provide a hitherto unrecognized
effect of ICs on osteoclastogenesis, providing a second
potent pathway whereby defined ICs could mediate
therapeutic benefit.
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9 Appendix 3 
 
Table 9.1 Comparison of SpA-488 ability to bind cells of the myeloid linage in the blood, 
damaged spinal cord and bone marrow after SCI. In C57BL/6 mice SCI was induced at the C5/6 
border. 24h after injury mice received either 500µg of SpA-488 i.p. After a further 2h mice were 
culled and the damaged portion of the spinal cord, blood and bone marrow were harvested and 
prepared for flow cytometric analysis on the MACS Quant. The mean ± SD MFI values for SpA-488 
binding in the damaged portion of the spinal cord, blood and bone marrow were determined. This 
experiment was carried out on two separate occasions; the data were then pooled together for 
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